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1. INTRODUCTION 
 
1.1 HEMATOPOIESIS 
Haematopoiesis (from Ancient Greek: αἷμα, "blood"; ποιεῖν "to make") literally means 
the formation of blood. Hematopoiesis is the process by which all the different cellular 
populations that constitute blood and immune system are generated starting from 
common multipotent hematopoietic stem cells (HSCs), through a succession of 
progressive differentiation pathways. Approximately 10
11–1012 new blood cells are 
produced every day in a human healthy adult in order to maintain proper hematopoietic 
homeostasis (Tristram G. Parslow, 2001). However the hematopoietic system is also 
able to immediately respond to higher cellular demands in response to stress signals like 
infection or bleeding, thus specifically producing more cells according to the peripheral 
needs. The capability to replenish all the different cell lineages is due to the presence of 
HSCs, rare cells with the unique capacity to self-renew and differentiate to all of the 
different mature blood cell types throughout all lifespan (Spangrude et al., 1988). The 
remarkable regenerative properties of HSCs are best illustrated by the success of 
marrow transplantation in human patients, a well-established therapy for a variety of 
genetic and acquired bone marrow (BM) diseases, and cancers.  
In the adult hematopoiesis occurs in the BM, were multipotent self-renewing HSCs 
generate a hierarchy of progenitors that ultimately produce the hematopoietic cell 
lineages. Some of them are directly released in the blood circulation as mature cells 
while others, like lymphocytes, reach their full maturation in secondary lymphoid 
organs. 
 
 
1.1.1 Hematopoiesis sites 
During the life of an individual, there are two hematopoietic waves, the first one named 
“primitive” and the second one named “definitive”. Both arise during embryonic 
development but only the second one persists in the adult. Primitive hematopoiesis has 
the primary function to provide red blood cells for oxygen transport to the rapid 
growing embryo, when the definitive specialized hematopoietic structures have not yet 
developed. It occurs (starting from E7.5 in the mouse) in the mammalian yolk sac in 
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aggregates of blood cells called blood islands, mainly composed of nucleated erythroid 
cells. An additional embryonic population of macrophages was detected in the yolk sac 
as early as the first erythrocytes, both in Zebrafish and in mouse (Bertrand et al., 2005; 
Herbomel et al., 1999; Palis et al., 1999). These cells bypass the conventional 
developmental pathway that lead to macrophage differentiation in the hematopoietic 
organs (Ginhoux et al.). The primitive hematopoietic system is transient and rapidly 
replaced by definitive hematopoiesis which starts within the embryo itself in the Aorta-
Gonad-Mesonephro (AGM) region, through a specific developmental specification 
pathway that finally leads to the formation of permanent hematopoietic stem cells 
(Figure 1.1.1). 
 
 
Figure 1.1.1 Developmental Regulation of Hematopoiesis in the Mouse. (A) Hematopoiesis occurs 
first in the yolk sac (YS) blood islands and later at the aorta-gonad mesonephros (AGM) region, placenta, 
and fetal liver (FL). YS blood islands are visualized by LacZ staining of transgenic embryo expression 
GATA-1- driven LacZ. AGM and FL are stained by LacZ in Runx1-LacZ knockin mice. (B) 
Hematopoiesis in each location favors the production of specific blood lineages. Abbreviations: ECs, 
endothelial cells; RBCs, red blood cells; LT-HSC, long-term hematopoietic stem cell; ST-HSC, short-
term hematopoietic stem cell; CMP, common myeloid progenitor; CLP, common lymphoid progenitor; 
MEP, megakaryocyte/erythroid progenitor; GMP, granulocyte/macrophage progenitor. (C) 
Developmental time windows for shifting sites of hematopoiesis (from (Orkin and Zon, 2008)). 
 
Definitive HSCs emerge from the Tie2-expressing haemogenic endothelium in the 
ventral wall of the dorsal aorta at embryonic day 10.5, although with little HSC activity, 
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whereas by day 11 engrafting activity is present. After this time, definitive HSCs 
isolated from the AGM are able to long-term reconstitute the entire blood system upon 
transplantation to irradiated mice (de Bruijn et al., 2000; Muller et al., 1994), whereas 
mouse yolk sac tissue does not (Cumano et al., 1996; Medvinsky and Dzierzak, 1996; 
Orkin and Zon, 2008). This is important since the presence of HSCs is defined by their 
reconstitution capacity.  
There are other sites in which additional hematopoietic activity is subsequently detected 
in the mouse embryo, like the umbilical arteries and the allantois in which 
hematopoietic and endothelial cells are colocalized (Inman and Downs, 2007). 
Umbilical veins lack hematopoietic potential, suggesting a specific correlation between 
HSCs and artery specification. In addition, significant numbers of HSCs are found in 
the mouse placenta (Gekas et al., 2005; Orkin and Zon, 2008; Ottersbach and Dzierzak, 
2005). The relative contribution of each of the above mentioned sites to the final pool of 
adult HSCs remains largely unknown. During embryo development the definitive 
hematopoiesis site moves from AGM first to the fetal liver, the main hematopoietic 
embryonic organ, then to thymus, spleen, and ultimately the bone marrow before birth, 
where it continues throughout adult life (Figure 1.1.1). In children, hematopoiesis 
occurs in the bone marrow of the long bones such as the femur and tibia, while in adults 
mainly in the pelvis, cranium, vertebrae, and sternum. In some cases liver, thymus, and 
spleen may resume their hematopoietic function, if necessary, leading to extramedullary 
haematopoiesis, which can support some medullary failure. 
 
1.1.2 The hematopoietic hierarchy 
Hematopoiesis proceeds through a hierarchical system with progressive levels of 
differentiation, at the apex of which there are rare HSCs that guarantee the presence of 
all terminally differentiated cells. While undergoing various cell divisions, HSCs 
generate progenitors with different degrees of maturation and increased restricted 
differentiation capacity, in a stepwise manner (Orkin, 2000). 
In this tree, HSCs (also called long-term hematopoietic stem cells, LT-HSCs) are the 
only ones bearing the two characteristics of self-renewal ability and multipotent 
differentiation capacity, which are hallmarks of all tissue stem cells. Self-renewal and 
multi-potency is progressively restricted along maturation (Figure 1.1.2), as early as in 
the first step of multi potent progenitors, often called “short-term” HSCs (ST-HSCs, see 
later) which have only limited self-renewal capacity even if able to extensively 
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proliferate. On the contrary, differentiation level increases and the so-called “cell fate 
decision” becomes more and more restricted until reaching only unipotent ability 
(Kawamoto and Katsura, 2009). Each step of the hematopoietic hierarchy has been 
dissected during the past two decades by utilizing cell surface marker analysis by flow-
cytometry in combination with functional analysis. However, there are continuous 
modifications in the branching scheme, according to newly identified intermediate 
populations, and these constant efforts to refine these heterogeneous populations often 
lead to changes in the nomenclature of the cell population  itself.  
In the classical model, LT-HSCs initially give rise to ST-HSCs, that are basically multi-
potent progenitors that possess only limited self-renewal and reconstituting ability yet 
keeping full-lineage differentiation potential (Christensen and Weissman, 2001; 
Morrison and Weissman, 1994), and then to MPPs, multi-potent progenitors without 
self-renewal and reconstituting capacity. Further downstream, MPPs branch towards 
two oligopotent lineage restricted progenitors: the common lymphoid progenitor (CLP) 
that have the potential to become lymphoid cells (Karsunky et al., 2008; Serwold et al., 
2009) and the common myeloid progenitor (CMP), which is responsible for the 
megakaryocyte/erythorid/myeloid cell fate (Akashi et al., 2000; Kondo et al., 1997; Luc 
et al., 2008) (Figure 1.1.2). The CMPs subsequently segregate into either myelo-
monocytic precursors, also called granulocyte/macrophage progenitors (GMPs), or to 
megakaryocyte/erythrocyte progenitors (MEPs) (Nakorn et al., 2003), which in turn 
differentiate into red blood cells and megakaryocyes which produce platelets. This 
hierarchical classification was subsequently refined with additional populations. For 
example it was demonstrated that the MPP population is not uniform (Adolfsson et al., 
2005; Arinobu et al., 2007; Christensen and Weissman, 2001; Forsberg et al., 2006; 
Kiel et al., 2005; Osawa et al., 1996) and it can be further divided in different groups 
according to the expression of specific surface markers and their degree of maturation 
and progressive loss of self-renewal ability (see later). In another study Pronk et al. have 
utilized new markers, like CD150, Endoglin, and CD41, to isolate additional myeloid 
progenitors, thus further modifying the existing hematopoietic tree with novel sets of 
intermediate progenitors (Pronk et al., 2007). Finally, according to more recent reports, 
a subgroup of multipotent progenitors can directly generate megakaryocyte/erythrocyte 
progenitors bypassing the common myeloid progenitor stage (Seita and Weissman, 
2010), although the issue is still debated (Figure 1.1.2). 
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Figure 1.1.2 Model of the hematopoietic hierarchy. The HSC resides at the top of the hierarchy, and is 
defined as the cell that has both the self-renewal capacity and the potential to give rise to all 
hematopoietic cell types (multipotency). Throughout differentiation, a HSC first loses self-renewal 
capacity, then loses lineage potential step-by-step as it commits to become a mature functional cell of a 
certain lineage. The cell surface phenotype of each population is shown for the mouse and human 
systems. Intermediate precursors between the first lineage committed progenitors and final mature cell, 
and different subsets of mature B- and T-cells are omitted. In the mouse system, heterogeneity of MPPs 
has been revealed by differences in cell surface marker phenotypes and functional differences of their 
subsets discussed. For example, evidence suggests that some of MPPs directly give rise to MEP without 
passing through a CMP stage (dashed arrow) (From Seita and Weissman 2010 (Seita and Weissman, 
2010)). 
 
Importantly, true HSCs are functionally defined: they are endowed with the ability to 
reconstitute a lethally irradiated host throughout life, thus showing in vivo their 
multipotency and self-renewal ability (Coulombel, 2004). Cells with these feautures 
have been prospectively isolated based on cell surface characteristics, however the 
haematopoietic stem cell definition in terms of unique cell surface markers profile is 
still a debated issue, since different laboratories often use slightly different combination 
of markers.  
Like HSCs all the cell populations constituting the hematopoietic system can be 
identified and prospectively isolated through combinations of surface markers that 
finely distinguish them. In general, stem cells (as well as MPPs) are all negative for 
markers used for detection of lineage commitment and are, thus, called Lin
-
. They also 
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express Sca1 and cKit leading to a phenotype which is commonly abbreviated as LKS, 
which include less than 10% of HSCs (see § 1.1.3.3). 
 
 
1.1.3 Hematopoietic stem cells (HSCs) 
1.1.3.1 The stem cells concept 
One of the earliest evidence of long-lived blood cell progenitors came from the 
observation that infusion of hematopoietic cells induced tolerance in fetal and neonatal 
mice, a discovery that was awarded the Nobel Prize in Medicine in 1960 (Billingham et 
al., 1953). Subsequently, the modern “stem cell” concept was first proposed by Till and 
McCulloch in a series of pioneering experiments on the in vivo blood system 
regeneration capacity, during the 1960s (Till and Mc, 1961). Briefly, they observed the 
formation of cellular colonies in the spleen of recipient mice ten days after transplanting 
a limited number of syngenic BM cells. Functional analysis of these colonies revealed 
that a very small sub-population of the donor BM cells possessed two remarkable 
properties: the ability to generate multiple types of myeloerythroid cells, and the ability 
to self-replicate (Becker et al., 1963; Siminovitch et al., 1963; Till and Mc, 1961; Wu et 
al., 1968).With these findings they defined the two hallmarks of stem cells i.e. multi-
potency and self-renewal. Bona fide HSCs are the only cells within the hematopoietic 
system that possess both capacities. Specifically, multi-potency is the ability to 
differentiate into all functional blood cells, while self-renewal is the ability to give rise 
to identical daughter HSCs without differentiation (Orkin and Zon, 2008; Weissman 
and Shizuru, 2008). Like other adult stem cells, HSCs are able to perform self-renewal 
and differentiation simultaneously since they are endowed with the capacity of 
asymmetric cell division, according to which when a stem cell divides one daughter cell 
retains the stem-cell fate (self-renewal) while the other differentiates (Betschinger and 
Knoblich, 2004; Doe and Bowerman, 2001; Yamashita and Fuller, 2005). Asymmetric 
division is a particularly attractive strategy because it manages both tasks with a single 
division. However it leaves stem cells unable to expand in number, thereby making 
symmetric cell division processes necessary (Morrison and Kimble, 2006). 
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1.1.3.2 HSC quiescence 
It has long been recognized that, although mature blood cells are produced at a rate of 
more than one million cells per second in the adult human (Ogawa, 1993), most of the 
HSCs from which they derive are slowly cycling (quiescent) and primarily in the G0 
phase of the cell cycle under homeostatic conditions (Rossi et al., 2007). However, 
HSCs are still heterogeneous. Studies on the cycling behavior of HSCs in vivo 
suggested the presence of two HSC fractions: a deeply dormant HSC (d-HSC) fraction 
and an active HSC (a-HSC) fraction (van der Wath et al., 2009; Wilson et al., 2008). 
These two HSC states have been identified through long-term label-retaining assays that 
are based on an initial labeling of stem cells followed by the label dilution over time. 
Since the label is halved with each division and is no longer detectable after about five 
divisions (Waghmare et al., 2008; Wilson et al., 2008), it is possible to calculate the 
division history of different stem cell populations from the label decay kinetics. With 
these assays, the LSK CD34
-
CD48
-
CD150
+
 HSC population (see §1.1.3.3) was shown 
to be composed by two subsets: a “dormant” HSC population (d-HSC), which 
represents about 15% and divide only about every 5 months, and an “active” HSC 
population (a-HSC) which divide about once every month and represent the 85%. 
Transplantation assays of these two isolated populations showed that the majority of 
long-term repopulation activity reside in dHSCs while the active fraction of HSCs, even 
with the same surface phenotype, shows significantly less self-renewal and fails to 
serially reconstitute lethally irradiated mice (Foudi et al., 2009; Wilson et al., 2008; 
Wilson et al., 2009). Due to their slow cycling, d-HSCs are unlikely to significantly 
contribute to the daily production of blood cells during homeostasis but they serve to 
maintain an HSC reservoir. The daily production of mature cells, as well as the rapid 
activation in response to injuries, resides in the active fraction of HSC and even more in 
the multi potent progenitors. The quiescent state is reversible since d-HSCs could be 
induced toward an active status (for example by administration of chemotherapeutic 
compound 5-Fluoro-Uracil) and go back to a dormant state after homeostasis has been 
re-achieved (Wilson et al., 2008). There is a strong correlation between quiescence and 
self-renewal since the number of HSC self-renewing divisions may be limited, and 
functional HSC exhaustion is reached by serially transplanting BM five to six times 
(Orford and Scadden, 2008). These features have been recently demonstrated also in a 
significant number of mouse mutants were HSCs show increased cycling activity. 
Although this initially causes an increase in HSC number, it mostly leads to the final 
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loss of stem cells likely due to their exhaustion, thus demonstrating the inverse 
correlation between stem cell proliferation and self-renewal capacity (Wilson et al., 
2009). Why is quiescence an advantage for HSCs? During homeostasis a low number of 
cell divisions minimize the number of DNA mutations that may result in oncogenic 
transformation. In addition, quiescent HSCs would have sufficient time to repair any 
DNA damage, if it occurs, prior to fix it to the next cell generation. Moreover in an 
injury condition, quiescence protects HSCs from external toxic drugs like 
antiproliferative chemotherapeutic agents (Essers et al., 2009; Randall and Weissman, 
1997; Venezia et al., 2004), allowing to a complete reconstitution of the hematopoietic 
system in which the more mature cells have been destroyed. 
 
1.1.3.3 Identification of HSCs 
Regarding morphology, HSC resemble lymphocytes and are small non-adherent round 
cells, with a rounded nucleus and low cytoplasm-to-nucleus ratio. 
There are different assays for identification of HSCs, mostly based on cell surface 
marker analysis by flow-cytometry, and evaluation of their function (Purton and 
Scadden, 2007). Nevertheless because no ex vivo assays can replace in vivo 
transplantation assay for measuring biological activity of HSCs, characterizing cell 
populations through their immunophenotype or by other in vitro assays cannot be 
synonymous of determining their function, especially in case of mutant mice.  
Immunophenotypical Analysis of HSC/Progenitors  
In the last 20 years, a number of different methods whereby HSCs (and progenitor cells) 
can be identified have emerged (Goldschneider et al., 1978; Spangrude et al., 1988; 
Visser and Bol, 1982; Visser et al., 1981), all of them relying on a combination of 
several positive or negative markers coupled with fluorescence-activated cell sorting 
(FACS) analysis (Weissman and Shizuru, 2008). Since the HSC population is rare (less 
than one out of 10
5
 BM cells), a common problem with these methods is to achieve a 
reasonable level of purity. Indeed, in all of them the obtained HSCs are still enrichment 
rather than pure populations. Nevertheless, with the different immunophenotyping 
methods the purity of HSC populations has progressively increased, reaching 
approximately 50%–96% of single cells able to long-term reconstitution after 
transplantation (Matsuzaki et al., 2004; Yilmaz et al., 2006a). 
The first immunophenotypic characterization was performed in 1988 by Weissman 
laboratory, which isolated short-term repopulating HSCs based on the expression of 
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stem cell antigen- 1 (Sca-1), low expression of Thy1.1, and lack of expression of 
lineage markers (Spangrude et al., 1988). The same population was shown to contain 
long-term repopulating HSCs in a subsequent study (Uchida and Weissman, 1992) and 
was further purified by the expression of the stem cell factor receptor, c-Kit, in 1992 
(Ikuta and Weissman, 1992). However, this combination of markers is not widely used 
since Thy1.1 is expressed only by a specific mouse strain but not by C57BL/6, 
worldwide used mice in HSC transplantation studies. Even if the Thy1.1 counterpart in 
C57BL/6 mice exist (Thy1.2) it does not have the same pattern of expression on HSCs 
(Spangrude and Brooks, 1992). Due to this important limitation, other 
immunophenotypical characterizations have been developed mostly based on the 
expression of c-Kit. After its first description as a marker of hematopoietic progenitor 
cells in 1991 (Ogawa et al., 1991), Suda and collaborators reported the isolation of 
HSCs from C57BL/6 mice in the Lin
-
Kit
+
, Sca-1
+
 (LKS
+
) population in 1992, following 
a similar protocol to that described by Weissman’s lab (Okada et al., 1992). However, 
as mentioned earlier LKS population is only partially enriched in HSCs. To further 
purify HSC population, more recently the expression of CD34 (Osawa et al., 1996) and 
Flk2 (CD135) (Adolfsson et al., 2001; Yang et al., 2005) has been used. With the 
combination of these two markers it has been possible to separate long-term 
repopulating HSCs, which are LKS
+
CD34
-
Flk2
-
, from short-term repopulating HSCs 
(LKS
+
CD34
+
Flk2
-
) and multi potent progenitors (LKS
+
 CD34
+
Flk2
+
) (Yang et al., 
2005). However this method shows some limitations like differential expression of 
CD34 according to the age of mice, as in mice younger than 8 weeks it is expressed also 
by HSCs (Matsuoka et al., 2001). 
Another strategy used to define HSC phenotype is based on fluorescent dyes efflux 
properties of HSCs, which identify HSCs as the so-called Side Population (SP). For this 
purpose two different vital dyes, the mitochondrial-binding dye rhodamine 123 and 
DNA-binding dye Hoescht 33342, have been used, either alone or in combination, to 
isolate HSCs (Goodell et al., 1996; Li and Johnson, 1992; McAlister et al., 1990; 
Phillips et al., 1992; Wolf et al., 1993). Both dyes are retained at very low intensity in 
HSCs due to high efflux capacity of these cells. The efflux is mediated by a membrane 
pump belonging to the ATP-binding cassette (ABC) transporter family. ABCs are 
highly expressed in HSCs and drive the efflux of drugs and other toxic molecules, 
including dyes, resulting in their low-retaining. HSCs labeled with these dyes are 
visualized by FACS analysis as SP cells by low emitting the dye. There are strong 
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technical limitations in the use of this method since it has been reported a poor 
reproducibility among different laboratories and even among different experiments, due 
to a high dependency on modifications in the staining techniques  (Lin and Goodell, 
2006) and to different performance of different batches of dyes (Matsuzaki et al., 2004). 
Furthermore the SP population is not as pure as HSCs enriched by other methods such 
as LKS
+
CD34
-
Flk2
-
cells, although it can be used in combination with those markers to 
further purify HSCs with extreme efficiency (reviewed in (Purton and Scadden, 2007).  
Additional improvement in HSC purity has been reached with the use of the signaling 
lymphocyte activation molecule (Arboleda et al.) code. Single cell reconstitution assay 
has shown that, using this code, is it possible to purify a population in which 
approximately 50% of the immunoidentified HSCs is able to long-term reconstitute 
lethally irradiated animals (Kiel et al., 2005; Wilson et al., 2009; Wilson and Trumpp, 
2006). SLAM proteins are a family of cell surface glycoproteins belonging to the 
immunoglobulin superfamily, originally known to be involved in T-cell stimulation. 
This family is a group of more than 10 molecules whose genes are located mostly in 
tandem in a single locus on chromosome 1 (in the mouse). CD150 being the founding 
member is thus also called slamF1 (SLAM family member 1). According to the SLAM 
code HSCs were first defined as CD150
+
CD48
-
CD244
-
. Subsequently it has been 
reported that CD150
+
CD48
-
 signature is sufficient. The use of SLAM signature 
overcomes most of the limitation of the previous methods for HSC identification, giving 
comparable stem cell purity in mice. Indeed, unlike Thy1.1 expression, the SLAM 
receptors appear to be expressed by many mouse strains (Kiel et al., 2005), and more 
faithfully detect HSCs in older, mobilized, or transplanted mice (Yilmaz et al., 2006a). 
However, recent work has shown that this method excludes a large number of HSCs and 
includes an equally large number of non-stem cells than the other methods do 
(Weksberg et al., 2008). In summary, we can conclude that the different HSC 
populations identified by SLAM code or CD34/CD135 are quite similar and the use of 
one combination rather than the other does not impair significantly HSC purity (see 
Figure 1.1.3, for schematic immunophenotypical analysis of HSC and progenitor cells, 
and Table 1.1.1, for summary of cell population immunophenotypes used in this study). 
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Figure 1.1.3 Immunophenotypical analysis of HSC and progenitor cells. Representative FACS plots 
show the gating strategy for identification of HSC and multipotent progenitors (A) and lineage restricted 
progenitors (common myeloid and common lymphoid progenitors) (B) that was used in our study. Both 
gating strategies refer to Lin
-
 enriched BM cells. See text for details.  
 
 
 
 
 
 
14 
 
 
Table 1.1.1 Hematopoietic stem and progenitor cell populations with the markers used in our study. 
Table show name, acronym and commonly used immunophenotype to identify and purify them.  
 
Irrespective of the combination of markers used, it has to be noted that reliability of all 
these markers is questionable in mutant mouse models, as the surface marker profile of 
HSCs and their progenitors may be distorted leading to phenotypically defined HSCs 
which not always correlate with their real number or quality (Purton and Scadden, 
2007).   
Functional Assays 
The functional potential of HSCs and progenitors cannot be measured only on the basis 
of immunophenotypical analysis; hence, functional assays have been developed. HSCs 
are operationally defined by their ability to reconstitute the entire blood system of a 
recipient and therefore the gold standard for measuring HSCs is the long-term 
repopulating assay. Nevertheless, during the past other functional assays have been 
used, although most of them are indirect or surrogate assays and reflect more the 
progenitors rather than the HSC function. The most used functional HSC assays, which 
can be divided into in vitro and in vivo assays, are listed below.  
One of the test most used worldwide is the colony-forming cell (CFC) assay, which 
evaluates progenitor cells in a given population using a well-defined methylcellulose-
based culture media supplemented or not with different cytokines. After a specific time 
of culture, cells develop visible colonies of differentiated cells that allow to determine 
the cell they originated from. The majority of colonies derive from lineage-restricted 
cells: erythroid colonies, further divided into the more immature burst-forming units-
erythroid (BFU-E) or colony-forming units erythroid (CFU-E); megakaryocyte-
restricted colonies (CFU-Mk); colony-forming units-granulocytes (CFU-G), colony-
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forming units-monocytes/macrophages (CFU-M) and colony forming units-
granulocytes/macrophages (CFU-GM). More immature colonies may also be detected 
like CFU-GEMM, which originate from earlier multi potent progenitors and contains 
granulocytes, erythrocytes, macrophages, and sometimes megakaryocytes. HSCs can 
give rise to CFU-GEMM too, although in a longer time-frame due to their initial 
quiescent state. The CFC assay allow myelo-erythroid differentiation, while to detect B 
and T lymphocyte progenitors specialized co-culture systems are necessary (Schmitt 
and Zuniga-Pflucker, 2002; Whitlock and Witte, 1982). As mentioned above CFC assay 
is informative about the progenitor cell content of a population but do not measure HSC 
activity. 
Another in vitro assay is the long-term culture-initiating cell (LTC-IC) assay, which 
detects the presence of very primitive hematopoietic progenitors. Hematopoietic cells 
are co cultured on a supportive feeder stromal layer, and after ≥ 4 weeks their sustained 
capacity to produce myeloid colonies is detected by CFC assay. Although in vitro, the 
LTC-IC is the best surrogate functional assay for long term HSC capacity (Verfaillie, 
1994; Woehrer et al., 2010). 
The gold standard assay to measure both HSC numbers and functional potential are long 
term in vivo assays. Different types of long-term repopulating assays exist, the most 
common of which is the competitive repopulation assay (Harrison, 1980), which 
measures the functional potential of the unknown source of HSCs against a known 
number of HSCs. Through a mathematical formula the number of repopulating units 
(RU) present in the donor cell population can be determined (Harrison et al., 1993; 
Yuan et al., 2005). This assay provides functional information about HSC capability to 
repopulate host compared to the competing bone marrow but do not give information 
about their frequency. Frequency of HSCs (from which the number of HSCs can be 
estimated) is commonly measured using a more complex variation of the former 
competitive repopulation assay which is the limiting dilution assay. In this assay, series 
of dilutions of the unknown donor cells compete against a defined number of competing 
bone marrow cells. From the number of mice showing no reconstitution in each cell 
dose (negative fraction) the frequency of HSCs is calculated using Poisson statistics 
(Szilvassy et al., 1989; Taswell, 1981). However, the limitation of this assay is the 
elevated number of mice required to achieve statistical significance (at least eight 
recipient mice per cell dose, with a minimum of three cell doses) (Szilvassy et al., 
1990). The most stringent test to measure HSC potential is the serial transplantation 
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assay in which the testing cells are transplanted into sequential serial recipients. Only 
the true (most immature) HSC is capable of sustaining hematopoiesis throughout serial 
transplantation (Lemischka et al., 1986; Purton et al., 2006; Rosendaal et al., 1979).  
Limitations to all these in vivo assays are their dependence upon correct homing and 
engraftment processes, which may be perturbed in mutant mice due to defects in the 
stem cell niche or to other defects without altering stem cell function per se. Therefore 
this kind of assay is informative only when homing and engraftment are not affected. 
 
1.1.3.4 HSC niche 
HSCs reside in the medulla of the bone (bone marrow) within a functionally 
tridimensional organized structure, termed niche, which is composed by different type 
of cells, all together contributing to maintain the proper HSC environment and 
functions. The concept of the “stem cell niche” was first proposed for the human 
hematopoietic system in the 1970s (Schofield, 1978), and a similar concept has been 
further proposed for stem cells in other tissues like the epidermis, intestinal crypts, 
nervous system and gonads (Fuchs et al., 2004; Suda et al., 2005). The hematopoietic 
niche is conceptually divided into two parts: an osteoblastic niche, located near the 
endosteum lined by osteoblasts (OBs) (Calvi et al., 2003), and a vascular niche, in 
association with sinusoidal endothelium (Kiel et al., 2005). 
The osteoblastic niche is mainly formed by osteoblasts (OBs), bone forming cells 
derived from mesenchymal stem cells, which represent a crucial component of the HSC 
niche in adult BM by maintaining HSC quiescence (Calvi et al., 2003; Zhang et al., 
2003). Moreover not only the quiescent status of HSC but also their number is regulated 
by the number and/or type of osteoblasts. For example an increasing number of 
osteoblasts expressing N-cadherin is positively correlated with an increase in HSC 
number (Zhang et al., 2003). 
Regarding the vascular niche a strong functional interaction between endothelial cells 
and HSCs has been demonstrated during development, since HSC emerge from the 
hemogenic endothelium. However a similar link between endothelial cells and adult 
BM HSCs was not evident until few years after the osteoblastic niche definition, when 
sinusoidal endothelial cells within the bone marrow were found strongly associated with 
HSCs. The association is not simply functional to provide metabolic sustenance but also 
provides inductive signals, thus suggesting the existence of another HSC niche 
(Avecilla et al., 2004; Heissig et al., 2002; Kiel et al., 2005), the so called vascular 
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niche, which is associated with HSC mobilization or proliferation and differentiation 
rather than quiescence and self-renewal. Indeed, it has been postulated that HSCs in 
these two niches are functionally different: in the endosteal niche HSCs appear 
quiescent whereas the perivascular niche seems to house actively self-renewing HSCs 
(Wilson et al., 2008). Thus vascular niche does not exclude osteoblastic niche since the 
two niches are two functional sites rather than two physical separated sites.  
Besides these two conventional niches, a third niche has been further proposed, 
composed by hematopoietic progenitor cells surrounding quiescent HSCs. Since it is 
well demonstrated that progenitor cells suppress proliferation of stem cells (by unknown 
factors) in other tissues (Gerber et al., 2002), a similar mechanism has been 
hypothesized also for the hematopoietic system. When the numbers of the surrounding 
progenitor cells decrease within the stem cell niche, for example after a myelo-ablative 
therapy, quiescent HSCs might be released from inhibition and start to divide, although 
this has not been formally demonstrated in the hematopoietic field yet (Suda et al., 
2005). 
Besides the cellular composition, there is an increasing interest regarding the signaling 
pathways that control HSC niche function. Indeed, together with the intrinsic cellular 
and molecular mechanisms, which have been extensively characterized and will be later 
discussed, the niche is thought to participate in regulating balance between self-renewal 
and commitment of stem cells. Thus regulatory molecules and signaling pathways have 
been further studied at the molecular level. Regarding functional interaction between 
HSCs and OBs important regulatory molecules include cell-adhesion molecules, such as 
N-cadherin and 1-integrin, and chemokines or chemoattractive proteins. N-cadherin is 
expressed both by quiescent HSCs and osteoblasts (Arai et al., 2004), while integrins 
4 1 and 5 1 are expressed only by HSCs and promote HSC adhesion to BM stromal 
cells (Whetton and Graham, 1999), Chemokines or chemoattractive proteins are also 
involved in the mobilization and interactions of stromal cells with HSCs (reviewed in 
(Suda et al., 2005). Among chemokines, one of the most intensively investigated is the 
CXC chemokine ligand 12 (CXCL12), also known as stromal cell-derived factor-1 
(SDF-1) from the cells in which it is highly expressed. CXCL12, together with its 
receptor CXCR4, is involved in HSC homing toward the BM and in maintaining HSC 
quiescence (Dar et al., 2006). Deletion of genes encoding either SDF-1 or CXCR4 
results in normal fetal liver hematopoiesis but failure in marrow engraftment (Nagasawa 
et al., 1996; Tokoyoda et al., 2004). In addition, overexpression of CXCR4 by human 
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hematopoietic progenitor cells, and other blood cells, enhances marrow engraftment in 
nude mice, whereas anti-CXCR4 antibodies inhibit it (Peled et al., 1999). However, 
because there are no experimental evidences of CXCR4 expression in quiescent HSCs, 
it is likely that factors involved in HSC engraftment are different from adhesion 
molecules in the osteoblastic niche. Other adhesion molecules, such as activated 
leukocyte cell adhesion molecule (ALCAM) (Arai et al., 2002) and osteopontin (Chen 
et al., 1993), are also expressed by osteoblasts and might be involved in HSC–osteoblast 
interactions. Also extrinsic factors, such as bone morphogenetic protein (BMP), the 
Notch ligand Delta and angiopoietins (Angs), are thought to participate in the functional 
HSC–osteoblast interactions (Suda et al., 2005). Regarding the vascular niche, 
angiogenic factors are thought to regulate functional interaction of HSCs with 
endothelial cells. Indeed, due to their common developmental origin, endothelial cells 
and HSCs co-express CD31, CD133 (prominin-A), Flk1 (vascular endothelial growth 
factor (VEGF) receptor), CD34 (the latter not in mouse long-term HSCs) and Tie2 
(Rafii et al., 2002). Thus, it is suggested that ligand–receptor signaling occurs between 
HSCs and endothelial cells. Indeed, HSCs themselves secrete Ang-1, which induces 
angiogenesis (Takakura et al., 1998).  
In addition to the classic osteoblast and vascular signals, other factors such as Dkk1, an 
inhibitor of the canonical Wnt signaling pathway (Fleming et al., 2008), thrombopoietin 
(Yoshihara et al., 2007) and membrane-bound SCF (Driessen et al., 2003) (see § 
1.1.3.5) have been implicated in the regulation of HSC self-renewal and quiescence in 
stem cell niches. Of note, emerging evidences support the involvement of miRNAs. Due 
to the established role of miRNAs in the regulation of HSC self-renewal and 
differentiation, as well as their involvement in maturation of the other niche cells, it is 
likely that miRNAs regulate HSC niche function. Furthermore, many of the miRNA-
regulated signaling pathways associated with stem cell differentiation also play an 
important role in HSC niches (Laine et al., 2012). The role of miRNAs in regulating 
HSC niche will be discussed in the specific miRNA section (§1.3.6). 
 
1.1.3.5 Regulation of HSC self-renewal 
The regulation of the balance between self-renewal and commitment of stem cells is a 
highly regulated network controlled by a combination of cell-intrinsic and external 
regulatory mechanisms, in part also coming from their protective microenvironments 
(niche).  
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Maintenance of HSC self-renewal mostly involves preservation of HSC dormancy, 
inhibition of differentiation, and protection from detrimental outside signals (Wilson et 
al., 2009). Regarding the external stimuli, there are numerous signaling pathways and 
adhesion molecules, coming from the niche environment, that maintain HSCs in an 
inactive quiescent stage preserving their self-renewal potential. One of these is 
represented by the interaction between the membrane bound Stem Cell Factor (mbSCF) 
on osteoblasts with the c-Kit receptor on HSCs (Czechowicz et al., 2007). This 
interaction is crucial for the binding of HSCs to OBs niche, and for the maintenance of 
HSC dormancy and function (Thoren et al., 2008). In addition to SCF two other 
signaling molecules are secreted by osteoblastic niche cells: Angiopoietin1 (Ang1) and 
Thrombopoietin (TPO). Both act through their receptors, Tie1/2 (see below) and c-Mpl 
respectively, to induce HSC dormancy. Mutants lacking either of the two result in 
increased HSC cycling followed by ultimate loss of HSCs due to exhaustion (Arai et al., 
2004; Yoshihara et al., 2007). 
In detail HSCs which express the receptor tyrosine kinase Tie2 are slow-cycling stem 
cells and Ang-1, which is a ligand for Tie2 (Davis et al., 1996), in the adult BM is 
expressed primarily by OBs. Tie2–Ang-1 signaling promotes tight adhesion of HSCs to 
OBs and maintains HSC self-renewal by blocking cell division and promoting their 
quiescence (Arai et al., 2004). Through chimeric studies, with mutant embryonic cells 
lacking Tie proteins (Tie1 and Tie2), it has been shown that Tie family is required for 
postnatal but not for fetal hematopoiesis (Puri and Bernstein, 2003). There are two 
possible mechanisms by which the Tie2–Ang-1 pathway blocks cell division. In a direct 
way, following Ang-1 binding, Tie2 phosphorylation results in activation of the 
phosphatidyl-inositol-3-kinase (PI3-K)–Akt signaling pathway in endothelial cells (Kim 
et al., 2000; Shiojima and Walsh, 2002), which in turn directly promotes HSC 
quiescence likely by p21 phosphorilation. Indirect effect of Tie2 is mediated by 
enhancing HSC cell adhesion properties to stromal cells in vitro, in a 1-integrin-
dependent manner, and to the bone surface in vivo (Arboleda et al., 2003). The tight 
attachment of HSCs to stromal cells likely affects their cell cycle status (Suda et al., 
2005). 
Intracellular control of HSC dormancy is regulated by other signals such as TGF , well 
known negative regulator of HSC proliferation, at least in vitro (Yamazaki et al., 2009). 
The mechanism by which this occurs seems indirect, as TGF  inhibits cytokine-
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mediated lipid raft clustering, which is essential for enhancing cytokine signals over the 
threshold required for HSCs re-entering in the cell cycle.  
Another example of HSC quiescence mediators is pre-B-cell leukaemia transcription 
factor 1 (Pbx1, see also §1.2), a global developmental regulator preferentially expressed 
in adult HSCs rather than in MPPs. It has been shown that Pbx1 promotes proliferation 
in several embryonic tissues while in the adult promotes HSC quiescence. Upon Pbx1 
conditional deletion, quiescence is lost with a consequent loss of long term self-renewal 
capacity, as shown by failure in serial transplantation assays (Ficara et al., 2008). 
Another protein acting in HSC quiescence is the chromatin remodeling protein Mi-2b, 
which regulates both gene silencing and activation through association with histone 
deacetylases and acetyltransferases, respectively (Wilson et al., 2009). Mi-2b 
inactivation causes HSCs exit of quiescence, which is accompanied by and increased 
and faster stem cell cycling. Moreover Mi-2b mutant BM cells fail to reconstitute likely 
due to HSC apoptosis and/or stem cell exhaustion (Yoshida et al., 2008). Other 
important regulators of HSC dormancy are Egr1 (Min et al., 2008), a transcription 
factors member of the immediate early response gene family, HOXB4 (Antonchuk et 
al., 2002), Notch1 (Varnum-Finney et al., 2000), SHH (Bhardwaj et al., 2001), Wnt 
(Reya et al., 2003) and p53 (Liu et al., 2009), among others. In contrast to the above 
mentioned mechanisms, all of which involved in maintaining HSC quiescence, the 
oncogene Evi-1 (ecotropic viral integration site-1) does not restrict, but promotes HSC 
proliferation and likely self-renewal  (Goyama et al., 2008). 
The balance between cycling and dormant HSCs is critical in order to maintain a self-
renewing stem cell pool. Decreasing cycling, enforcing quiescence and forcing HSCs in 
G0, lead to an insufficient production of more committed progenitors and terminally 
differentiated cells, finally leading in hematopoietic failure. Conversely, promoting 
cycling of normally quiescent HSCs leads to a sustained production of downstream 
progeny at the expense of self-renewal, which finally results in the inability to 
reconstitute due to HSC exhaustion  (Wilson et al., 2009). 
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1.1.4 Multipotent and lineage restricted progenitors  
In addition to HSCs, the hematopoietic hierarchy is critically dependent on various 
progenitors, including the transiently reconstituting multipotent progenitors (MPPs), 
and the downstream lineage restricted progenitors, which are characterized by 
increasing lineage-restriction. All these intermediate progenitors can be identified 
through immunophenotype analysis. Similar to HSCs, MPPs and lineage restricted 
progenitors are negative for lineage markers, but they can be further distinguished using 
other combinations of specific markers. MPPs are, as previously mentioned, a 
heterogeneous population (Christensen and Weissman, 2001; Kiel et al., 2005; Osawa et 
al., 1996) and may be divided in at least three different subgroups. MPPs are 
phenotypically defined as LKS/CD34
+
, and can be further divided into three fractions 
according to Flk2 expression: Flk2
-
 MPPs, previously called short-term HSCs, Flk2-
intermediate MPPs (Flk2
int
) and Flk2
high
MPPs. MPPs negative, or with lower expression 
of Flk2 are progenitors with robust myeloid maturation potential (Flk2
-
MPPs and Flk2
int
 
MPPs) while MPPs with the higher expression of Flk2 are lymphoid-primed MPPs 
(Flk2
high
, also known as LMPPs) (Mansson et al., 2007). 
Regarding lineage committed progenitors, they can be identified with a combination of 
other markers. CLPs are identified as Lin
-
 cells that express IL7 receptor and low level 
of cKit and Sca-1 (thus they are Lin
-
/IL7R
+
/cKit
low
/Sca
low
), and by their high level of 
expression of Flk2 (Karsunky et al., 2008; Kondo et al., 1997), while CMPs can be 
distinguished among the c-Kit positive, but Sca-1 negative population. Within this 
population CMPs can be further separated from downstream GMPs and MEPs, 
according to the different expression of CD34 and CD16/32 (FcR II/III) markers. In 
detail, CMPs are Lin
-
/cKit
+
/CD34
int
/CD16/32
int
, GMPs are Lin
-
/cKit
+
/CD34
+
/CD16/32
+
, 
and finally MEPs are Lin
-
/cKit
+
/CD34
-
/CD16/32
-
 (Akashi et al., 2000) (For a 
representative scheme of the immunophenotypical analysis of these different 
populations see fig 1.1.3 §1.1.3.3). Recently the heterogeneity of GMPs and MEPs has 
been further highlighted, and other subpopulations with higher degrees of purity have 
been identified (Pronk et al., 2007), with CMPs generating Pre GM immediately 
upstream of GMPs, and with MEP now comprising a hierarchy having Pre MegE at the 
top, which give rise to Pre CFU-E and to MkP (Megakaryocyte Precursors).  
Correct regulation of multi potent and lineage restricted progenitors is fundamental to 
guarantee a constant and adequate pool of undifferentiated cells which are able to 
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perform a rapid proliferative expansion in responses to peripheral stresses such as 
infection or bleeding. This rapid response is especially important in the myeloid lineage, 
given the short life span of granulocytes and monocytes, and the lack of ‘memory’ cells 
in contrast to the lymphoid lineage. Moreover it has been proposed that lineage-
restricted progenitors may serve as targets for oncogenic transformation. In addition to 
their intrinsic proliferative capacity they might acquire upstream stem cell properties 
normally lost during differentiation, like unlimited self-renewal capacity, which 
ultimately confer them leukemia stem cell potential (Cano et al., 2008; Cleary, 2009; 
Krivtsov et al., 2006; Minami et al., 2008; Signer et al., 2010; Somervaille et al., 2009; 
Tremblay et al., 2010; Wojiski et al., 2009). Thus it is important to understand whether 
factors regulating HSC self-renewal, such as Pbx1, are also implicated in maintaining 
progenitor reservoirs. 
 
1.1.5 Regulation of hematopoiesis 
As a stem cell matures it undergoes changes that progressively limit its multipotency 
and make it closer to a specific cell type. All differentiation programs are tightly 
regulated both by external signals and lineage specific regulators. Regarding the 
external stimuli, three main factors stimulating production of committed stem cells, 
called colony-stimulating factors (CSFs), exist. They include granulocyte-macrophage 
CSF (GM-CSF), granulocyte CSF (G-CSF) and macrophage CSF (M-CSF), all of 
which are active on either progenitor cells or more mature cells. To drive myeloid 
progenitors towards the megakariocytic/erithroid lineage, erythropoietin is required for 
erythrocyte differentiation while thrombopoietin for megakaryocytes differentiation 
(specifically to obtaining thrombocyte-forming cells) (Harvey Lodish, 2012). Other 
relevant hematopoietic factors are the interleukins, a group of multifunctional cytokines, 
which act at different level of the hematopoietic hierarchy mainly driving lymphoid 
lineage differentiation and activation. Among them IL-3 exerts a pleiotropic activity 
supporting proliferation and differentiation of a wide spectrum of hematopoietic cells 
(Ihle, 1992). IL-3 stimulates the differentiation of multipotent hematopoietic stem cells 
into myeloid progenitor cells and, in combination with IL-7, into lymphoid progenitor 
cells. Moreover IL-7 in combination with other cytokines further modulates 
differentiation and activation of lymphoid progenitor cells into B and T lymphoid cells 
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(Ceredig and Rolink, 2012). These factors are added in cell culture media in the 
different in vitro differentiation assays. 
Cytokines act through specific signal transduction pathways that activate lineage 
specific transcription factors (TFs) which in turn modulate proper gene expression 
pattern to drive differentiation. Several lineage specific TFs have been identified that 
regulate critical steps in hematopoiesis and their expression can be generally reconciled 
with the simple hierarchical hematopoietic tree. The key lineage-restricted TFs are 
endowed with the complementary roles of promoting their own lineage differentiation 
while simultaneously preventing other choices (reviewed in (Orkin and Zon, 2008). 
Numerous TFs acting in this alternative lineage programming mechanism have been 
described. For example GATA-1 and PU.1 promote 
erythroid/megakaryocytic/eosinophil and myeloid differentiation, respectively. The two 
proteins physically interact and antagonize each other (Galloway et al., 2005; Rhodes et 
al., 2005). One of the most striking example of lineage selection repression is provided 
by Pax5, a TF normally required for proper B-cell development (Adams et al., 1992; 
Nutt and Kee, 2007; Urbanek et al., 1994). Pax5-null B cell-progenitors assume a 
multipotential phenotype and fail to restrict their lineage choice (Nutt et al., 1999). 
Under appropriate growth factor conditions, mutant B cell progenitors develop into 
several hematopoietic cell types, including macrophages, osteoclasts, granulocytes T-, 
NK-, or dendritic cells and even erythroid precursors. So, commitment to B-cell 
development is driven by Pax5 and involves suppression of alternative lineage choices 
(Busslinger et al., 2000; Orkin, 2000). 
Beyond their presence or absence, TFs can influence lineage choice and differentiation 
also in a concentration-dependent manner. The level of GATA-1 regulates lineage 
outcome in the transformed chicken progenitor system (Kulessa et al., 1995), with 
eosinophils formation at lower levels of GATA-1, and erythroid and megakaryocytic 
development at higher levels. These findings have been demonstrated also in mice 
(McDevitt et al., 1997). PU.1 also regulates differentiation in a concentration- 
dependent manner, since high levels of PU.1 favors macrophage development, while 
low levels B cells development (DeKoter and Singh, 2000; Orkin, 2000). 
Besides TFs, an additional level of regulation is provided by microRNAs (miRNAs) 
(Shivdasani, 2006; Stadler and Ruohola-Baker, 2008)  which have been demonstrated to 
play a central role in controlling all the different stage of hematopoiesis. Specific 
miRNAs are highly expressed in specific hematopoietic lineages and manipulation of 
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their levels correlates with strong defects in cellular properties or differentiation (Chen 
et al., 2004). For example, miR-150 regulates B cell differentiation (Xiao et al., 2007), 
whereas miR-155 is required for T helper cell generation and germinal center activity 
(Rodriguez et al., 2007; Thai et al., 2007). Detailed role of miRNAs in hematopoiesis is 
discussed in the specific session (§1.3.5 and §1.3.6), however in summary, TFs and 
miRNAs may regulate each other in a complex regulatory network acting in concert in 
lineage decisions, stem cell to progenitor transitions, and niche control. 
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1.2 The Pbx1 transcription factor 
 
Pbx1 (pre-B-cell leukaemia transcription factor 1) is the product of a proto-oncogene 
originally discovered at the site of a chromosomal translocations in a pediatric B acute 
lymphoblastic leukaemia (B-ALL), where Pbx1 is fused with E2a leading to the 
formation of an oncogenic protein (Kamps et al., 1990; Nourse et al., 1990). Pbx1 is a 
transcription factor that binds DNA in complex with a wide subset of homeodomain 
proteins (like Hox, Meis and Prep, the last also known as PKnox), with which it forms 
hetero-oligomeric complexes (Moens and Selleri, 2006). In these dimeric and/or 
trimeric complexes, Pbx1 critically regulate developmental gene expression through 
modulation of Hox proteins binding and specificity to DNA, thus finely modulating 
their transcriptional effector functions in a context-dependent way (Saleh et al., 2000). It 
has recently been highlighted that Pbx1 also functions through other Hox-indipendent 
mechanisms to regulate gene expression. Moreover it may act marking specific genes 
for activation by penetrating repressive chromatin before other proteins that are later 
recruited as co-activators (Berkes et al., 2004). By modulating gene expression it 
regulates numerous embryonic processes, including morphologic patterning, axes 
specification and correct organogenesis. It is involved for example in skeletal 
patterning, pancreas development, nephrogenesis and ureteric branching in the 
developing kidney, and in hematopoiesis (DiMartino et al., 2001; Kim et al., 2002; 
Manley et al., 2004; Schnabel et al., 2003a; Schnabel et al., 2003b; Selleri et al., 2001). 
Pbx1 exerts different roles in development and adult life. During embryogenesis, it has 
been shown that Pbx1 promotes progenitor proliferation in multiple tissues (Moens and 
Selleri, 2006), including the hematopoietic system (DiMartino et al., 2001), while in the 
adult it positively regulates HSC quiescence (see §1.2.4). 
As mentioned, Pbx1 was originally isolated as a proto-oncogene due to its disruption in 
a t(1:19) chromosomal translocations, in a subset of pediatric acute lymphoblastic 
leukemias. In detail, the t(1;19) rearrangement determines the fusion of the Pbx1 
homeodomain with the transcriptional activation domains of the immunoglobulin 
enhancer–binding protein E2a (Kamps et al., 1990; Nourse et al., 1990). The derived 
E2a-Pbx1 chimeric oncoprotein retains the ability to bind DNA in complex with Hox, 
but not with other Pbx1 partners like Meis proteins (Chang et al., 1997), and causes 
aberrant proliferation of hematopoietic progenitors, finally leading to the leukemic 
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transformation by aberrant activation of Pbx1/Hox target genes (DiMartino et al., 2001; 
Moens and Selleri, 2006).  
 
1.2.1 Pbx1 classification and structure 
Pbx1 and the other Pbx proteins (Pbx2, Pbx3 and Pbx4) are mammalian homologues of 
the extradenticle (Exd) protein, first identified as cofactor for homeobox (Hox) 
transcription factors in Drosophila (Rauskolb et al., 1993). In addition to Hox, Pbx 
proteins form complexes with other homeodomain proteins like Meis and Prep, which 
have a role in controlling nuclear localization and promoting alternative DNA binding 
pattern (Berthelsen et al., 1999; Chang et al., 1997; Gonzalez-Crespo et al., 1998) 
(Figure 1.2.1).  
 
 
 
Figure 1.2.1 Phylogeny of Hox cofactors. TALE homeodomain proteins are divided into two groups: 
the PBC family, including the vertebrate Pbx proteins, fly Extradenticle and worm Ceh-20, and the MEIS 
family, including vertebrate Meis and Prep, fly Homothorax (Hth) and worm Unc-62. Orange letters 
indicate mouse proteins, purple lettering indicates their zebrafish orthologs (from Moens and Selleri, 
2006). 
 
Structurally Pbx1 belongs to the TALE (Three-Amino acid Loop Extension) 
superfamily of homeodomain transcription factor. Among this big TALE family, Pbx1 
is further classified in a particular subclass designed as the PBC subfamily, due to a 
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conserved PBC motif which is N-terminal to the TALE homeodomain (Burglin, 1997, 
1998) (Figure 1.2.1 and 1.2.2). The PBC subclass comprises the proteins Pbx1, Pbx2, 
Pbx3 (Monica et al., 1991) and Pbx4 in mammals (Wagner et al., 2001), Lazarus or Lzr 
in zebrafish (Popperl et al., 2000; Waskiewicz et al., 2001), as well as Extradenticle (or 
Exd) in Drosophila and Ceh-20 in C. elegans (Shanmugam et al., 1999; Shen et al., 
1999) (reviewed in (Laurent et al., 2008). 
 
 
 
Figure 1.2.2 Structure of TALE homeodomain proteins. Prototype members of PBC and MEIS classes 
are shown here. ‘‘a’’ and ‘‘b’’ refer to splice isoforms of Pbx and Meis proteins. See text for details. 
(from (Moens and Selleri, 2006)). 
 
All TALE homeodomain proteins are characterized by this divergent homeodomain 
(HD) composed by a 3 amino acid loop extension (TALE) located between the first and 
second a-helices.  The TALE motif virtually always contains a proline (P)– tyrosine 
(Y)– proline (P) in positions 24– 26 (Burglin, 1997, 1998) (Figure 1.2.2), which is the 
domain responsible for the interaction with the hexapeptide motif of Hox proteins 
(Piper et al., 1999). The HD contains a DNA-binding motif and interacts with a subset 
of different Hox proteins, enhancing their DNA binding affinities and specificities. Tale 
proteins act together in a complex transcriptional regulatory network whose function in 
vivo is not fully understood, since most of the data about DNA sequence specificity of 
these factors are based on in vitro studies and on the analysis of a limited number of 
endogenous target sequences. The in vivo binding property of these proteins is more 
complex, since Pbx proteins and their partners have preferential functional interactions 
that also change their DNA binding site specificity (see also §1.2.3). 
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1.2.2 Pbx1 isoforms 
Pbx2 and Pbx3 were discovered on the basis of their homology to Pbx1, while Pbx4 
was first identified in zebrafish as a mutant in which Hox-dependent patterning events 
were disrupted (Popperl et al., 2000; Waskiewicz et al., 2002). Subsequently, Pbx4 gene 
has been identified in mammals. Pbx4 is expressed exclusively in the testis (Wagner et 
al., 2001) and is not orthologous to zebrafish pbx4 (Moens and Selleri, 2006). Pbx1, 
Pbx2, Pbx3 and Pbx4 genes encode products with high level of sequence identity. 
Alternative splicing of these genes leads either to larger (Pbx1a, Pbx2, Pbx3a and Pbx4) 
or shorter (Pbx1b, Pbx3b, Pbx3c and Pbx3d) isoforms (Milech et al., 2001; Monica et 
al., 1991; Wagner et al., 2001). The different Pbx proteins and isoforms can be 
discriminated on the basis of biochemical studies, either by their DNA binding 
properties or their dimerization capacity. First, Pbx proteins show different DNA 
binding properties. Indeed, although in vitro they recognize the same DNA consensus 
sequence, Pbx1 is not able to bind DNA without partners, while Pbx2 and Pbx3 can do 
it. Second, there are some differences in the homo dimerization ability of Pbx proteins. 
Some studies demonstrated that homodimerization is only a Pbx3 capability 
(Neuteboom and Murre, 1997), while others reported it also for Pbx1a and Pbx1b 
(Calvo et al., 1999). However, all these studies are based only on in vitro approaches 
and the results remain controversial. Nevertheless the Pbx homodimerization could be 
important for gene regulation through a competitive mechanism between Pbx itself and 
various partners for binding to specific gene promoters (Laurent et al., 2008). 
Regarding the functions of these different Pbx genes, the early studies reported in 
zebrafish suggested that the functional differences between Pbx isoforms are likely due 
to differences in their expression rather than in their activities (Popperl et al., 2000). 
Consistent with this observation, the in vitro DNA-binding properties of different Pbx 
proteins appear very similar (Chang et al., 1996). Nevertheless in mammals the situation 
appears more complex and there are several evidences of functional differences among 
the different Pbx isoforms. Indeed with the differential splicing Pbx proteins loose 
functional domains leading to proteins with different function and dimerization 
capabilities (Ferretti et al., 1999). 
Another example of divergent properties between different Pbx isoforms comes from 
studies on interaction between Pbx1 and the pancreatic specific homeodomain factor 
Pdx1 (Peers et al., 1995). The dimer Pdx1/Pbx1b acts as a transcriptional activator 
through the Pdx1 activation domain, while the other dimer Pdx1/Pbx1a acts as a 
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transcriptional repressor complex. The difference is due to different capability of co-
repressors recruitment. Indeed, the Pbx1a isoform possesses a C-terminus domain that 
binds co-repressor proteins SMRT and NcoR, while the Pbx1b isoform lacks this 
domain and is consequently unable to recruit these factors (Asahara et al., 1999). In 
addition to their different biochemical properties, Pbx isoforms exhibit also some 
specificity in expression pattern both in a tissue specific and developmental specific 
manner. For example Pbx1a isoform is restricted to the brain, whereas Pbx1b is 
expressed in the whole body. Furthermore, Pbx1b is the major embryonic isoform while 
Pbx1a is found mostly during adulthood (Schnabel et al., 2001). Moreover, expression 
of some Pbx isoforms seems to be preferential in certain pathologic contexts. Indeed, 
expression of Pbx3d is observed in normal cells, whereas Pbx3c expression is mostly 
found in leukaemia cells (Milech et al., 2001) (reviewed in (Laurent et al., 2008). 
 
1.2.3 Pbx1 partners 
Hox proteins 
The best known class of Pbx1 partners is the Hox protein family. Hox proteins 
form a family of transcription factors, characterized by a very highly conserved DNA-
binding homeodomain (HD), that specify antero-posterior identities during development 
throughout the animal kingdom. In mammalians there are 39 Hox genes, classified in 13 
paralog groups within four separate clusters (A, B, C and D). Although these proteins 
regulate developmental programs in a very specific manner, they all bind in vitro to a 
TAAT core sequence which is very frequent along the DNA and occurs approximately 
once every 500 base pair within the genome (Galant et al., 2002). Chromatin 
Immunoprecipitation (Calvi et al.) experiments performed in vivo to search Hox target 
genes confirmed that these proteins bind DNA in a widespread fashion on TAAT 
sequences (Carr and Biggin, 1999; Walter et al., 1994; Williams et al., 2005). Moreover 
the binding affinity is not very high. To explain this apparent paradox between the low 
DNA specificity and the high specificity in regulating distinct developmental programs 
of these proteins, a “quantitative model” was hypothesized, according to which the level 
of Hox proteins could be more important rather than their nature (Duboule, 2000). This 
theory is consistent with some elegant experiments in which the coding sequence of 
mouse Hoxa3 and Hoxd3 genes were exchanged, showing a total functional equivalence 
between the two paralogs (Greer et al., 2000). However, other data clearly demonstrate 
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that the quantitative model is not exhaustive and that there are specific differences in the 
biochemical properties of Hox proteins, which specifically regulate their function. For 
example mice in which the Hoxa11 HD has been exchanged with the Hoxa13 HD 
exhibit an abnormal development, resulting from a Hoxa13 posterior mediated 
phenotype (Zhao and Potter, 2001). These data demonstrate that, despite the HD is 
highly conserved and some Hox proteins could have overlapping functions, there are 
some differences which lead nevertheless to a different regulation of genetic programs. 
Another explanation for the low Hox DNA binding specificity is that it increases and 
changes according to recruitment of different cofactors. Indeed, oligomerization with 
TALE cofactors increases Hox DNA binding specificity since Hox/Pbx DNA sites 
occur once every 8,200 base pair and Hox/Pbx/Meis once every 420,000 base pairs 
(Laurent et al., 2008). 
 
Meis and Prep 
Another class of TALE homeodomain proteins, which regulates both Hox and 
Pbx activities, is the Meis/Prep subclass (Berthelsen et al., 1998; Burglin, 1998; Chang 
et al., 1997; Chen and Capecchi, 1997; Knoepfler et al., 1997; Moskow et al., 1995). 
The MEIS class includes Homothorax (Hth) in flies and the Meis and Prep proteins in 
vertebrates (Figure 1.2.1). Meis/Prep proteins interact directly with Pbx proteins and are 
important for the DNA binding of the Pbx/Hox complex, recognizing a specific 
sequence on the regulatory regions of target genes (Ebner et al., 2005; Ferretti et al., 
2000; Jacobs et al., 1999; Mann and Affolter, 1998; Ryoo et al., 1999). Moreover, 
Meis/Prep proteins are involved in nuclear targeting (Abu-Shaar et al., 1999; Berthelsen 
et al., 1999; Jaw et al., 2000; Mercader et al., 1999; Rieckhof et al., 1997) and stability 
(Jaw et al., 2000; Longobardi and Blasi, 2003; Waskiewicz et al., 2001) of Pbx proteins 
(reviewed in (Moens and Selleri, 2006). As mentioned above, Pbx1 interacts with 
Meis1/pKnox1 predominantly with the N-terminal domain. The architecture of the 
Pbx1/Meis1–DNA complex is similar to that of Pbx/Hox–DNA complexes but with 
some differences. Meis1, like Hox proteins, is thought to bind 3’ of the TGAT Pbx1 
half-site but DNA-binding specificity and stability of Pbx/Meis complexes are very 
different from those of Pbx/Hox complexes, since they equally recognize some DNA 
motif while specifically some others. Therefore Pbx/Meis and Pbx/Hox complexes 
could regulate either distinct or overlapping subsets of genes (Knoepfler et al., 1997). 
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Both Prep1 and Meis1 dimerize with Pbx and recognize similar DNA sequences in vitro 
but there are some functional differences in the region where they bind. While Prep1 
interacts preferentially with promoters and nearby regions, Meis shows preferential 
binding for intergenic and intragenic regions away from transcription starting site 
regions. Prep could thus be directly involved in regulating promoter, while Meis sites 
coincides with enhancers functions. In addition, Prep mostly participates in dimer 
formation with Pbx, while Meis is predominantly found in trimeric complexes together 
with Pbx/Hox (Penkov et al., 2013). 
Since Pbx1 is also able to bind to Meis/Prep proteins but in interaction surfaces 
independent from those of Hox, it can form trimers with Prep or Meis and Hox, thus 
further modulating the DNA-binding selectivity of the individual proteins (Ferretti et 
al., 2000; Jacobs et al., 1999; Penkov et al., 2013; Ryoo et al., 1999). 
While earlier work on in vitro Pbx1-Hox binding sites suggested that the sequence 
specificity of a given Pbx/Hox complex was defined (Chan et al., 1997; Ryoo et al., 
1999), more recent evidences have indicated that the sequence requirements for DNA 
binding by Hox complexes are difficult to predict (Ebner et al., 2005). The complexity 
is based not only on the multiple possible combinations between Pbx and the numerous 
members of the Hox family, but also on the existence of various isoforms of Pbx 
proteins. Indeed, most of the studies on Hox/Pbx interactions were performed with 
Pbx1, or the drosophila analogue Exd, while other PBC proteins were assumed to 
behave identically (Laurent et al., 2008).  
 
Other Pbx1 binding proteins 
Increasing evidences showed that Pbx function is not restricted to partnership 
with Hox or other homeodomain proteins. A recent two-hybrid screen revealed that only 
6% of putative Pbx1 partners correspond to homeodomain proteins and only 18% are 
transcription factors. For example other Pbx interacting proteins are involved in 
cytoskeleton assembly and/or regulation (Huang et al., 2003). The increasing amount of 
non-homeodomain Pbx1 partners points out that Pbx proteins exert some of their roles 
in development via still unexplored Hox-independent pathways (Laurent et al., 2008). 
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1.2.4 Pbx1 in hematopoiesis 
In the hematopoietic system Pbx1 shows different roles in the embryo compared to the 
adult. During murine development Pbx1 is expressed in hematopoietic progenitors, 
where it promotes their proliferation, and its absence results in severe anemia and 
embryonic lethality at embryonic day 15 (E15) or E16 (DiMartino et al., 2001). 
Conversely, in the adult it is preferentially expressed in HSCs compared MPPs 
(Forsberg et al., 2005; Kiel et al., 2005), and positively regulates their quiescence. 
Postnatal hematopoiesis is profoundly perturbed in the absence of Pbx1, with severe 
reduction of HSCs due to an extreme self-renewal defect leading to non-functional stem 
cells (Ficara et al., 2008). Indeed, using two Pbx1 conditional knockout mouse models, 
it was demonstrated that its absence in postnatal HSCs causes their excessive 
proliferation and premature differentiation, ultimately leading to their exhaustion, an 
effect possibly mediated by perturbation of the TGF  pathway. In addition to the HSC 
defect, Pbx1 conditional knockout mice also exhibit significant reductions in multi-
potent and lineage-restricted progenitors, both common myeloid progenitors (CMPs) 
and common lymphoid progenitors (CLPs) (Ficara et al., 2008). The role of Pbx1 in 
multi-potent and lineage restricted progenitors will be the object of the result section 
(§3.1). 
 
1.2.5 Pbx1 knock-out (KO) mouse models 
The study of Pbx functions takes advantage from several mouse models in which 
individual Pbx proteins are constitutively or conditionally deleted. 
Constitutive KO for Pbx1, 2 and 3 have been generated (Rhee et al., 2004; Selleri et al., 
2001; Selleri et al., 2004). Some of these mice show partially overlapping phenotypes, 
indicating some redundant Pbx functions. In addition, while Pbx1 KO mice (especially 
those with no Pbx1 or Pbx3) exhibit some overlapping features with Hox deficient 
mice, thus highlighting the role of Pbx proteins as Hox cofactors, they do not perfectly 
phenocopy single or multiple mutants for Hox genes, showing also Hox-indipendent 
Pbx functions  (Laurent et al., 2008). 
Constitutive Pbx1 KO mice die at E15.5/16.5, displaying severe hypoplasia (lungs, 
liver, stomach, gut, kidneys and pancreas), ectopia (thymus and kidneys) or aplasia of 
multiple organs (spleen, adrenal gland), as well as widespread skeletal malformations 
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(Selleri et al., 2001). Pbx3-deficient mice die a few hours after birth from central 
respiratory failure due to abnormal activity of inspiratory neurons where Pbx3 is highly 
expressed (Rhee et al., 2004). In contrast with the premature death of Pbx1 or Pbx3 KO 
mice, Pbx2-deficient mice are viable and display no evident phenotype, despite the 
widespread expression of the gene during embryogenesis (Selleri et al., 2004). This 
suggests that loss of Pbx2 is compensated by other Pbx members. 
Since Pbx1 KO mice are embryonic lethal, to study its function in the adult it is 
necessary to conditionally inactivate it. For the experiments described in the Results 
session two Pbx1-conditional KO mouse models were used, Tie2Cre
+
.Pbx1
-/f
 mice and 
Mx1Cre
+
.Pbx1
-/f
 mice. To generate both models Floxed-Pbx1 (Pbx1
f/f
) mice are 
intercrossed with mice expressing Cre recombinase under a specific promoter able to 
induce Pbx1 deletion starting from HSCs  (Joseph et al., 2013).  
In the Tie2Cre
+
.Pbx1
-/f
 mice, that we used in the present study, Pbx1 deletion occurs 
specifically in HSCs and endothelial cells starting early during development, in the 
AGM region. In detail, these mice are obtained by intercrossing homozygous Pbx1 
floxed mice (Pbx1
f/f
), in which Pbx1 gene is flanked by Lox-P sites, with 
Tie2Cre
+
.Pbx1
+/-
 mice, harboring a heterozygous deletion in the Pbx1 allele (Selleri et 
al., 2001) and the Cre recombinase under the control of the Tie2 promoter (Figure 
1.2.3). Tie2Cre
+
.Pbx1
+/-
 mice are obtained in our animal house by crossing Tie2Cre
+
 
with Pbx1
+/-
 mice (see matherials and meyhods, §5.1). 
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Figure 1.2.3 Crossing scheme to generate Pbx1 conditional KO mice. Mutant mice are generated by 
crossing Pbx1
f/f 
mice with mice expressing Cre recombinase under a specific promoter able to induce 
Pbx1 deletion in HSCs. Bottom right: schematic representation of pharmacological Cre induction by 
poly(I:C) treatment in Mx1Cre
+
.Pbx1
-/f
 mice. Tie2Cre
+
.Pbx1
+/-
 and Mx1Cre
+
.Pbx1
+/-
 breeders are not 
commercially available and need to be generated by crossing Cre
+
 mice with Pbx1
+/-
 mice. Those lines 
are then maintained by intercrossing with C57BL/6 wt mice. 
 
Tie2 encodes a tyrosine kinase receptor specific to angiopoietin which is expressed both 
by endothelial cells, where it is important for angiogenesis (Maisonpierre et al., 1997; 
Schnurch and Risau, 1993), and by hematopoietic cells, where it plays a critical role in 
HSC quiescence (Arai et al., 2004; Takakura et al., 1998). Consistent with the role of 
Tie2 in angiogenesis and hematopoiesis, Cre-recombinase under the control of the Tie2 
promoter (as in Tie2Cre mice) specifically drives Cre expression in endothelial cells 
and HSCs (Chang et al., 2004; Constien et al., 2001; Kisanuki et al., 2001; Tang et al., 
2010). In our model, one Pbx1 allele is constitutively deleted while the other is floxed. 
In this way Cre-mediated Pbx1 inactivation is more efficient. When Cre recombinase is 
expressed, tissue-specific inactivation of Pbx1 is achieved, due to deletion of exon 3 of 
the floxed allele. With this crossing scheme (Figure 1.2.3, left) 25% of mutant mice are 
obtained. Tie2Cre
+
.Pbx1
-/f
 mice are viable but display a short life span and die of 
unknown causes between 3 and 7 weeks of age. 
Another Pbx1 KO mouse model is the Mx1Cre
+
.Pbx1
-/f
 inducible KO (Figure 1.2.3, 
right). In this model Pbx1
f/f 
mice are crossed with the inducible Mx1Cre
+
 line in which 
the Cre expression is driven by the Myxovirus resistance-1 (Mx1) promoter. Mx1 is a 
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component of the defense mechanism against viruses and its expression can be highly 
induced in response to type I interferon. Cre recombinase under the control of the Mx1 
promoter can be pharmacologically activated by the administration of Poly(I:C), a 
synthetic analog of double-stranded RNA (dsRNA) (Kuhn et al., 1995). Poly(I:C) is 
recognized by toll like receptor 3 (TLR3) and mimics a viral infection leading to the 
activation of NF-kB and the production of cytokines, which in ultimate activate the 
interferon-inducible Mx promoter and, in this case, the consequent deletion of the Pbx1 
gene.  
The two models are equivalent in term of the resulting HSC phenotype (Ficara et al., 
2008), although in The Mx1-Cre models in a minority of cells Pbx1-deletion does not 
occur. Despite this functional equivalence there are advantages and disadvantages in 
using these two mouse models, which make them more useful for some experiments 
than others. Mice with complete deletion of Pbx1, like in the Tie2Cre
+
.Pbx1
+/f
 model, 
display severe defects in lineage restricted progenitors (CLPs and CMPs) in addition to 
HSCs (Ficara et al., 2013; Ficara et al., 2008), and therefore, even if they are more 
difficult to manage, due to their precocious death and the fact that their BM have fewer 
cells, represent the ideal system for studying Pbx1 function not only in the HSC 
compartment but also in their downstream progenitors. Conversely, the Mx1Cre
+
.Pbx1
-/f
 
model gives the advantage, being inducible, to delete Pbx1 when mice are adult 
enabling an easier management of the mouse colony and, more important, a higher 
number of cells, since Pbx1-null HSCs can be analyzed prior to their exhaustion (that 
occurs as a consequence of Pbx1 deletion).  On the other hand, even if Pbx1 deletion is 
quite efficient in HSCs from the inducible model, the very few un-deleted cells have a 
selective advantage in generating downstream progeny. Thus this model is not suited for 
the experiments performed with progenitors downstream to HSCs.   
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1.3 Micro-RNAs 
MicroRNAs (miRNAs) are small (18-24 nucleotides) endogenous single-stranded non-
protein coding RNA molecules that have emerged as crucial transcriptional and 
posttranscriptional regulators of gene expression. They act by binding messenger RNA 
(mRNA) sequences through an imperfect match, mostly in the 3’UTR of the transcript 
(Ambros, 2004; Chen and Rajewsky, 2007). Their binding to the mRNA target leads 
either to mRNA degradation or to the inhibition of its translation into protein, ultimately 
resulting in gene silencing (Baek et al., 2008; Bartel, 2004; Rana, 2007).  
The first miRNAs were identified in the early 1990s in C. elegans (Lee et al., 1993). 
However they were not recognized as a distinct class of biological regulators with 
conserved functions until 2001, when the term “microRNA” was used for the first time. 
Indeed at that time this mechanism of gene regulation was thought to be restricted to 
nematodes rather than to be a broad evolutionary conserved process. Since their 
discovery a lot of progresses have been made in studying miRNA expression and in 
understanding their function and mechanisms of action, and thousands of miRNAs have 
been found in many other organisms, from plants to mammalians. In plants and animals, 
although core components of the microRNA pathway are highly conserved, there are 
some differences in miRNA function and biogenesis, suggesting that they arose 
independently in the two kingdoms. Plant miRNAs usually have perfect or near-perfect 
pairing with their mRNA targets and induce gene repression through degradation of 
their target transcripts (Brodersen et al., 2008; He and Hannon, 2004). Moreover plant 
miRNAs may bind their targets both in coding regions and untranslated regions (He and 
Hannon, 2004). In contrast, animal miRNAs typically have only partial 
complementarity to their target, and induce their down regulation both by inhibition of 
translation and mRNA degradation. In addition, most of the animal miRNAs bind to the 
3’UTR of their targets. Regarding prokaryota, whilst short RNA sequences (50 – 
hundreds of base pairs) of a broadly comparable function occur in bacteria, bacteria lack 
true microRNAs  (Fahlgren et al., 2010).  
By finely affecting gene regulation, miRNAs are likely to be involved in several 
biological processes, starting from development to adult life. It is now well established 
that they are involved in the proper function of different organs and tissues (Brennecke 
et al., 2003; Chen et al., 2004; Cuellar and McManus, 2005; Harfe et al., 2005; Lagos-
Quintana et al., 2002; Lim et al., 2005; Poy et al., 2004; Wilfred et al., 2007) and that 
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they are key regulators in several critical cellular processes including proliferation, cell 
cycle progression, metabolism, survival, apoptosis and response to changes in 
environment (Bartel, 2009). Moreover, miRNAs have been shown to be important 
regulators of stem cell development by playing a critical role both in their maintenance 
and differentiation (Yi and Fuchs, 2011). 
As transcription factors, different sets of miRNAs are expressed in different cell types 
and tissues, and misregulation of their expression is also associated with several 
diseases including cancer where miRNAs could have tumour suppressive or tumour 
promoting functions depending on the nature of their target mRNAs (Calin and Croce, 
2006). Regarding the role of miRNAs in disease, there are also new emerging miRNA-
based therapies under investigation (Trang et al., 2008). 
According to Sanger miRNA registry (miRBase version 20), 1186 precursors and 1908 
mature miRNAs have been identified in the mouse genome to date, which may target 
about 60% of the genes (Friedman et al., 2009; Lewis et al., 2005), making them one of 
the most abundant class of gene-regulatory molecules in animals. Each miRNA could 
repress the expression of many, perhaps hundreds, of target genes, and one gene could 
be regulated by several miRNAs, thus leading to a widespread change in gene 
expression and highlighting the extent of this form of regulation in mammals 
(Berezikov et al., 2005; Selbach et al., 2008). 
 
1.3.1 Nomenclature 
There is a standard nomenclature system for miRNAs, strictly regulated by the miRBase 
Registry on the basis of established guidelines (Ambros et al., 2003). In order to 
minimize gaps and misunderstanding in the naming scheme, and to guarantee the 
validity of submitted miRNAs through a peer review process, names are assigned by the 
Registry after a manuscript describing their discovery is accepted for publication. 
Official gene names should be incorporated into the final version of the manuscript. The 
nomenclature guidelines require that novel miRNA genes are experimentally verified by 
cloning or with evidence of expression and processing (except for homologous miRNAs 
from related organisms identified by sequence analysis methods, the name of which can 
be assigned without further experimental evidence) (Ambros et al., 2003; Griffiths-
Jones et al., 2006; Griffiths-Jones et al., 2005). According to these rules, microRNA are 
named with the prefix "mir" followed by a dash and a number which often indicates 
progressive order of naming. The uncapitalized "mir" refers to the pre-miRNA, while a 
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capitalized "miR-" refers to the mature form. An additional lower case letter following 
the main identification number identifies miRNAs with nearly identical sequences 
except for one or two nucleotides. For example, miR-123a would be closely related to 
miR-123b. Regarding the precursors, pre-miRNAs that give rise to identical mature 
miRNAs but are located in different sites in the genome are indicated with an additional 
dash-number suffix, always following the main identification number. For example, the 
pre-miRNAs mir-194-1 and mir-194-2 lead to an identical mature miRNA (miR-194) 
but are located in different genome regions. When two different mature microRNAs 
arise from the two opposite arms of the same pre-miRNA, they are identified with a -3p 
or -5p suffix, and when the relative expression levels of the two forms are known, an 
asterisk following the name indicates the miRNA expressed at lower levels relative to 
the miRNA in the opposite arm of a hairpin. For example, miR-123 and miR-123* 
would share a common pre-miRNA hairpin, but miR-123 would be found higher 
expressed. The species of miRNAs origin is designated with a prefix of three-letter, e.g., 
mmu-miR-123 is a mouse (Mus musculus) miRNA and hsa-miR-123 is a human 
miRNA. There are also other common prefixes including 'v' for viral, which are miRNA 
encoded by a viral genome, and 'd' for Drosophila miRNA. 
 
1.3.2 miRNA biogenesis and mechanisms of action 
Mature miRNAs are generated by multiple processing steps of sequential 
endonucleolytic cleavages (Figure 1.3.1), which occur in part into the nucleus and in 
part into the cytoplasm. Micro-RNA genes are encoded by genomic DNA and can be 
found either within protein coding genes, both in introns and exons, or transcribed from 
their own genes in intergenic regions. The majority of characterized miRNA coding 
sequences are intergenic or oriented antisense to neighboring genes. However, as much 
as 40% of miRNA coding sequences may lie in the introns of protein and non-protein 
coding genes or even in exons of long non protein-coding transcripts (Lau et al., 2001). 
In the latter case the microRNA sequence could be transcribed together with its host 
gene leading to a coupled regulation of miRNA and protein-coding gene. Other miRNA 
genes show a common promoter and their transcription gives rise to a polycistronic unit 
containing multiple discrete loops, from each of which mature miRNAs are processed 
(Reinhart et al., 2000; Rodriguez et al., 2004). The common promoter does not 
necessarily imply that mature miRNAs of a family will be homologous in structure 
and/or function. Moreover, from the common transcript only part of the individual 
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miRNAs may be finally processed. Alternatively, certain miRNAs, such as the miR-17–
92 family, which are grouped in clusters on a single unprocessed transcript, are 
expressed together. 
 
 
Figure 1.3.1 miRNA biogenesis. Canonical and non-canonical pathways of miRNA biogenesis are 
shown. See text for details. (from (Gangaraju and Lin, 2009)) 
 
Micro-RNAs are mostly transcribed in the nucleus by RNA polymerase II, even if a 
small contribution by RNA polymerase III has also been described (Borchert et al., 
2006), and regulation of transcription is performed by the same transcription factors that 
control transcription of coding genes (Cai et al., 2004; Lee et al., 2004). The first 
product of the transcription is a large RNA primary transcript, called pri-miRNA, which 
is thousands nucleotide long and contains a characteristic hairpin stem loop structure. 
As the traditional messenger RNAs, Pri-miRNAs are capped with modified nucleotides 
at the 5’ end and polyadenlylated with multiple adenosines (poly(A) tail) at the 3’ end  
(Lee et al., 2004; Reinhart et al., 2000). A single pri-miRNA may contain from one to 
six miRNA precursors. As mentioned above, the transcription of some miRNAs is 
mediated by RNA polymerase III although this mechanism is less represented. RNA 
polymerase III (Pol III) indeed transcribes only some miRNAs, especially those with 
upstream Alu sequences, transfer RNAs (tRNAs), and mammalian wide interspersed 
repeat (MWIR) promoter units (Weber, 2005). In the canonical pathway, pri-miRNAs 
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are then processed in the nucleus into an intermediate structure, called pre-miRNAs, by 
a microprocessor complex, which contains the RNase III enzyme Drosha and the 
double-stranded RNA-binding protein DiGeorge syndrome critical region gene 8 
(DGCR8; also known as Pasha in invertebrates) (Denli et al., 2004; Kim and Kim, 
2007; Lee et al., 2003). Recent data suggest that this processing occurs co-
transcriptionally (Morlando et al., 2008). In this complex, DGCR8 recognizes the 
double-stranded RNA structure in the hairpins of the pri-miRNA and correctly orients 
the catalytic RNase III domain of Drosha in order to cleave the hairpins from pri-
miRNAs. The resulting product is a shorter 60–70 nucleotides hairpin structure 
precursor with a two-nucleotide overhang at its 3’ end (Figure 1.3.2). 
An alternative miRNA biogenesis pathway has been recently reported (Figure 1.3.1). 
Specifically, some miRNAs, called “mirtrons” (since they are embedded within an 
intron of a gene) have been shown to be generated directly from the intron by 
spliceosome and a debranching enzyme that yields a short hairpin structure ready for 
further processing. Thus following this alternative splicing pathway they bypass the 
Microprocessor complex processing (Ruby et al., 2007). In both the canonical and 
mirtron pathways, pre-miRNA hairpins are then subsequently translocated from the 
nucleus into the cytoplasm by the nucleo-cytoplasmic shuttle Exportin-5-Ran-GTP 
(Bartel, 2009). Exportin-5, which is a member of the karyopherin family, recognizes the 
two-nucleotide overhang left by Drosha at the 3' end of the pre-miRNA hairpin and 
mediates the transport to the cytoplasm through GTP bound to the Ran protein 
(Bohnsack et al., 2004; Gregory et al., 2006). 
Upon reaching the cytoplasm, the pre-miRNA hairpin is further processed by another 
RNase III enzyme, Dicer. This endoribonuclease interacts with the 3' end of the hairpin 
and cuts away the single stranded loop yielding a shorter imperfect paired double-
stranded miRNA (miRNA duplex) about 22 nucleotides long with 2 nt overhangs on the 
3′ end. Overall hairpin length and loop size influence the efficiency of Dicer processing, 
and the imperfect nature of the miRNA duplex also affects cleavage (Berezikov et al., 
2007; Kawahara et al., 2008). The duplex is unwound by Dicer and one strand is then 
loaded, again by Dicer, into the multicomponent ribonucleoprotein complex called 
RISC (RNA-induced silencing complex) (Ambros, 2004; Bartel, 2009), which is the 
cellular machinery for ultimate gene regulation. RISC contains an Argonaute-subfamily 
member, which binds to the miRNA and guides RISC towards the mRNA target. 
Argonaute proteins are essential to RISC function. They contain two conserved RNA 
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binding domains: one of them, a PAZ domain, binding the single stranded 3’ end of the 
mature miRNA, and the second one, a PIWI domain, that interacts with the 5’ end of the 
guide strand. These two domains act together in order to bind the mature miRNA and 
properly orient it for subsequent interaction with the mRNA target. Although both 
strands of the duplex may potentially act as miRNAs, only one strand is usually 
functional and incorporated into the RISC, on the basis of its thermodynamic instability 
and weaker base-pairing relative to the other strand (Ji, 2008; Lelandais-Briere et al., 
2010). Indeed, the strand of the duplex with a less thermodynamically stable 5’ end, 
called the guide strand miRNA, is preferentially embedded with (RISC) (Schwarz et al., 
2003). The other strand, called the passenger strand and denoted with an asterisk 
(miRNA*), is released and degraded (Krol et al., 2010). However, in some cases both 
strands of the duplex may be incorporated into RISC and function as miRNAs that 
target different mRNA populations (Schwarz and Zamore, 2002). The mature miRNA 
associated to the RISC interacts with the mRNA target mostly through an imperfect 
match between the miRNA and the 3’UTR (the sequence located downstream of the 
stop codon) or, in few cases, the coding region of the target mRNA leading to inhibition 
of translation and/or a decrease in mRNA stability (Chekulaeva and Filipowicz, 2009; 
Filipowicz et al., 2008; Rigoutsos, 2009). mRNA cleavage occurs when the 
complementarity is perfect while inhibition of protein translation when complementarity 
is imperfect (Ambros, 2004; Bartel, 2009). A critical miRNA sequence is responsible 
for target recognition. This sequence, called “seed sequence” is composed by 
nucleotides 2–8 (counted from the 5’ end) and is the part of the mature miRNA that 
hybridizes nearly perfectly with the target mRNA (Bartel, 2009; Lai, 2002). As 
previously described, the mechanism by which miRNAs regulate gene target silencing 
depends on the degree of complementarity between the miRNA and the target mRNA 
(Figure 1.3.2). If complementarity is perfect, miRNA induces degradation of the target 
mRNA through endonuclease activity of Ago2. This mechanism is frequent in plants 
but rare in mammalian cells (Yekta et al., 2004). Conversely, imperfect pairing results 
in repression of target mRNA translation. This occurs either at the initiation step or at 
the elongation step, and/or by sequestration of target mRNAs into cytoplasmic 
processing bodies (P-Bodies) where mRNA targets will be degraded through 
deadenylation pathways (Guo et al., 2010a). However these mechanisms are not entirely 
understood. Regardless of the mechanism, the final outcome is a reduction in protein 
levels. 
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Figure 1.3.2 complementarity on miRNA/mRNA drives mechanism of gene repression. See text for 
detail (from (Esquela-Kerscher and Slack, 2006)) 
 
 
Although the main conventional miRNAs function is to silence gene expression, it has 
been shown that miRNAs could occasionally work by activating the translation of its 
targets and regulating their stability (Vasudevan et al., 2007). However additional 
experiments are needed to better understand this phenomenon. 
The degree of downregulation of a single target is quantitatively modest (generally less 
than 50%), therefore miRNAs can induce subtle changes and fine tune gene expression 
(Baek et al., 2008). Nevertheless there is a strong synergistic effect since a single 
miRNA can potentially target hundreds of different target genes simultaneously and, at 
the same time, multiple miRNAs can target a single mRNA (Ambros, 2004; Bartel, 
2009). The outcome of this complex network is a widespread gene expression 
regulation by miRNAs. 
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1.3.3 Regulation of miRNA 
miRNA biogenesis is subject to tight regulation at multiple levels, since a defined 
spatiotemporal pattern of miRNA expression is very important for their proper function. 
In this regard, regulatory mechanisms by which cells control miRNA production and 
function have recently come into light (Davis-Dusenbery and Hata, 2010; Krol et al., 
2010). The regulation of miRNA expression and function mainly occurs at three levels: 
transcription, processing and subcellular localization. miRNAs are initially regulated at 
the transcriptional level by transcription factors, which regulate the expression of 
different pri-miRNAs in a cell type- or development-dependent way or in response to 
different environmental stimuli. The transcription itself is regulated in a similar manner 
to the protein coding genes, with several mechanisms including DNA methylation and 
histone modification of the miRNA promoter. A second level of regulation occurs 
during miRNA processing, where several post-transcriptional regulatory mechanisms 
have been recently identified. These mechanisms function at various stages of miRNA 
processing, starting from the initial primary transcript to the delivery of mature, single 
stranded miRNAs to the target mRNAs. Thus, miRNAs coming from the same 
polycistronic transcript can be expressed differently (Tsuchida et al., 2011). Examples 
of factors involved at this level are the small mother against decapentaplegic (SMAD) 
proteins. These transcription factors, upon activation by TGF- and bone morphogenic 
protein signaling, enhance processing of pri-miRNAs, such as mir-21, which in turn 
regulate cell differentiation (Davis et al., 2008). Another example is the tumour 
suppressor protein p53, which has an important role in miRNA processing following the 
onset of DNA damage. p53 forms a complex with Drosha and induces increased 
maturation of pri-miRNAs to pre-miRNAs, especially those miRNAs that suppress cell 
growth (Suzuki et al., 2009). Both mechanisms (mediated by SMAD and p53) involve 
binding to an RNA helicase (p68) that boosts microprocessor function. Moreover, after 
transport into the cytoplasm, some pre-miRNAs are subjected to post-transcriptional 
modifications catalysed by terminal uridylyltransferase 4 (TUT4). For example lin-28, 
which is one of the let-7 targets, can physically interact with the pre-let-7 in the 
cytoplasm of embryonic stem cells, promoting its polyuridylation. This modification 
directly inhibits Dicer processing and induces degradation of pre-let-7, thus preventing 
its further processing and inhibiting its function (Hagan et al., 2009; Heo et al., 2008; 
Heo et al., 2009). Regulation of miRNAs can also be mediated by subcellular 
localization mechanisms. For example on reaching maturation, delivery of the RISC 
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containing fully processed miRNA guide strand to target mRNA has been shown to 
involve importin 8 (Weinmann et al., 2009).  
Another non canonical level of regulation is RNA editing, although only a small 
fraction of pre-miRNAs may be altered through this mechanism (Blow et al., 2006; 
Luciano et al., 2004). RNA editing is the site-specific modification of RNA sequences 
which leads to products that are different from those encoded by their DNA. It occurs 
most commonly through adenosine deaminases enzymes acting on RNA (ADARs) 
which catalyze adenosine to inosine transitions.  
The last level of miRNA regulation is their turnover. Despite miRNAs are highly stable 
molecules, with a half-life of hours or even days (Krol et al., 2010), turnover of mature 
miRNAs is needed to allow the rapid changes in their expression profiles, which is in 
turn necessary to regulate the developmental and differentiation status of the cells where 
they act. Often these processes must occur rapidly and miRNA levels should change 
accordingly. Thus, miRNA decay needs to be tightly regulated and recent studies have 
identified specific exonucleases regulating miRNA turnover in plants and worms 
(Chatterjee and Grosshans, 2009; Ramachandran and Chen, 2008). Decay of mature 
miRNAs in C. elegans is mediated by the 5´-to-3´ exoribonuclease XRN2, also known 
as Rat1p (Chatterjee et al., 2011), while in plants, SDN (small RNA degrading 
nuclease) family members degrade miRNAs in the opposite (3'-to-5') direction. Similar 
enzymes are encoded in animal genomes, however a specific role for miRNAs turnover 
control in mammals is under investigation (Krol et al., 2010).  
Finally miRNA function could be also regulated by controlling levels and activity of the 
key processing proteins, like Drosha, Dicer and their partners (Davis-Dusenbery and 
Hata, 2010). For example, during immune responses, cytokines such as interferons have 
been shown to inhibit Dicer expression, decreasing the processing of pre-miRNAs 
(Wiesen and Tomasi, 2009). This mechanism could also be employed to accumulate 
several pri-miRNAs, without being fully processed, until the right developmental or 
environmental stimuli arise (Thomson et al., 2006). 
 
 
1.3.4 Strategies for identifying miRNA targets 
Common strategies for identifying miRNA targets include the use of different 
bioinformatics predictive tools, which allow prediction of putative miRNA targets on 
the basis of the complementarity (perfect o near perfect) between miRNA and mRNA 
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sequences, mostly in the 3’UTR. These predictive tools may be combined with mRNA 
microarray data obtained from cells in which a particular miRNA is overexpressed or 
knocked down. Another powerful use of these bioinformatics predictive tools is the 
comparison of a miRNA profile obtained from a specific tissue or cell population with 
the mRNA microarray obtained on the same samples, as described in the present thesis 
(§3.2.4). This tool allows to search for those miRNAs whose expression inversely 
correlate with the expression of mRNA that is predicted to be one possible target. 
Although these methods have been successfully used to analyze miRNA function and to 
identify important miRNA targets, they have limitations (reviewed in (Navarro and 
Lieberman, 2010)). Bioinformatics algorithms typically predict hundreds or even 
thousands of targets of a single miRNA and have high false positive rates. Algorithms 
that rely on 3’UTR miRNA seed sequences seem to work better, but they still fail to 
predict biologically relevant targets, which have been experimentally proven such as 
Ras for let-7 and E2F2 and Myc for miR-24 (Johnson et al., 2005; Lal et al., 2009). 
Importantly they fail to analyze seedless miRNA binding sites or sites in the coding 
region or 5’UTR of genes that, even if less frequent, can mediate recognition of 
biologically relevant miRNA targets (Lal et al., 2009; Tay et al., 2008). Beyond these 
observations, a major caveat in using gene microarrays to study miRNA function is that 
often the changes in mRNA levels due to their miRNAs targeting are modest and not 
detectable by the microarray hybridization techniques.  Moreover, this method does not 
distinguish direct mRNA targets from those transcripts whose change in expression is 
indirectly mediated by miRNAs and, most importantly, misses targets that are regulated 
primarily through translational inhibition. To overcome these limitations, other 
alternative biochemical approaches, based on proteomic analysis coupled with 
radiolabeling of the proteins or immune precipitation techniques, have been recently 
developed (Easow et al., 2007). However all of them show several limitations due either 
to their technical complexity or to the need of a large amount of samples (which is not 
always possible) or to their high costs, which strongly limit their use. 
 
 
1.3.5 miRNAs in hematopoiesis 
A key role for miRNAs in regulating the multiple cell-fate decisions governing 
hematopoietic differentiation is currently emerging: miRNAs can act together with 
lineage-specific TFs to finely regulate gene expression during hematopoietic 
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differentiation. They can also target TFs, and can be themselves regulated by TFs, 
giving multiple levels of regulation. In general the overall miRNA expression increases 
with cell differentiation, suggesting that miRNAs might play a role in shutting down 
genetic programs that are required for maintaining alternative cell fates or that prevent 
differentiation more generally (Mathieu and Ruohola-Baker, 2013). 
MicroRNAs are differentially and dynamically expressed during hematopoiesis and 
regulate hematopoietic differentiation in almost every stage. They show different roles 
in different population in the hematopoietic hierarchy, inhibiting or promoting a specific 
lineage, and their aberrant expression has been associated with many diseases, including 
hematological malignancies, where microRNAs can act as oncogenes or tumor 
suppressors by mechanisms not yet completely understood. The first study 
demonstrating the relationship between microRNAs and hematopoiesis was published 
in 2004 (Chen et al., 2004). In this study, Chen and colleagues cloned 150 microRNAs 
from mouse bone marrow and found that three microRNAs (mir-181, mir-223 and mir-
142) were preferentially expressed in hematopoietic cells. Further characterization 
revealed that miR-181 was highly expressed in the murine thymus and differentiated B 
lymphocytes, whereas it was detectable at lower levels in undifferentiated progenitor 
cells; miR-223 expression was confined to myeloid cells and miR-142 expression was 
highest in B-lymphoid tissues (Chen et al., 2004). Ectopic expression of miR-181 in 
hematopoietic stem and progenitor cells resulted in B lymphocyte proliferation in vitro. 
Consistent with the in vitro data, subsequent transplantation of these cells into lethally 
irradiated mice resulted in a significant increase of the B-cell lineage (CD19
+
 cells), 
with a substantial decrease of T cells (especially CD8
+
 T cells) also in vivo. However, 
ectopic expression of miR-142 or miR-223 did not induce any obvious phenotype (Chen 
et al., 2004). Following this pioneer study, many groups have investigated the 
expression and function of miRNAs during hematopoiesis. Notably, Ramkinssoon et al., 
studying expression profiles of mir-142, mir-181, mir-223 and mir-155, founded 
substantial differences in expression patterns between human and mouse hematopoietic 
cells (Ramkissoon et al., 2006).  
The essential requirement for miRNAs during hematopoietic differentiation was further 
demonstrated with the complete inactivation of miRNA formation by conditionally 
deleting Dicer in specific hematopoietic compartments. As Dicer knockouts are 
embryonic lethal (Bernstein et al., 2003), the in vivo role of Dicer in adult 
hematopoiesis can only be studied by conditional knockouts. Targeted deletion of Dicer 
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in the thymus blocks peripheral CD8
+
 T cell development and reduces the CD4
+
 T cell 
compartment (Muljo et al., 2005). Moreover Dicer-deficient CD4
+
 T cells show reduced 
cell proliferation, increased apoptosis, and a skewing toward the Th1 lineage. Targeted 
deletion of Dicer at early stages of B cell differentiation blocks B cell development at 
the pro- to pre-B cell transition, with a pronounced increase in pre-B cell apoptosis 
(Koralov et al., 2008). However, if Dicer is conditionally deleted at an early stage of T-
cell development, it does not seem to be essential for CD4/CD8 lineage commitment 
(Cobb et al., 2005). Likewise, embryonic stem cells deficient for Dgcr8 accumulate in 
the G1 phase of the cell cycle and exhibit defective differentiation (Wang et al., 2008; 
Wang et al., 2007). Furthermore, conditional inactivation of Ago2 led to severe 
hematopoietic defects in the lymphoid and erythroid precursors (O'Carroll et al., 2007). 
Up to date, a number of different miRNAs have been associated with the regulation of 
hematopoietic development and differentiation, as reviewed by (Bissels et al., 2011a; 
Havelange and Garzon, 2010). Below there is a brief summary of relevant miRNAs in 
the different branches of hematopoietic differentiation (Figure 1.3.3).  
A combined approach involving miRNA profiling of human stem-progenitor cells from 
bone marrow and mobilized peripheral blood, coupled to microarray analysis and 
bioinformatics prediction of mRNA targets, revealed that distinct miRNA signatures 
fine regulate almost every step of hematopoiesis, including HSCs and MPPs. For 
example, miR-128 and miR-181 are expressed in early progenitor cells and prevent the 
differentiation of all haematopoietic lineages. mir-146 impairs differentiation of 
multipotent progenitor cell (MPP) into common lymphoid progenitors (CLP), while 
mir-155, mir-24a and mir-17 may inhibit the differentiation of MPP into common 
myeloid progenitor (CMP). miR-16, miR-103 and miR-107 may inhibit the 
differentiation of CMP into granulocytic macrophage progenitor (GMP) whereas miR-
221, miR-222 and miR-223 control the terminal differentiation pathways (Georgantas et 
al., 2007; Starczynowski et al., 2011) (reviewed in (Gangaraju and Lin, 2009)) 
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Figure 1.3.3 Expression levels and regulatory networks of miRNAs during hematopoiesis. CLP, 
common lymphoid progenitor; CMP, common myeloid progenitor; DN, double negative T-cell 
precursors; DP, double positive (CD4
+
CD8
+
 T cells); EMP, erythrocyte-megakaryocyte precursor; EP, 
erythrocyte precursor; GMP, granulocyte-monocyte precursor; GP, granulocyte precursor; HSC, 
hematopoietic stem cells; MP, megakaryocyte precursor. Dashed green arrows means positive regulation; 
Red dashed lines means negative regulation; Black thick arrows follows hematopoiesis development and 
differentiation hierarchy; Small black arrows (up or down) means miRNA expression during a specific 
hematopoietic stage. MiRNA targets or transcription factors involved in the regulation of miRNAs are 
shown using blue letters (from (Havelange and Garzon, 2010)). 
 
 
Analyzing in detail one of the first lineage-specific decision during hematopoiesis, 
which is the differentiation of multi potent progenitor cells into either common 
lymphoid or common myeloid progenitors, it has been shown that miR-223 and miR-
181 are expressed less abundantly in the progenitor cells and are upregulated upon 
differentiation into the myeloid and lymphoid lineages, respectively (Chen et al., 2004). 
However, less is known about miRNA acting upstream to multipotent progenitors and 
only very recently their specific role in HSCs is beginning to be elucidated (Guo et al., 
2010; Ooi et al., 2010) (see § 1.3.6). 
Like in other systems, lineage-specific TFs can also regulate the levels of some lineage-
specific miRNAs thus indirectly determine the fate of those stem cells. For example, 
PU.1, a TF that is essential for monocytic differentiation, activates miR-424, which in 
turn targets the TF nuclear factor I/A (NfI-A) and induces monocytic differentiation 
(Rosa et al., 2007). 
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1.3.6 miRNA in Stem cells 
Recently, the stem cell and miRNA fields have converged with the identification of 
stem-cell-specific miRNAs (Houbaviy et al., 2003), and it is now clear that miRNAs 
provide a new dimension to the regulation of stem cell functions. Due to their role in 
gene silencing and to their fast mechanism of action, miRNAs seem to regulate stem 
cell fate and behaviour by fine-tuning the protein levels required for stem cell or niche 
cell functions. Earlier evidences demonstrating essential requirement for miRNAs in 
stem cells came from studies on complete inactivation of miRNA formation in humans 
and mice ES cells, through generation of DGCR8 and Dicer mutants, respectively. 
Dicer is essential for early mouse development since its absence is embryonic lethal 
(Bernstein et al., 2003). However, embryonic lethality does not seem to be due to the 
absence of ES cells. Dicer-null mouse ES cells are viable, although they show severe 
defects in growth and differentiation. Dicer-null ES cells fail to express endodermal and 
mesodermal differentiation markers, even under specific differentiation conditions, and 
have prolonged G1 and G0 phases of the cell cycle (Kanellopoulou et al., 2005). 
DGCR8-deficient human ES cells show similar defects, since they also exhibit delayed 
differentiation, reduced expression of differentiation markers and delayed kinetics of 
cell cycle progression (Wang et al., 2007). Most DGCR8-deficient ES cells are arrested 
in the G1 phase, which indicates that the main function of the miRNA pathway is to 
promote the ES cell cycle at the G1–S-phase transition. In addition, DGCR8-null ES 
cells fail to silence the expression of self-renewal markers, such as Oct4, Rex1, Nanog 
and Sox2, and do not produce teratomas in xenotransplantation assays as wt ES cells 
normally do  (Wang et al., 2007), highlighting a differentiation defect also in vivo. The 
similar phenotype of DGCR8 and Dicer mutants further confirms that the predominant 
function of miRNAs is to regulate cell cycle progression during stem cell differentiation  
(Gangaraju and Lin, 2009). Micro-RNA function has also been intensively explored in 
somatic tissue stem cells, highlighting multiple roles of miRNAs in almost each adult 
stem cell populations. For the purposes of our study we focus on miRNAs involved in 
regulation of HSC and how they control their proper self-renewal and differentiation. 
miRNAs in HSCs  
Emerging evidences demonstrate that miRNAs regulate self-renewal and proliferation 
of HSCs and of their downstream multipotent progeny (Laine et al., 2012). For instance, 
increased expression of miR-125a (Guo et al., 2010) or miR-125b (Ooi et al., 2010) in 
mouse HSCs was reported to enhance HSC function and expand them in vivo. Both 
 
 
50 
 
miRNAs probably act by suppressing multiple proapoptotic genes, like Bak1, a direct 
target of miR-125a, or Bmf and Klf13, targets of miR-125b. A similar regulatory 
function has been suggested for miR-33, since it was found to inhibit the expression of 
p53 tumor suppressor protein, thus promoting mouse HSC self-renewal (Herrera-
Merchan et al., 2010). Furthermore, in HSCs high expression of miR-29a has been 
associated with their self-renewal capacity. In detail, miR-29a was shown to be highly 
expressed in normal HSCs and primary human AML, and down-regulated in more 
committed hematopoietic progenitors.  An analogous expression pattern is demonstrated 
in mouse hematopoietic populations. Ectopic expression of miR-29a in mouse 
hematopoietic stem and progenitor cells leads to increased myeloid differentiation and 
proliferation at the level of MPP, with concomitant acquisition of self-renewal capacity 
by more committed myeloid progenitors. Moreover, enforced miR-29a expression 
reveals a biased myeloid differentiation, and the development of a myeloproliferative 
disorder that progresses to acute myeloid leukemia (AML), which is serially 
transplanted by miR-29a-expressing myeloid progenitors. These findings suggest miR-
29a as a possible oncomir able to transform myeloid progenitors into self-renewing 
leukemik stem cells (LSCs). Although the direct targets of this miRNA are unknown, it 
seems that miR-29a positively regulates progenitor proliferation by expediting G1 to 
S/G2 cell cycle transitions (Han et al., 2010). Another recently HSC-associated miRNA 
is miR-126, which is involved in control of HSC pool size in human and mice (Gentner 
et al., 2009; Gentner et al., 2010; Lechman et al., 2012). miR-126 is expressed and 
functionally active in human and mouse HSCs and early progenitors, but not in more 
committed progeny where it is progressively down regulated. miR-126 expression can 
be used also as a marker to prospectively isolate human HSCs with xenograft 
repopulating potential (Gentner et al., 2010). Gain- and loss-of-function studies 
demonstrate that miR-126 regulates HSCs and early progenitor cells. In detail, lentiviral 
mediated miR-126 knockdown (using a lentiviral “sponge”) led to increased cell-cycle 
progression and in vivo HSC expansion, without exhaustion. Conversely, enforced 
expression of miR-126 impaired cell-cycle entry and resulted in increased HSC 
quiescence followed by reduced hematopoietic output. Thus, miR-126 may play a key 
role in maintaining HSC quiescence by restricting cell-cycle progression. Mechanisms 
through which miR-126 can exert these functions likely involve the 
PI3K/AKT/GSK3 pathway, where several miR-126 targets are reported  (Lechman et 
al., 2012). 
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It is well known that HSC function is tightly controlled not only by intrinsic cellular 
signals but also by their cellular microenvironment, the HSC niche, which has a direct 
impact on hematopoiesis (Schofield, 1978; Wilson and Trumpp, 2006). In this regard, it 
is interesting that miRNAs could also have a role in modulating HSC 
microenvironment. To support this notion there is evidence that secretion of the chemo-
attractant stromal derived factor 1 (SDF1 or CXCL12) is also influenced by miR-886-
3p, which specifically targets the 3´UTR of SDF1 mRNA, thereby modulating the 
expression of this chemokine that plays a critical role in hematopoietic regulation 
(Bissels et al., 2011a; Pillai et al., 2010). 
The role of miRNAs in the regulation of self-renewal and of the early steps of HSC 
differentiation has not yet been clearly understood in part due to technical problems 
relative to HSC isolation (Bissels et al., 2011a). MiRNA expression profiling in HSCs is 
hampered by the low number of available cells and by the wide spectrum of surface 
marker combinations that are normally used for their enrichment. Moreover, expression 
of miRNAs in human and mouse has been analyzed in different populations, obtained 
from different sources (such as bone marrow, peripheral blood, mobilized peripheral 
blood and cord blood) and with different combination of markers. These populations are 
not always properly enriched neither comparable to each other. Indeed, a comparison of 
the available miRNA profiles of primitive human hematopoietic cell populations [data 
of (Bissels et al., 2011b; Han et al., 2010; Jin et al., 2008; Liao et al., 2008; Merkerova 
et al., 2009)], reveals considerable variation in miRNA expression profiles of HSCs in 
different studies that can be attributed to the different stem cell fractions used for 
comparison. Like for ES cells, improving methods to separate specific cell populations 
and homogeneous starting material will overcome, at least in part, these problems, thus 
increasing knowledge about miRNA expression in HSCs  (Bissels et al., 2011a). 
As described in §1.2.4, Pbx1-null HSCs have a profound self-renewal defect. Therefore, 
in the second part of this thesis (§3.2), we employed Pbx1 conditional KO mice as a 
model for studying if miRNAs play a role in balancing self-renewal versus 
differentiation in HSCs. Our interest in characterizing the role of miRNAs in this model 
arises from the fact that they have been extensively linked to the main processes that are 
defective in Pbx1-null HSCs (differentiation and self-renewal). Moreover self-renewal 
itself, which is the main characteristic of stem cells, is progressively lost in the normal 
HSC-to-MPP transition, making also the characterization of miRNA in the 
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physiological transition an important issue to address. Importantly, the transcriptional 
profile previously performed on HSCs (Ficara et al., 2008) revealed that in the absence 
of Pbx1 there is a premature up-regulation of Dgcr8 transcript. These observations lead 
to the hypothesis that Pbx1 loss in HSCs may result in altered expression of Dgcr8 and 
miRNAs, and prompted the investigation of a possible link between self-renewal 
regulation and miRNAs in HSCs, similarly to what has been proposed for ES cells 
(Wang et al., 2007). In support to this hypothesis, direct link between Dgcr8, miRNAs 
and HSC defect has been recently demonstrated in Xenopus models during embryonic 
development. Xenopus Dgcr8 morfant embryos fail to correctly specify HSCs and 
display early hematopoietic differentiation defects  (Nimmo et al., 2013).  
 
 
53 
 
2. AIMS OF THE STUDY 
Hematopoiesis is highly regulated at each step of differentiation. For a constant supply 
of short-lived terminally differentiated blood cells, as well as for rapid response to 
several hematopoietic stresses, HSCs are endowed with the ability to continuously 
provide more mature progenitors while properly maintaining their pool size, without 
exhaustion, throughout life. This equilibrium is finely maintained on one hand by 
precisely balancing self-renewal and differentiation in HSCs, and on the other hand by 
regulating proliferation and differentiation also of their downstream progenitors, 
including lineage choice. 
Pbx1 was shown to be a negative regulator of HSC differentiation by affecting their 
quiescence. Postnatal hematopoiesis is profoundly perturbed in the absence of Pbx1, 
with a severe reduction of HSCs both in number and functionality (Ficara et al., 2008), 
and severe reduction of committed lymphoid and myeloid progenitors. However, the 
precise molecular mechanisms through which Pbx1 exerts its function in HSCs and its 
role in progenitor biology are two issues still unexplored. In particular, it is not known 
whether Pbx1 function is also mediated by micro-RNAs, crucial new players in the 
regulation of proliferation and differentiation in several tissues. 
We speculate that Pbx1 regulates the balance between self-renewal versus maturation 
not only in HSCs but also in downstream progenitors, and we want to address whether it 
does so also through micro-RNAs, at least in HSCs. Taking advantage of Pbx1 
conditional KO mice, in the present thesis we addressed these issues through the 
following specific aims: 
Aim1. To understand if Pbx1 plays a role in multipotent and lineage committed 
progenitors, by analyzing the capacity of Pbx1-mutant progenitors to proliferate and 
differentiate toward myeloid, erhythroid and lymphoid cells. 
Aim2. To establish if microRNAs are part of the program downstream of Pbx1 
that regulates self-renewal versus differentiation in HSCs. This aim will be pursued on 
one hand by comparing the micro-RNA expression profile of Pbx1-conditional KO 
HSCs (which have a self-renewal defect) versus wt HSCs, and on the other hand by 
comparing the micro-RNA expression profile of wt HSCs and wt Flk2
-
 multipotent 
progenitors (Flk2
-
MPPs), where loss of self-renewal occurs for the first time in the 
hematopoietic hierarchy. 
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3. RESULTS 
 
3.1 Pbx1 role in multipotent and lineage 
restricted progenitors 
3.1.1 Experimental background 
Three main experimental evidences suggest that, in addition to HSCs, Pbx1 may play 
important roles in lineage-restricted progenitors. 
3.1.1.1 Pbx1-null lineage restricted progenitors are reduced 
Pbx1 conditional knockout mice (Tie2Cre
+
.Pbx1
-/f
, see §1.2.5) exhibit significant 
reduction of common myeloid progenitors (CMPs) and a drastic reduction of common 
lymphoid progenitors (CLPs), as shown by multicolor FACS analysis of total BM 
((Ficara et al., 2008) and Figure 3.1.1A-B). Quantification of the data reveals a 90% 
reduction of CLPs and 50% of CMPs in mutant mice compared to control (analysis 
from 14 and 15 control and mutant mice respectively; *p=0.05) (Figure 3.1.1C). 
However, although lymphocytes are reduced in the BM and in the thymus, mature 
myeloid cell numbers are unaffected despite significant CMP reduction. This contrasts 
with several mouse models carrying mutations in genes implicated in maintaining HSC 
self-renewal and/or cell cycle properties. In these models, either no phenotypes in the 
myeloid progenitor compartment are observed (Galan-Caridad et al., 2007), or they are 
characterized by myeloproliferative-like diseases (Metcalf et al., 2006; Santaguida et 
al., 2009; Tothova et al., 2007; Viatour et al., 2008; Yilmaz et al., 2006b) as a 
consequence of the HSC defect. This difference with our model suggests a specific role 
for Pbx1 in progenitors. 
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Figure 3.1.1 Pbx1-null progenitors are reduced. (A) Representative FACS analysis of CLPs from 
control (Tie2Cre
-
.Pbx1+/f) or mutant (Tie2Cre+.Pbx1-/f) mice. Contour plots on the left are referred to 
the Lin- gate. Percentages are relative to the parent gate. (B) Representative FACS analysis of CMPs and 
GMPs from control or mutant mice. Contour plots are referred to the Lin-cKit+Sca1+ gate. Percentages 
are relative to the parent gate. (C) Quantitative data from FACS analysis shown in (A) and (B). 
Histograms represent the average CLP and CMP percentage within the BM of control or mutant mice 
(n=14 and 15, respectively; *P<0.05) (from (Ficara et al., 2013)) 
 
3.1.1.2 Pbx1-null common myeloid progenitors (CMPs) have a higher 
proliferation rate 
Data from Dr. Cleary’s laboratory at Stanford University revealed that the CMP 
reduction observed in vivo did not correlate with a reduction of their proliferation 
capacity. Conversely, prospectively isolated Pbx1-null CMPs, placed in liquid culture 
and exposed to growth factor stimulation (SFC, IL6 and IL3), displayed a higher 
proliferation rate compared to controls (Figure 3.1.2). 
 
 
Figure 3.1.2 CMP proliferation rate. Liquid culture of prospectively isolated CMPs (2000–10,000 
cells), in presence of cytokines. The graph shows the ratio of Pbx1-null cell number versus control at 
different time points (n=3, *P=0.003) (from (Ficara et al., 2013)). 
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This higher proliferation rate is massive during the first three days of culture, but 
decreases at later time points. In other words, the number of Pbx1-null cells increased at 
a much lower rate compared to controls toward the end of the culture period, resulting 
in an inverted ratio of mutant CMPs versus wild-type CMPs at day 8 (Ficara et al., 
2013). The observed phenotype could not be ascribed to increased cell death, since 
Annexin V assays previously performed in Cleary’s lab did not reveal any alteration in 
apoptosis process (not shown). 
Hence, the reduced number of Pbx1-null CMPs is not due to an intrinsic defect in 
proliferation, but rather to their aberrantly higher proliferation rate, leading to the 
hypothesis that, in the absence of Pbx1, progenitors exhaust faster in the myeloid 
lineage.  
3.1.1.3 Transcriptional profile of Pbx1-null CMPs suggests premature 
maturation toward the GMP stage  
To explain this aberrant myeloid phenotype we took advantage of the transcriptional 
profiling performed in Cleary’s lab on Pbx1-null CMPs, in order to find Pbx1-
dependent genes potentially involved in the CMP defect. Microarray analysis was 
performed on prospectively isolated CMPs and their immediate downstream progenitors 
GMPs, both from mutant and control mice. Analyzing first the normal CMP-to-GMP 
transition, statistical analysis of microarray (SAM) shows 592 non-redundant 
differentially expressed (DE) transcripts. This gene set of DE transcripts was compared 
to the one obtained from the transcriptome analysis of mutant vs wild-type CMPs. As 
schematically shown in Figure 3.1.3 by Venn diagrams, this analysis reveals that 
123/305 (40%) non-redundant DE transcripts in mutant vs wild-type CMPs were also 
differentially regulated in the normal CMP-to-GMP transition. 
 
 
Figure 3.1.3 Overlap between the Pbx1-null CMP gene set and the gene set defining the normal 
CMP-to-GMP transition (from (Ficara et al., 2013)). 
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The gene set defining the normal CMP-to-GMP transition was compared to gene set of 
mutant vs wild-type CMP DE transcripts also by employing Gene set enrichment 
analysis (GSEA) (Mootha et al., 2003; Subramanian et al., 2005). Transcripts down 
regulated in mutant CMPs were highly enriched for normal CMP-specific genes, 
whereas transcripts upregulated in mutant CMPs correlated with normal GMP genes 
(Ficara et al., 2013).  
Thus, in the absence of Pbx1, phenotypically defined CMPs prematurely express a 
subset of genes typical of their downstream GMP progeny, making them more similar 
to GMPs than to CMPs, at least from a transcriptional point of view.  
 
3.1.2 Faster kinetics of myeloid differentiation in Pbx1-null 
CMPs 
Since the described data suggested that Pbx1 may maintain common myeloid progenitor 
number and identity, possibly by restraining proliferation and differentiation, in the 
present thesis we tested the in vitro differentiation ability of Pbx1-null CMPs toward 
myeloid and erythroid cells.  
In order to assess whether the increased proliferation observed in Pbx1-null CMPs in 
short-term culture is associated with a normal or aberrant differentiation capacity, we 
plated FACS-sorted CMPs in liquid culture in 96 multi well (MW) plates in medium 
supplemented with cytokines (SCF, IL3 and IL6), and analysed them by FACS at two 
different time points (one and three days later), to check for the expression of a typical 
myeloid marker (Mac-1) and/or the concomitant loss of their immature phenotype, 
revealed by the expression of cKit.  
 
 
58 
 
 
Figure 3.1.4 Premature differentiation of Pbx1-null CMPs. (A) Representative FACS analysis of the 
progeny of CMPs prospectively isolated from control or mutant mice (representative of five). Dot plots 
on the right are relative to the c-Kit+Mac-1- gate at day 3. Percentages are relative to the parent gate. (B) 
Histograms summarize data shown in (A), day 3 (n=5, *P<0.05) (from (Ficara et al., 2013)). 
 
After only one day of culture, a higher proportion of Pbx1-null CMPs had acquired 
Mac-1 expression compared to controls (Figure 3.1.4A). This faster differentiation 
tendency became more evident at the next time point. At day three cultures derived 
from mutant CMPs contained a smaller proportion of immature c-Kit
+
Mac-1
-
 cells, and 
a higher fraction of differentiating c-Kit
-
Mac-1
+
 cells. We then analyzed more in detail 
the immature fraction of cells (c-Kit
+
Mac-1
-
) for the expression of Fc RII/III and CD34 
markers, which allow to distinguish CMPs (Fc RII/III
int
 and CD34
int
, middle gate) and 
GMPs (Fc RII/III
high
 and CD34
high
, upper gate). Representative FACS analysis shows 
that mutant CMPs loose their immature phenotype more rapidly than their wt 
counterparts (Figure 3.1.4). Quantification of these data shows a more evident reduction 
of all the immature fraction of cells (c-Kit
+
Mac-1
-
 and CMPs), with a concomitant 
increase of the differentiating (Mac-1
+
) fraction. Concomitant FACS analysis for CFSE 
and Mac-1 after 2 days of culture showed that cells that had acquired Mac-1 had also 
diluted CFSE (not shown), indicating that the observed premature differentiation by 
Pbx1-null CMPs was not due to an absence of proliferation. Overall, these data 
demonstrate that Pbx1-null CMPs differentiate more rapidly. This can account for the 
partial transcriptional overlap between mutant CMPs and wt GMPs (Figure 3.1.3). 
We then performed colony-forming-cell assays on CMPs from mutant and control mice 
to test their clonogenic and differentiation capability. After 7 days of culture, we 
counted colonies and scored them for myeloid and erythroid differentiation. Pbx1-null 
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and control cells gave rise to a similar number of colonies (Figure 3.1.5A). However 
colonies from Pbx1-null CMPs tended to be smaller compared to wt (not shown) and, 
after pooling all colonies, a lower number of total cells was obtained (Figure 3.1.5B). 
This is in agreement with the previous mentioned results of liquid culture at day 8 
(Figure 3.1.2), at which time point the number of Pbx1-null cells is lower compared to 
controls. In addition, in cultures of mutant CMPs there was an inversion in the relative 
proportion of myeloid and erythroid colonies, with a significant reduction in erythroid 
colonies and a concomitant increase of the myeloid ones (Figure 3.1.5C).  
We then harvested a pool of Pbx1-null colonies and performed a cytospin preparation to 
check if the cellular composition of the colonies was altered. May-Grunwald/Giemsa 
staining of the spotted cells clearly shows a lower proportion of ‘blast-like’, not 
terminally differentiated cells in the cytospin preparations from pooled mutant colonies 
compared to controls with a number of blast-like cells per field of 11.5+/- 1.25 and 
1.2+/-0.57 in control and mutant respectively (n=10,  P<0.0001) (Figure 3.1.5D). 
 
Figure 3.1.5 Premature differentiation of Pbx1-null CMPs. (A) Methylcellulose CFC assay from 
prospectively isolated CMPs and MPPs (average of four independent assays, each performed in duplicate 
(*P≤0.02). (B) and (C) Methylcellulose CFC assays from prospectively isolated CMPs. Histograms 
represent the average of four and two independent assays, respectively, each performed in duplicate 
(*P≤0.02). (D) Cytospin and May-Grunwald and Giemsa staining of pooled colonies from A and B. 
Arrowheads on cytospin images indicate blast-like, not terminally differentiated cells (from (Ficara et al., 
2013)). 
 
Overall, these data indicate that in Pbx1-null CMPs there is an accelerated maturation to 
the next stage of the hematopoietic hierarchy with a concomitant loss of their adequate 
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self-renewal capacity and a preferential skewing towards the myeloid (granulocytic-
monocytic) lineage respect to the erythroid one.  
This premature myeloid differentiation likely contributes to the observed reduction of 
CMPs in the absence of Pbx1, despite the unaffected mature myeloid cell numbers, 
since they differentiate more rapidly. 
 
3.1.3 Pbx1-null Common Lymphoid Progenitors (CLPs) show 
reduced differentiation capacity toward B cells 
Pbx1 conditional knockout mice exhibit not only alteration in CMPs but also, and with 
an even more severe phenotype, in CLPs. In this case there is also a severe reduction of 
differentiated lymphocytes in the BM and in the thymus. To test whether a faster and 
aberrant differentiation could account also for the CLP defect, we performed lymphoid 
differentiation assays to assess the capacity of mutant lymphoid progenitors to 
differentiate toward B cells (Figure 3.1.6). One thousand prospectively isolated CLPs 
from control or mutant mice were seeded on OP9 stromal cell layers plated the day 
before, in medium supplemented with cytokines (SCF, Flt3 and IL-7). In these 
conditions lymphoid progenitors differentiate towards B cells in around 10 days and 
develop visible colonies of hematopoietic cells growing on the stroma. This progeny 
was harvested and analyzed by FACS at two time points (four and eleven days) for the 
presence of B220 and CD19, typical B cell markers. Figure 3.1.6 shows representative 
contour plots of the two time points. The plots are referred to the hematopoietic gate. 
Any residual stromal cells were excluded on the basis of their light scatter 
characteristics, and lack of expression of B cell markers (Ficara et al., 2013). 
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Figure 3.1.6 Differentiation of Pbx1-null CLPs. Representative time course FACS analysis of 
differentiation assays at two time points (day 4 and day 11) from control (upper lane) or mutant (bottom 
lane) CLPs. Percentages are relative to the parent gate (from (Ficara et al., 2013)). 
 
Both Pbx1-null and control CLPs differentiated into B220
+
CD19
+
 cells in vitro, without 
detectable differences. This is in contrast with what observed in the myeloid lineage, in 
which there was an evident accelerated differentiation, as mentioned above (see Figure 
3.1.4). However, data from Cleary’s lab indicated that the in vivo lymphoid outputs 
from Pbx1-null CLPs were lower compared to wt (not shown), suggesting that Pbx1 
may maintain lymphoid potential. Since our in vitro experiments were performed on 
bulk cultures, in which potential differences might be missed, we repeated the in vitro 
B-cell differentiation assays in limiting dilution, to highlight potential defects not 
detectable with bulk cultures. 
Limiting dilution analysis aims to determine the frequency of cells having a particular 
function that are present in a mixed population of cells. Freshly isolated CLPs were 
seeded in limiting dilution in 96 MW plates on OP9 stromal cells plated the day before, 
in medium supplemented with cytokines as described. In this way, if there is at least one 
bona fide lymphoid progenitor in the cell population, it will differentiate developing a 
colony of B cells. Since cells were plated at limiting dilution conditions, we also 
expected a fraction of negative wells, in which no visible colonies are formed. After 10 
days we selected the positive wells (the ones with visible hematopoietic colonies), 
harvested them and analyzed them individually by FACS for the presence of B220± and 
CD19± surface markers. To definitively exclude positive wells we checked the 
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remaining wells three days later, harvesting cells from additional wells in which small 
colonies were non evident before. Due to the drastic CLP phenotype in mutant mice 
(Figure 3.1.1), we could plate Pbx1-null cells only at three different concentrations (the 
minimum to have statistical significance). We plated different concentrations of control 
and mutant cells (3, 10 and 30 cells/well for control, 10, 30 and 90 cells/well for the 
mutant) to have an informative read out. In fact preliminary experiments, performed to 
set up the assay, had suggested a reduced frequency of these progenitors in the mutant 
mice. For each condition we seeded a high number of wells (summary table in Figure 
3.1.7 is representative of one experiment) to reach statistical significance, with higher 
number of wells for the lower cell doses. However, for Pbx1-null CLPs, the number of 
wells was limited by the number of cells that we were able to obtain from mutant mice. 
Figure 3.1.7 shows the gating strategy used for the analysis, with representative plots 
from FACS analysis of different wells. 
 
 
Figura 3.1.7 Differentiation of Pbx1-null CLPs in limiting dilution. Representative FACS analysis of 
the progeny of prospectively isolated CLPs from control or mutant mice, cultured in limiting dilution in 
presence of cytokines. Percentages are relative to the parent gate. Summary table in the bottom shows the 
number of wells in one experiment for each condition (representative of two).  
 
From this experiment different progenies can be expected, with great variability from 
well to well. Indeed this differentiation assay will favor lymphoid differentiation while 
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the myeloid differentiation is prevented. Nevertheless these populations, although 
purified, represent an  enrichment, since cells unable to differentiate toward B lineage 
can be found. Thus myeloid “contaminating” cells can be obtained, especially when 
lymphoid progenitors are only a small fraction of the plated cells.  Therefore, we set the 
staining including antibodies for myeloid (Gr1 and Mac-1) and dendritic (CD11c) cell 
markers, in addition to B-lymphoid markers, in order to exclude them from the analysis. 
In detail, the scatters plot (representing physical parameters) shows that the 
hematopoietic population is homogeneous and separated from stromal cells. On the gate 
of “live” cells, we first excluded cells expressing myeloid and/or dendritic cell markers, 
and we then analyzed the expression of the lymphoid markers B200 and CD19. B220 is 
expressed from the earliest stages of the B cell development (Pre-pro B cells), while 
CD19 expression defines a more mature differentiation stage (from Pro B to mature B 
cells). In our experiments, the vast majority of B cells were double-positive for B220 
and CD19, as expected after 10 days of culture since we plated a committed lymphoid 
progenitor. Importantly, both mutant and control cells generated B220
+
CD19
+
 cells, 
indicating that the reduced number and frequency of Pro- and Pre-B cells observed in 
vivo (Ficara et al., 2008) is not due to an intrinsic differentiation defect from CLPs. 
Interestingly, the progeny of control CLPs contained only B cells. Conversely, after 
plating mutant CLPs we found several wells containing myeloid cells, some of them 
without the presence of B cells. In detail, myeloid cells were detected in about 1/3 of the 
wells. On one hand, this may be due to the fact that the shortage of mutant CLPs renders 
the sorting less accurate, thus we might have plated a less pure cell population (purity of 
mutant CLPs was never assessed due to the low number of cells obtained after sorting). 
However our favored hypothesis is that phenotypically defined CLPs from mutant mice 
might not be all true functional CLPs, as it happens for HSCs. In other words, the Lin
-
IL7R
+
Flk2
+
Sca1
low
cKit
low
 cell population from mutant mice likely contains fewer 
lymphoid progenitors than wt.  
After analyzing all samples we calculated the negative fraction (F0), i.e. the fraction of 
wells without CD19 positive cells, and then we plot this data in a semi logarithmic 
graph, in function of the plated cell dose for each culture (Figure 3.1.8). 
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Figure 3.1.8 CLP limiting dilution analysis. Plots of limiting dilution analysis (representative of two) 
show the frequency of control or mutant CLPs able to develop into CD19
+
 B cells in co-culture with OP9 
stromal cells (R
2
=0.92 and 0.96, respectively) (from (Ficara et al., 2013)). 
 
A straight line is obtained by linear regression from which, interpolating at F0
 
= 
 
0.37, 
we obtained the cell dose in which there is one cell with the function we are analyzing, 
in this case the frequency of lymphoid progenitors in each population. The rationale 
beside this calculation rely on the Poisson Distribution (Szilvassy et al., 1990; Szilvassy 
et al., 1989; Taswell, 1981), which assumes in a simplified manner, that you have the 
same probability to plate one cell or zero cell (or even more than one cell) when plating 
an ideal single cell suspension. This probability is mathematically calculated at 37%. 
Since you start from a mixed population, you cannot discriminate if the experimental 
read out comes from only one cell or more than one, but you can count the negative 
read outs, you make a function of these negative fractions. Whichever dilution of cells 
giving rise to 37% of negative read outs represents the frequency of the cells you are 
looking for (in this case the frequency of lymphoid progenitor in each population). The 
semilogaritmic plots show a lower frequency of functional CLPs from Pbx1-null mice 
(1/20 in the control mice vs 1/42.5 in the Pbx1-null in this example) (Figure 3.1.8). 
Therefore, the in vivo CLP reduction cannot be ascribed to a faster and aberrant 
differentiation capacity, but rather to their decreased frequency. 
Thus, in absence of Pbx1, both myeloid and lymphoid progenitors are able to 
differentiate into mature progeny but with a premature kinetic (a higher efficiency) for 
the myeloid lineage and a decreased efficiency in the lymphoid (and erythroid) lineage. 
 
3.1.4 Pbx1 drives lineage choice from MPPs 
These data led us to hypothesize that Pbx1 may drive lineage choice in hematopoietic 
progenitors. We investigated this aspect further at the level of multi potent progenitors 
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(LMPPs and MPPs), to study if a possible lineage choice defect in Pbx1-null mice is 
already present up-stream of CLPs and CMPs. For this purpose mutant and control 
MPPs were flow-sorted into three fractions according to Flk2 expression (Figure 3.1.9 
and Table 1.1.1) and analyzed by FACS. As described in §1.1.4, MPPs are 
phenotypically defined as LKS CD34
+
, and can be further divided into three fractions 
according to Flk2 expression: Flk2
-
MPPs, frequently called “short-term” HSCs, Flk2-
intermediate MPPs (Flk2
int
) and Flk2
high
 MPPs. MPPs negative or with low expression 
of Flk2 are progenitors with robust myeloid maturation potential (Flk2
-
MPPs and 
Flk2
int
MPPs) while MPPs with higher expression of Flk2 are lymphoid-primed MPPs 
(Flk2
high
, also known as LMPPs) (Mansson et al., 2007). Figure 3.1.9 shows 
representative FACS analysis of MPPs from control and mutant mice (contour plots are 
relative to the LKS gate) with the relative quantification of the FACS data, in term of 
percentage and absolute numbers per mouse.   
 
 
Figure 3.1.9 Evaluation of multi-potent progenitors in Pbx1-conditional knockout mice. (A) 
Representative FACS analysis of MPPs from control or mutant mice, relative to the LKS gate. (B) 
Quantitative data from FACS analysis shown in (A). Histograms show the percentage of Flk2-negative, 
Flk2-intermediate and Flk2-high MPPs within the LKS (left) or their absolute numbers per mouse (right); 
*P=0.01, n=8 (from (Ficara et al., 2013)). 
 
The analysis of these MPP subsets revealed a significant decrease, both in the 
percentage and in the absolute number, of LMPPs in mutant mice compared to control 
(Figure 3.1.9 B). Of note, the mean fluorescence intensity was similar in mutants and 
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controls, indicating that the reduction in progenitor subpopulations was not due to an 
altered expression of the markers used to define them (Ficara et al., 2013). Moreover, in 
addition to the already observed decrease in CMPs ((Ficara et al., 2008) and Figure 
3.1.1), here we also observed an associated reduction of the absolute number of their 
Flk2
int
 progenitors (Figure 3.1.9 B). These data strongly support the hypothesis that the 
lineage choice defect in Pbx1-null mice potentially arises at the level of multi potent 
progenitors. Thus, in addition to HSCs and restricted progenitors, Pbx1 may serve 
important roles in maintaining the normal MPP frequencies. To assess if Pbx1 regulates 
the ability of multi potent progenitors to differentiate into down-stream progeny, we 
tested the differentiation capability of Flk2
+
MPPs (including both Flk2
int
 MPPs and 
LMPPs) towards both myeloid and in lymphoid lineage in vitro, through the same 
assays previously performed with CMPs and CLPs.  
To test the myeloid differentiation capacity, Flk2
+
MPPs were prospectively isolated for 
methylcellulose colony assays. Colonies were counted and scored at day 9 for their 
myeloid versus erythroid output. 
 
 
 
Figure 3.1.10 Myeloid differentiation ability of Pbx1-null multi-potent progenitors. (A) 
Methylcellulose colony assay of prospectively isolated Flk2+MPPs. Erythroid and myeloid colonies were 
counted 9 days after plating. The histogram on the left represents pooled colonies from three independent 
experiments. The histogram on the right represents the average of four independent assays, each 
performed in duplicate (*P≤0.04). (B) Pictures of representative myeloid colonies (CFU-GM) taken with 
the same magnification (from (Ficara et al., 2013)). 
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Similarly to what observed with CMPs, there is no statistical difference between the 
number of colonies arising from Pbx1-null and control MPPs (Figure 3.1.5A). However, 
similarly to CMPs, the relative proportion of erythroid and myeloid colonies was 
inverted (Figure 3.1.10 A, right). Moreover, colonies were smaller (Figure 3.1.10 B), 
and when they were collected in pool at the end of the assay, they yielded a reduced 
number of total cells (Fig 3.1.10 A, left).   
We then plated the same type of prospectively isolated MPPs in liquid culture in 
presence of cytokines for several days to analyze their progeny for myeloid markers 
expression by FACS (Figure 3.1.11). 
 
 
Figure 3.1.11 Myeloid differentiation ability of Pbx1-null multi-potent progenitors. (A) Time-course 
FACS analysis (representative of four) was performed on prospectively isolated MPPs from control or 
mutant mice, cultured in the presence of serum and cytokines for 3 or 6 days. Contour plots show events 
within the live/forward and side light scatter gate. (B) Histograms show quantitation of average 
percentage of Mac-1+ cells in (A) (from (Ficara et al., 2013)). 
 
FACS analysis demonstrated that Pbx1-deficient cells up-regulated the expression of 
myeloid markers Mac-1 and Gr-1, and furthermore they were prone to do it with a faster 
kinetics compared to wt cells (Figure 3.1.11). Moreover, if we analyze the immature 
fraction of cells, looking at the expression of cKit and Sca1 on the Gr1
-
Mac-1
-
 gate, we 
can note that mutant MPPs extinguished their immature phenotypes (cKit
+
Sca1
+
 
population) earlier compared to controls (not shown). Thus, as in CMPs, there is an 
accelerated myeloid differentiation in Pbx1-deficient MPPs suggesting that Pbx1 may 
normally restrain MPP differentiation along the myeloid lineage (Ficara et al., 2013). 
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To test the in vitro lymphoid differentiation ability of multipotent progenitors we 
prospectively isolated LMPPs (LKSF
high
) from control and mutant mice. Similarly to 
what described for CLPs, we investigated the lymphoid differentiation potential of 
control and Pbx1-null LMPP in limiting dilution in vitro B-cell differentiation assays. 
We plated freshly sorted control LMPPs at 3, 10 and 30 cells/well and Pbx1-null 
LMPPs at 10, 30 and 90 cells/well. For each condition we seeded a very high number of 
wells (summary table in Figure 3.1.12 is representative of one experiment), and after 10 
days we selected the positive wells to analyze them by FACS for the presence of B220 
and CD19. As in the previous limiting dilution experiments, we also included CD11b, 
CD11c and Gr1 markers to identify also myeloid and/or dendritic cells. At day 13 we 
checked again the plates to make sure not to exclude positive wells with colonies too 
small for being evident after 10 days. Figure 3.1.12 shows representative FACS analysis 
of different wells. 
 
Figure 3.1.12 Pbx1-null LMPPs differentiation in limiting dilution. Representative FACS analysis of 
progeny of prospectively isolated LMPPs from control or mutant mice, cultured in limiting dilution in 
presence of cytokines. Percentages are relative to the parent gate. Summary table in the bottom shows the 
number of wells in one experiment for each condition (representative of two). 
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As described for CLPs, after gating on “live” cells, we first excluded cells expressing 
myeloid and dendritic cell markers. On the negative fraction we analyzed the expression 
of the lymphoid markers B220 and CD19. LMPPs gave rise to three different progenies. 
In the first column of Figure 3.1.12 there is an example of a more differentiated B cell 
population, expressing both B220 and CD19. In the second column there is an example 
of partial B cell differentiation in which there are Pre-Pro B cells expressing B220 but 
not yet CD19.  Finally, in the last column, an example of a positive well (i.e. a well with 
cells grown on the stroma), but in which all the cells are myeloid, without any B cells. 
The greater variability of LMPP outputs in this assay compared to CLPs highlights the 
more immature state of the former population. LMPPs are lymphoid-primed (not 
restricted) MPPs, still harboring some myeloid potential, while CLPs are lymphoid 
committed cells. This variability underlines the importance of performing limiting 
dilution analysis as opposed to bulk cultures. The semi logarithmic plot obtained after 
the analysis shows that there is a markedly lower frequency of B cell progenitors from 
Pbx1-null LMPPs compared to control LMPPs, meaning that the frequency of bona fide 
lymphoid progenitors is 3 fold higher in the control compared to Pbx1-null LMPPs 
(1/19 vs 1/62.5) (Figure 3.1.13).  In contrast, in vitro myeloid output from Pbx1-null 
LMPPs was increased compared to controls.  
 
Figure 3.1.13 LMPP limiting dilution analysis. Plots of limiting dilution analysis (representative of 
two) show the frequency of control or mutant LMPPs able to develop into CD19
+
 B cells in co-culture 
with OP9 stromal cells (R
2
=0.91 and 0.98, respectively) (from (Ficara et al., 2013)). 
 
The difference between control and mutant cells is more pronounced than the one 
observed in the CLP population (see Figure 3.1.8), in accordance with the hypothesis 
that in Pbx1-null mice the CLP reduction is mainly due to up-stream defects.  
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Taken together, we can conclude that Pbx1 affects lineage choice of MPPs by 
restraining myeloid differentiation and allowing lymphoid differentiation. 
 
Notably these experiments, together with other previous data obtained in Cleary’s lab, 
led to the publication of the following paper:  
“Pbx1 restrains myeloid maturation while preserving lymphoid potential in 
hematopoietic progenitors.”  
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3.2 microRNAs in Pbx1-null hematopoietic stem 
cells (HSCs) and multipotent progenitors (MPPs) 
 
 
In the secon part of this thesis we took advantage of Pbx1-conditional KO mice first to 
identify miRNAs involved in the maintenance of self-renewal, and secondly to study 
whether they are modulated by Pbx1 or if they regulate Pbx1-dependent pathways. To 
address these questions we performed a miRNA profiling of HSCs and their immediate 
downstream progenitors Flk2
-
MPPs from both mutant and control mice, and combined 
it with the transcriptional profile of the same populations previously performed on these 
mice. 
 
3.2.1 miRNA profiling of wt and Pbx1-null HSCs and MPPs 
To perform the miRNA profiling, highly purified HSCs (LKS
+
Flk2
-
CD34
-
) and their 
immediate downstream progeny (LKS
+
Flk2
-
CD34
+
, also called ST-HSCs, here Flk2
-
MPPs os simply MPPs) were prospectively isolated from poly(I:C)-treated Pbx1-
conditional KO mice crossed with the inducible Mx1Cre
+ 
line ((Ficara et al., 2008) and 
Figure 1.2.3). This is another Pbx1 conditional KO mouse model in which the 
expression of the Cre recombinase is induced by the administration of the polyinosinic-
polycytidylic acid (poly(I:C) (see §1.2.5). This experiment was conducted in 
collaboration with Cleary’s lab, since in our Institute we only maintain the 
Tie2Cre
+
.Pbx1
-/f
 conditional KO mice line. As described in §1.2.5, we choose to use 
those mice since the MxCre model gives the advantage, being inducible, to delete Pbx1 
when mice are adult enabling us to obtain a higher number of cells. 
HSCs and Flk2
-
MPPs were sorted, as previously mentioned, from the bone marrow of 5 
Pbx1 mutant and 4 control individual mice. The number of cells obtained was 1600 on 
average for HSCs (ranging from 1400 to 2000), and 6000 for Flk2
-
MPPs, which was 
sufficient for the miRNA profiling purpose performed with the PreAmplification 
strategy (see below), without pooling RNA from different mice.  
RNA was extracted from the sorted samples with a method that specifically preserves 
small RNAs together with the longer RNA transcripts and the MegaPlex TaqMan® 
 
 
72 
 
Assays system was used to perform the microRNA profiling (see materials and methods 
§5.5). MegaPlex TaqMan® Assays system is a highly sensitive and specific technology, 
based on real-time PCR, which enables analysis of small number of cells and allows 
simultaneous detection of more than 300 different miRNAs, including those expressed 
at low level, as opposed to other technologies with lower sensitivity like fluorescent-
based miRNA microarrays. Moreover, the inclusion of a PreAmplification step in the 
protocol further enhances miRNA profiling sensitivity, which is particularly useful in 
our case since the paucity of the cells. For profiling purpose the RT step was performed 
in Multiplex fashion, in which all the mature miRNAs are simultaneously reversed 
transcribed into cDNAs in one reaction using a specific pool of miRNA-stem looped RT 
primers designed to detect and quantitate up to 380 miRNAs. The same RT step can be 
performed with individual TaqMan miRNA Assays for single analysis purposes, 
performed later for validation of the profiling (see §3.2.5). We performed 14 rounds of 
PCR amplification, according to the manufacture protocol. Preamplified cDNA was 
loaded in a 384 MW plate in which 376 TaqMan miRNA and 8 different control assays 
were preloaded (in collaboration with Dr. Yuley Wang in Applied Biosystem). 
Of the profiled miRNAs 45% (177 on 384 including controls) was expressed within at 
least one group and were further analyzed, whereas the remaining 207 were filtered out 
(Ct level ≥ 35). 
 
 
3.2.2 Selection of the normalization strategy 
On the 177 expressed miRNAs we had to choose the correct normalization method 
before performing complex bioinformatics analysis. This is crucial since the 
normalization strategy strongly impacts the final results. For this part we collaborated 
with the Bioinformatics group of the Center for Advanced Studies, Research and 
Development in Sardinia (CRS4).  
The most appropriate normalization strategy has been selected on the basis of the 
smallest variation among replicates, measured by the coefficient of variation (CV = 
standard deviation/mean) (Deo et al., 2011). CV indicates to which extent the 
expression of an individual miRNA varies among samples.  
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In detail, we compared three normalization strategies:  
1. Endogenous control normalization 
2. Quantile normalization  
3. Median normalization 
Regarding the endogenous control, we applied several algorithms (normFinder, gNorm, 
Delta CT and BestKeeper) to facilitate the identification of an endogenous normalizer 
consistently stably expressed across all samples. Among the endogenous controls 
present in the array, the most stable controls, after comprehensive ranking of all four 
methods, were MammU6 and snoRNA202 that were used for further comparison with 
the other normalization strategies. 
Looking then at the overall signal distribution, we also compared the distribution of 
normalized values for each sample with the distribution of not normalized data (Figure 
3.2.1). This analysis reveals that the quantile normalization method generates the most 
homogeneous distribution.  
Finally, for each normalization strategy, we calculated the CV based on the set of the 
filtered miRNAs  (Table 3.2.1). After applying the normalization, a lower CV indicates 
a good performance of the normalization method. Quantile and median normalization 
show the best performance, since both of them reduce variability across the replicates.  
 
 
 
74 
 
 
Figure 3.2.1 Choice of the best normalization strategy. (A) Overall signal distribution. Distribution of 
normalized values for each sample compared to the distribution of not normalized data. (B) Variation 
among replicates. The boxplots show the distribution of the coefficent of variation (CV) of the 
normalized versus raw data. Quantile and Median normalization show the best performance (see text for 
details). Raw data filtered: not normalized data; MammU6: endogenous normalization using mammU6; 
snoRNA202: endogenous normalization using snoRNA202; quantile: quantile normalization; median: 
median normalization 
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Table 3.2.1 Summary table of coefficient of variation (CV) median values (from CV graphically showed 
in fig 3.2.1)  
 
Looking at the CV within the single experimental groups we realized that quantile 
normalization outperforms median normalization since it has the lowest CV in 3 out of 
4 sample groups. Thus, quantile normalization shows the overall best performance 
compared to all the other methods and was therefore chosen for the analysis of the 
miRNA profile. The complete list of normalized data is shown in Appendix A. 
 
3.2.3 Global miRNA analysis: hierarchical clustering and 
differential expression (DE) analysis 
After filtering and normalization, we performed a thorough bioinformatics analysis of 
the miRNA profiling data of wt and Pbx1-null highly purified HSCs and Flk2
-
MPPs, 
which allowed drawing different conclusions.  
A global analysis through unsupervised hierarchical clustering, using Pearson’s 
correlation as distance measure and average linkage as agglomerative algorithm, 
indicates for the first time a clear distinction between HSCs and Flk2
-
MPPs at the level 
of miRNA expression (Figure 3.2.2), suggesting that miRNAs might regulate the first 
transition step in the adult hematopoietic development.  
Within each group, mutant and control cells clustered separately, suggesting that Pbx1 
directly or indirectly regulates miRNA expression in those populations. 
A differential expression analysis through SAM (Statistical Analysis of Microarray) 
(Tusher et al., 2001) revealed that in the absence of Pbx1 several miRNAs are 
differentially expressed (DE) in HSCs and Flk2
-
MPPs compared to their relative wt 
controls, with putative targets in the list of Pbx1-dependent mRNAs (see later).  
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Figure 3.2.2 Heat map showing the hierarchical clustering of HSC and Flk2-MPP relative miRNA 
expression. The color scale represents Z-score transformed signal intensity (see text for details). 
 
In detail, focusing first on the HSC group, we found 48 DE miRNAs in Pbx1-null HSCs 
compared to controls (q-value < 0.1), of which 25 were down-regulated and 23 up-
regulated. Importantly, the expression of most of the DE miRNA changes more than 
two fold (Figure 3.2.3 and Table 3.2.2). Similarly, concentrating on the MPP group, 67 
DE miRNAs were found in Pbx1-null Flk2-MPPs compared to their controls, of which 
38 were down-regulated and 29 up-regulated (Figure 3.2.3 and Table 3.2.3). 
The two lists of DE miRNAs in Pbx1-null HSCs and in Pbx1-null Flk2
-
MPPs, both 
compared to their relative controls, only partially overlap, with about 50% of the DE 
miRNAs in Pbx1-null HSCs which is different from the DE miRNAs in Pbx1 null Flk2
-
MPPs (Figure 3.2.3 B). This suggests that Pbx1 may have different roles in different 
cell subpopulations and motivates us to profile additional downstream progenitors in the 
future, to search for additional role of Pbx1 and miRNAs during the later steps of 
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hematopoietic differentiation. In this regard, we already collected and stored RNA from 
wt and mutant LMPPs (three pools of 2000-5000 cells each), which we know are 
defective in generating lymphocytes in the absence of Pbx1, as demonstrated in §3.1. 
 
Figure 3.2.3 Results of miRNA differential expression analysis. (A) Hierarchical cluster dendrogram 
of relative expression of differentially expressed miRNAs. The color-scale represents Z-score 
transformed signal intensity (i.e. number of standard deviation from the miRNA average value). (B) 
Overlap of deregulated miRNAs in different conditions. The significance of the overlap has been 
computed by hypergeometric test: top, p-value 0.014; bottom, p-value 5e-05. 
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On the other hand, the fact that the other half of the DE miRNAs in Pbx1-null HSCs are 
also DE in Pbx1-null MPPs compared to their relative controls suggests that Pbx1 might 
be responsible, directly or indirectly, for their regulation. To support this hypothesis, we 
performed a promoter analysis through TRANSFAC
®
 (a database on Transcription 
Factor Binding Sites which collects data on eukaryotic transcription factors, their 
experimentally-proven binding sites, consensus binding sequences and regulated genes) 
and MAST algorithm (Bailey and Gribskov, 1998), searching for Pbx1 binding sites in 
different regions upstream of the miRNA start sites (5000bp, 10000bp and 15000bp). 
The binding sequence selected for applying MAST algorithm is the matrix containing 
both the Pbx1 core binding site motif (TGAT) and a general Hox core binding site motif 
that is conserved across the Hox family (TGAT). This because using Pbx1 binding site 
alone, which is only four base long, would generate high quantity of non specific results 
and, however, Pbx1 normally acts as heterodimer, mostly with Hox proteins (see 
Introduction, §1.2.3). Promoter analysis revealed the presence of putative Pbx1-Hox 
binding sites in DNA regions up-stream of the coding region of a few miRNAs common 
to the two lists. However, those miRNAs are either expressed at a very low level, or 
change less than 2-fold in Pbx1-null HSCs compared to control, and will not be further 
investigated, even if this analysis would suggest a possible direct regulation by Pbx1-
Hox binding. However, since Pbx1 can form complexes also with other homeodomain 
proteins, like Meis and Prep, and the binding specificity of the complexes is different 
according to the proteins involved, we will improve this analysis checking also for 
different binding site combinations (see Discussion, §4).  
This miRNA profiling gave us the opportunity to analyze miRNAs specifically 
expressed during the physiological transition from HSCs to the first MPP stage, thus 
generating for the first time a list of DE miRNAs in the more primitive stages of normal 
hematopoietic differentiation. Comparison of miRNA profiling of control HSCs versus 
control Flk2
-
MPPs revealed 71 DE probes, 37 of them up regulated and 34 down 
regulated during this differentiation step (Figure 3.2.3 and Table 3.2.4). By comparing 
this list with the previous one of 48 DE miRNAs in Pbx1-null HSCs versus wt, we 
found that 65% (31/48, hypergeometric p-value = 5e-05) of the DE miRNAs in Pbx1-
null HSC are also DE in the normal HSC-to-MPP transition (Figure 3.2.3 B). This is 
similar to what occurs at the transcriptional level, where Pbx1-null HSCs exhibit a 
transcriptional profile typical of their immediate downstream progeny, making mutant 
HSCs more similar to the first MPP stage than bona fide HSCs (Ficara et al., 2008). 
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This observation is in accordance with our hypothesis that Pbx1 might control miRNAs 
involved in HSC differentiation.  
 
Table 3.2.2 DE miRNAs in Pbx1-null HSCS. List of miRNAs DE in mutant versus wt HSCs as 
assessed by SAM analysis. In bold miRNAs which are common with the DE miRNAs in the normal 
HSC-to-MPP transition. In boxes miRNAs which are common with DE miRNAs in mutant versus wt 
MPPs. miRNAs highlighted in yellow are of potential interest for this study  (Abbreviations: FD=Fold 
Difference; Av= Average; PT= Predicted Target; Y=presence of PT among the DE mRNAs, with the 
number of PT specified for some; N=absence of PT). 
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Table 3.2.3. DE miRNAs in Pbx1-null MPPs. List of miRNAs DE in mutant versus wt MPPs. In boxes 
miRNAs which are common with DE miRNAs in mutant versus wt HSCs (Abbreviations: FD=Fold 
Difference; Av= Average). 
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Table 3.2.4. DE miRNAs in wt HSC-to-MPP transition. List of miRNAs DE in wt HSCs versus MPP. 
In bold miRNAs which are common with the DE miRNAs in mutant versus control HSCs 
(Abbreviations: FD=Fold Difference; Av= Average). 
 
3.2.4 mRNA-miRNA integrated analysis 
The miRNA profile was then compared to the previously published transcriptional 
profile data relative to mutant and wt HSCs (Ficara et al., 2008), searching for miRNA 
predicted targets whose change in expression inversely correlates with those of 
miRNAs. (Figure 3.2.4).  
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Figure 3.2.4 Schematic representation of miRNA:mRNA integrated analysis. See text for details. 
 
On the DE miRNAs we performed an in-silico prediction of their targets, which relyes 
on a combination of multiple algorithms, (PITA, TargetScan, miRanda, mirTarBase, 
miRecords, DianaMicroT, MirTarget2, picTar, starBase) also combined with 
experimental reports. This multiple combinatorial algorithm was developed by our 
bioinformatics collaborators and allows the simultaneous and interactive combination of 
the outputs of the different tools. Putative predicted targets were then compared with the 
transcriptional profile data searching for overlaps between DE mRNA and DE miRNA 
predicted targets whose expression inversely correlates with those of miRNAs. A 
hypergeometric test was applied for statistical evaluation of the significance of the 
overlap. 
Focusing first on the comparison between mutant and control HSCs, 40 out of 48 
miRNAs were found to have predicted anti-correlated targets within the list of DE 
mRNAs (p 0.1). Of these, 24 have more than 10 predicted targets and change more than 
2-fold compared to controls. In addition to providing anti-correlated miRNA-mRNA 
pairs, we also identified genes co-targeted by different miRNAs and functionally related 
genes within the same pathway. These analyses suggest that the same transcripts might 
be target of several miRNAs at the same time, and vice versa that the same miRNA can 
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target different DE genes (Table 3.2.5). Genes with multiple miRNA target site could be 
subjected to a stronger regulation and therefore could be potential important regulators 
of the mutant phenotype. The most targeted genes are Usp24 and Msi2, targets of 15 DE 
miRNAs, and Hlf, target of 11 DE miRNAs (Figure 3.2.5 A). Sheme of co-target 
analysis of the top targeted transcripts is summarized in Table 3.2.5. 
This combined multiple analysis (co-targeting) is particularly useful since the regulatory 
miRNA effect could be mediated by simultaneous action of different miRNAs rather 
than by a single miRNA:mRNA interaction. 
We also performed a gene set enrichment analysis (GSEA) of anti-expressed targets to 
search if in our gene set there is enrichment for genes common to other published gene 
sets from microarray studies which, in turn, can suggest biological and/or pathological 
function as well as molecular pathways possibly involved. This analysis revealed that 
anti-expressed targets common to different miRNAs are enriched for typical HSC 
genes, and for genes involved in differentiation, cell cycle, and immune system, among 
others (Figure 3.2.5 B). These findings nicely correlate with the phenotype of Pbx1-null 
HSCs, which display reduced self-renewal and aberrant differentiation. 
 
 
Figure 3.2.5 Cotargeting analysis. (A) Summary of the top genes targeted by ≥ 10 miRNAs highly 
expressed in Pbx1-null HSCs. (B) Summary of GSEA of anti-expressed miRNA targets. Bar graph shows 
the number of gene sets belonging to different functional groups that are enriched in the anti-expressed 
predicted targets (PT) of miRNAs up-regulated in the absence of Pbx1. Only miRNAs with ≥5 PT were 
included in the analysis (n=19 miRNAs). 
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Table 3.2.5. Cotargeting analysis. The matrix shows top genes targeted by multiple miRNAs and 
miRNAs which regulate multiple genes. Gene in bold were selected for future luciferase validation 
assays. Predicted miRNA:mRNA interactions are shown by red boxes. Experimentally validated target is 
shown in yellow box.  
 
We focused our analysis on miRNAs which have anti-correlated targets among the DE 
transcripts but, we don’t exclude a priori other miRNAs with no predicted targets 
among the DE genes, especially those with the highest level of fold difference, since 
mRNA-miRNA pairing may result in inhibition of translation rather that mRNA 
degradation (see introduction). Unfortunately we don’t have proteomic profiling data on 
Pbx1-null HSCs (it would be technically challenging). 
Since miRNA can be either intragenic or extragenic we also studied their genomic 
position. Intragenic miRNAs are expected to change concordantly with the host gene, 
however none of the DE miRNAs in mutant HSCs or Flk2
-
MPPs and their 
corresponding controls is located within a transcript detected in the microarray.  
 
 
3.2.5 Validation 
To validate some of the profiling data, we sorted HSCs and Flk2
-
MPPs from adult wt 
mice to extract RNA and perform Multiplexed RT and PreAmplifications. Of note, for 
validation we could purify miRNA and mRNAs from the same sample, although these 
populations are extremely rare. The possibility of comparing miRNAs and transcripts 
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within the same sample greatly improves our confidence on the results of the 
miRNA:mRNA integrated analysis.  
We were able to obtain enough HSCs and MPPs for reliable detection of miRNAs and 
mRNAs (Figure 3.2.6) from the same sample only by pooling BM of two-three mice. 
First, we assessed that the cDNA pre-amplification procedure, that we used also for 
mRNA, did not artificially alter transcript expression levels (Figure 3.2.6 B).  
 
 
Figure 3.2.6 miRNA and mRNA detection. (A) Representative amplification plot from a real-time PCR 
experiment showing expression of the ubiquitous small RNA mamm-U6 (in blue) and a representative 
miRNA (miRNA-223, in purple) in wt HSCs and Flk2-MPPs, after cDNA pre-amplification. (B) 
Expression level measured by real-time PCR of CD34 and Pbx1 in Flk2-MPPs relative to HSCs, in 
samples with or without cDNA pre-amplification (left and right, respectively). Data are normalized with 
-Actin and refer to two independent experiments (each performed in triplicate with pooled RNA from 
two-three mice).  
 
Higher expression of the CD34 marker and lower expression of Pbx1 in wt Flk2
-
MPPs 
compared to HSCs is expected, and confirmed the good quality of the samples and the 
sorting procedure, even if sorting purity is routinely checked by FACS analysis (not 
shown). 
We then confirmed some of the miRNA profiling data with independent real-time PCRs 
on these control samples (Figure 3.2.7) using individual TaqMan miRNA Assays. 
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Figure 3.2.7 Validation of miRNA expression. Expression level measured by real-time PCR of miR-
223 and miR-221 in wt Flk2
-
MPPs relative to HSCs, in pre-amplificated samples. Data are normalized 
with mamm-U6 and refer to three independent experiments (each performed in triplicate with pooled 
RNA from two-three mice). 
 
Interestingly, we found that the most up-regulated miRNA in the normal HSC-to-MPP 
transition is miR-221. This observation represents an important positive control of our 
analysis, since miR-221 has been previously predicted to be an important regulator of 
HSC maturation, thanks to its ability to repress cKit, based on data from human CD34
+
 
cells (Felli et al., 2005). 
Validation of miRNA profiling data and mRNA analysis is more complicated with 
mutant mice, due to the severe phenotype leading to early death and to an extremely 
low number of HSCs. This forces us to pool cells from mutant Tie2Cre
+
Pbx
-/f
 mice. 
However, we pool the frozen samples only after confirming  the Pbx1 deletion by PCR 
on genomic DNA extracted from blood or from colonies generated in CFC assays 
obtained from BM or spleen cells (Figure 3.2.8).  
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Figure 3.2.8 PCR to check for deletion of Pbx1. PCR on genomic DNA extracted from tail biopsies and 
from CFC colonies show correct Cre-mediated deletion of  the floxed allele in mutant hematopoietic 
cells, where Cre is expressed. 
 
Only by pooling three-four samples we are able to obtain enough HSCs 
(LKS
+
CD150
+
CD48
-
Flk2
-
) and Flk2
-
MPPs (LKS
+
CD150
+
CD48
+
Flk2
-
) for further 
analysis (miRNA validation is ongoing). 
 
3.2.6 Selection of candidate miRNAs 
After correlation with mRNA profiling data, we are currently selecting few miRNA 
candidates with the future aim of studying the mechanism(s) through which they exert 
their function, and their potential regulation by Pbx1. The first selection of specific DE 
miRNAs in mutant versus wt HSCs is being made on the basis of the following criteria: 
1. Relative abundance in HSCs (Ct levels in our miRNA profiling lower than 31 in 
at least one of the two groups); 
2. Fold difference (we arbitrarily chose to consider FD higher than 2,8); 
3. Presence of at least 10 anti-correlated predicted targets in the list of DE mRNAs. 
According to these criteria, we have initially selected five miRNAs (mir-532-5p, miR-
15a, miR-146a, miR 139-5p, miR-342-3p, Table 3.2.2), all up-regulated in the absence 
of Pbx1. Most of them are miRNAs that would also normally change in the HSC-to-
MPP transition (Table 3.2.4), and have putative targets potentially interesting in HSC 
biology (Table 3.2.5). 
On the other hand, in the list of miRNAs down-regulated in Pbx1-null HSCs, few 
miRNAs are potentially interesting even if condition 3 is not satisfied. They include 
miR-127 and miR-1 (Table 3.2.2), that are 92- and 12-fold decreased in the absence of 
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Pbx1, and that are also among the top down-regulated miRNAs in the normal HSC-to-
Flk2
-
MPP transition (Table 3.2.4). 
We are currently planning luciferase assays on few putative targets of those miRNAs in 
order to validate the bioinformatics results. Targets have been short-listed on the basis 
of their function, their fold-change in Pbx1-null HSCs compared to controls, and on the 
co-targeting studies. Selected miRNAs and their targets are indicated in bold in  the 
Table 3.2.2. Table 3.2.4 and Table 3.2.5. 
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4. DISCUSSION 
 
In this study, we demonstrate that Pbx1 functions as a brake on cell differentiation in 
multi-potent and myeloid-restricted progenitors, to maintain progenitor reservoirs and 
lymphoid potential. Moreover, we show that in the absence of Pbx1 HSCs display an 
altered micro-RNA profile, which resembles the normal MPP profile, suggesting a role 
for miRNAs in maintaining HSC identity. 
Understanding mechanisms of regulation of self-renewal versus differentiation of HSCs 
and downstream progenitors is a central issue in stem cell field since tiny alteration of 
these mechanisms may lead to hematopoietic failure and disease. If too few progenitors 
are produced, or if production of mature cells is unbalanced at the expense of one 
population respect to the others, the hematopoietic system will not be able to guarantee 
proper blood function, with different severity according to the cell population missing 
or more present (anemia, trombocytopenia, leucopenia, pancytopenia). Moreover, when 
HSC differentiation into committed progenitors is not accompanied by the typical loss 
of self-renewal capacity, or if downstream progenitors fail to fully differentiate into 
mature blood cells (Reya et al., 2001), leukemic transformation may occur (Weissman, 
2005). Moreover, increasing evidences show that lineage-restricted progenitors might 
be targets for oncogenic transformations rather than HSCs. They may acquire stem 
properties normally lost during differentiation, like unlimited self-renewal capacity that, 
in addition to their intrinsic proliferative capacity, may confer them leukemia stem cell 
potential (Cano et al., 2008; Cleary, 2009; Krivtsov et al., 2006; Minami et al., 2008; 
Signer et al., 2010; Somervaille et al., 2009; Tremblay et al., 2010; Wojiski et al., 
2009). In this perspective, the discovery of factors and pathways restraining progenitors 
or HSC differentiation is crucial for understanding leukemic stem cell biology and for 
future therapies. 
Regulation of HSC differentiation into myeloid and lymphoid lineages has been 
intensively studied, and several transcription factors displaying lineage-instructive roles 
in specific progenitors have been identified (Orkin and Zon, 2008; Rothenberg, 2007) 
(reviewed in (Iwasaki and Akashi, 2007)). However factors that limit progenitor 
maturation and guarantee continuous presence of undifferentiated progenitor cells ready 
for transient expansion are poorly known, as well as factors important for maintaining 
the proper levels of specific peripheral lymphoid and myeloid mature cells, without 
improper skewing towards one lineage respect to the other. In addition, whether the 
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same factors regulating HSC self-renewal are also implicated in maintaining progenitor 
reservoirs is unknown.  
Here, we show that Pbx1-null myeloid and multi-potent progenitors are characterized 
by a shorter cell cycle and a more rapid maturation rate toward the myeloid lineage at 
the expense of their expansion and of lymphoid lineage potential, making Pbx1 an 
essential regulator of progenitor lineage choice.  
Previous developmental studies on Pbx1 deficiency have attributed the hypoplasia or 
aplasia of multiple organ systems to a progenitor proliferation defect (Schnabel et al., 
2003a; Schnabel et al., 2003b; Selleri et al., 2001). In contrast, the gene expression 
profile of Pbx1-deficient CMPs, which reveals premature expression of downstream 
GMP genes, indicated that the reduction in myeloid-restricted progenitors is linked to an 
accelerated myeloid maturation rather than a proliferation defect. This was confirmed 
by our analysis of hematopoietic progenitors that shows increased short-term 
proliferation, rather than reduction, of MPPs and CMPs, followed by their premature 
exhaustion as they differentiate through myeloid fate. Accelerated maturation has also 
been observed in embryonic Pbx1-null chondrocytes, which undergo premature 
ossification (Selleri et al., 2001). Taken together, these data suggest that the primary 
myeloid defect caused by Pbx1 deficiency is accelerated maturation that shortens the 
temporal range of myeloid progenitor proliferative expansion, resulting in their final 
reduction.   
In addition to functioning as a brake on myeloid differentiation, Pbx1 also maintains 
lymphoid potential in hematopoietic progenitors. A blastocyst complementation assay, 
in which Pbx1-deficient ES cells were used to generate chimeric Rag1-deficient mice, 
indicated a specific role for Pbx1 in lymphoid development (Sanyal et al., 2007). This 
experimental approach allows the evaluation of Pbx1 function in lymphocyte 
development overcoming the Pbx1-null embryonic lethality prior to formation of a 
lymphoid compartment. In this system lack of Pbx1 completely depletes CLPs and most 
of their lymphoid progenies (B and NK cells). T-cells are also decreased, but detectable. 
In our Pbx1 mutant model, progenitors having primed or restricted lymphoid 
differentiation capacity (LMPPs and CLPs, respectively) are reduced both in number 
and in function, with decreased lymphoid outputs in culture. The severe CLP reduction 
may be due either to a cell-intrinsic requirement for Pbx1 in CLPs or alternatively be 
the consequence of insufficient CLP generation due to an aberrant differentiation 
program initiated by Pbx1 null multipotent progenitors, as suggested by our B cell 
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differentiation assay from LMPPs. Moreover, a role for Pbx1 in maintaining proper 
lymphoid potential in HSCs has been hypothesized in previous studies showing 
compromised lymphoid gene expression in HSCs in the absence of Pbx1 (Ficara et al., 
2008). 
In the second part of this study, we investigated a possible role for miRNAs in 
modulating HSC self-renewal, by studying the transition from HSCs to Flk2
-
MPPs, 
where loss of self-renewal occurs. Due to the profound self-renewal defect of Pbx1-null 
HSCs, Pbx1 conditional KO mice represent a useful tool to study whether the self-
renewal defect induced by Pbx1 loss is mediated by miRNAs. 
Cellular signals other than transcription factors that regulate the balance between self-
renewal and differentiation in HSCs are poorly understood, including any role for 
miRNAs. Moreover, it has been demonstrated that miRNAs regulate almost each 
hematopoietic differentiation step but whether they function also at the top of the 
hematopoietic tree, regulating the first transition from self-renewing HSC to non-self-
renewing multipotent cells, is still unclear. The interest in studying the role of miRNAs 
in HSC self-renewal is not unexpected, since it has been demonstrated that miRNAs 
have fundamental roles in hematopoietic development and they can be instructive 
determinants of cell fate, similarly to what transcription factors do (Graf and Enver, 
2009). Moreover they have been extensively linked to differentiation and self-renewal, 
which are the main defective processes in Pbx1-null HSCs. 
To elucidate the role of miRNAs in HSCs and/or progenitors, in this study we have 
generated a list of DE miRNAs in HSCs and Flk2
-
MPPs in the absence of Pbx1 
compared to wt. Moreover, combining miRNA data with the published transcriptional 
profile data of the same populations (Ficara et al., 2008) allowed searching for miRNA 
predicted targets whose change in expression inversely correlates with those of mRNAs. 
This analysis, coupled with extensive bioinformatics studies (such as promoter analysis, 
co-targeting and GSEA) allowed ultimate selection of very few candidate miRNAs to 
be further studied for their specific role in maintaining HSC self-renewal, and their 
possible regulation by Pbx1. In addition to a list of Pbx1-dependent miRNAs in HSCs 
and MPPs, this study analyzes for the first time miRNAs characteristic of the normal 
transition from HSCs to the first MPP stage, which represent an important finding for 
understanding physiological hematopoietic stem cell self-renewal and differentiation 
mechanisms. Indeed, in a few very recent studies a similar profiling has been performed 
on wt cells. However, additional studies are needed since either the complete list of 
 
 
92 
 
differentially regulated miRNAs has not been disclosed (Han et al., 2010; Ooi et al., 
2010), or HSC and MPP populations were purified using markers that do not allow high 
level of enrichment (Petriv et al., 2010). In this context, our study represents an 
important step forward. 
A substantial overlap (50%) in the lists of DE miRNAs in Pbx1-null HSCs and MPPs 
compared to their relative controls leads us to hypothesize a direct role of Pbx1 in their 
regulation. Although promoter analysis predicted the presence of Pbx1-Hox binding 
sites upstream of the coding region of few miRNAs, they are not relevant in our system 
according to our selection criteria. Nevertheless, chromatin immunoprecipitation 
sequencing (ChIP-seq) and ChIP-on-Chip experiments performed on tissues from wt 
and Prep hypomorphic E11.5 embryos demonstrate that Pbx1 directly binds some 
miRNA promoters (Penkov et al., 2013). Some of the miRNA genes, which showed a 
direct Pbx1-Meis binding are DE in mutant HSCv versus wt (mmu-let-7i, mmu-miR-
148a and mmu-miR-99b), however with small fold change. Differences in the 
developmental stage and in tissues, and above all in the Pbx1 molecular partner chosen, 
may account for differences in the listed miRNAs.  
Combinatorial miRNA:mRNA analysis reveals a tight connection between DE miRNAs 
and DE genes in Pbx1-null HSCs. Several genes are predicted targets of several 
miRNAs simultaneously and vice versa. Genes with multiple miRNA target sites could 
be subjected to a stronger regulation and therefore could be potential important 
regulators of the mutant phenotype. The most targeted genes are Usp24 and Msi2, 
targets of 15 DE miRNAs, and Hlf, target of 11 DE miRNAs (Figure 3.2.5 and Table 
3.2.5). All of them are down-regulated targets of up regulated miRNAs. Musashi-2 
(MSI2) is RNA binding-protein which increases proliferation of normal and malignant 
blood stem cells. Through inhibition of Numb transcription, Msi2 is a master switching 
regulator that is 'on' in normal HSCs and leukemic stem cells, and decreases in 
differentiating progenitors (Moore, 2010). This observation well correlates with the 
phenotype of Pbx1-null stem and progenitor cells, since in mutant HSCs, Msi2 is 
prematurely down-regulated. In human, higher expression of Msi2 correlates with poor 
prognosis in acute myeloid leukemia (Byers et al., 2011) and in adult B-cell acute 
lymphoblastic leukemia (Mu et al., 2013). Usp24 belongs to a large family of cysteine 
proteases that function as de-ubiquitinating enzymes and is involved in protein 
modifications and turnover (Zhang et al., 2012), while Hlf is a regulator of circadian 
rhythms, which influences HSCs (Mendez-Ferrer et al., 2009), and promotes resistance 
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to cell death (Waters et al., 2013). As Pbx1, Hlf is responsible for a subset of childhood 
B-lineage acute lymphoid leukemias characterized by the t(17;19) chromosomal 
translocation, which causes the formation of a fusion protein with the E2A gene 
(Hunger et al., 1996; Hunger et al., 1992; Waters et al., 2013). 
Besides the aforementioned proteins, other putative multiple-miRNAs target are of 
particular interest (see Figure 3.2.5 and Table 3.2.5). Meis1, which is a well-known 
Pbx1 functional partner, is generally considered a typical HSC gene, due to its high 
expression in the most immature hematopoietic populations and its down-regulation 
upon differentiation (Argiropoulos and Humphries, 2007; Pineault et al., 2002). Meis1 
regulation by Pbx1 is unexpected considering that it is a Pbx1 dimerization partner 
(Chang et al., 1997), although is consistent with a recent study showing compensatory 
increase in Pbx1 levels in response to loss of Meis1 (Unnisa et al., 2012). Moreover 
direct regulation of Pbx1 partners by Pbx1 itself has been reported in spleen progenitor 
cells during spleen ontogeny where Pbx1 directly regulates Hox11, and in turn, Hox11 
regulates its own promoter in complex with Pbx1 (Brendolan et al., 2005). Direct or 
indirect regulation of Meis1 by Pbx1 has been hypothesized (Ficara et al., 2008). It will 
be interesting to study whether miRNAs paly a role in this regulation. 
Another multiple-miRNA target is HoxA5, a transcription factor that plays important 
roles in embryogenesis, hematopoiesis, and tumorigenesis (Chen et al., 2005b). It is 
expressed during early myelopoiesis and simultaneously exerts inhibition of 
erythropoiesis and promotion of myelopoiesis, suggesting its role in lineage 
differentiation choice at the upstream multipotent progenitor stage (Fuller et al., 1999). 
Since HoxA5 could be a partner of Pbx1 and Pbx1 regulates different gene expression 
programs according to the different complexes it forms, modulation of the level of these 
proteins acting cooperatively with it, also maybe by miRNAs, could represent another 
mechanism through which Pbx1 acts. Moreover being HoxA5 implicated in lineage 
choice, it could be a possible downstream mediator of the defect in lineage choice 
showed in Pbx1-null progenitor cells.  
Nuclear factor of activated T cells (NFAT) is involved in proper regulation of T cells 
development and differentiation, as well as in granulocyte and dendritic cell activation. 
NFAT also negatively regulates myeloid lineage development, likely acting at the 
progenitor stage, since hematopoietic ‘stem cell-like’ cell lines (derived from BM cells 
transduced with constructs encoding the Nucleoporin 98 (NUP)-HOXB4 fusion 
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protein), expressing an NFAT-inhibitory peptide, develop an enhanced myeloid 
compartment both in vitro and in vivo (Fric et al., 2012) . 
Of note also Pbx1 is present among the putative targets of multiple miRNAs. If 
confirmed, this finding highlights a possible autocrine feed-back loop, as previously 
reported for other Pbx1 partners and for other miRNA-target pairs. 
Following the selection criteria (see §3.2.6), we selected few miRNAs for future 
experiments. Among them, miR-146a is of particular interest due to its role in impairing 
differentiation of multipotent progenitor cells into common lymphoid progenitors 
(Starczynowski et al., 2011). Overexpression of miR-146a in hematopoietic stem and 
progenitor cells, followed by bone marrow transplantation, resulted in a transient 
myeloid expansion with a concomitant impaired lymphopoiesis. Moreover, impaired 
reconstitution of recipient mice and reduced survival of hematopoietic stem cells is 
observed upon enforced expression of miR-146a. miR-146a is mainly expressed in 
primitive hematopoietic stem and progenitor cells and T lymphocytes, however specific 
role for miR-146a in HSCs have not be investigated. According to our miRNA profile 
data, miR-146a is highly expressed in HSCs and Flk2
-
MPPs and is down regulated (FD 
= 3,3) in the normal HSC-to-MPP transition, while it is upregulated in Pbx1-null HSCs 
compared to control. Thus we can speculate that normal miRNA-146a down regulation 
might allow MPPs to subsequently differentiate towards lymphoid lineage. This 
correlates with what observed in Pbx1-null HSCs where miR-146a is aberrantly 
upregulated. 
So far, we have focused our analysis on miRNAs which have anti-correlated targets 
among the DE transcripts, however we do not exclude a priori other miRNAs with no 
predicted targets among the DE genes, especially those with an high level of fold 
difference, since mRNA-miRNA pairing may result in inhibition of translation rather 
that mRNA degradation. 
Overall, this analysis set the basis for the discovery of miRNAs involved in the 
regulation of self-renewal versus differentiation. 
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5. Materials and Methods 
 
5.1 Mice 
Tie2Cre
+
.Pbx1
-/f
 and Mx1Cre
+
.Pbx1
-/f
 conditional knockout (KO) mouse models have 
been previously described (Ficara et al., 2008).  
Tie2Cre
+
.Pbx1
-/f mice, also referred to as “mutant” mice in this thesis, are generated in 
two steps. First, Pbx1 heterozygous mice (Selleri et al., 2001), in which one Pbx1 allele 
is interrupted by the neomycine resistance gene (Neo) in exon 3, are crossed with 
Tie2Cre
+
 mice, in which the Cre recombinase is under the control of the Tie2 promoter 
(Kisanuki et al., 2001), to obtain Tie2Cre
+
.Pbx1
+/-
 mice. The latter are then routinely 
mated with homozygous Floxed-Pbx1 (Pbx1
f/f
) mice, in which Pbx1 exon 3 is flanked 
by Lox-P sites (Koss et al., 2012), to generate Tie2Cre
+
.Pbx1
-/f
 mutant mice with a 25% 
frequency. The other littermates (Tie2Cre
+
.Pbx1
+/f
, Tie2Cre
-
.Pbx1
-/f
, Tie2Cre
-
.Pbx1
-/f
) 
do not differ in any of the described phenotypes hence were used indifferently as 
controls. All mice are in a C57BL/6 background. Mutant mice display a short life span 
and die between 2 and 4 weeks of age in our animal facility, slightly earlier than 
previously described.  
Mice were genotyped by PCR on genomic DNA using a combination of three individual 
PCR reactions (one for the Cre recombinase, one for the presence of the Neo in one 
Pbx1 allele, and one for the Pbx1-floxed insertion). Genotyping is performed within 
week three of age. Genomic DNA was extracted from tail biopsies following standard 
Protein Kinase (Kanellopoulou et al.) digestion and chloroform-ethanol extraction 
protocol.  
 
Primer sequences: 
Pbx1 Fw:  5’ TGA GTA TTC GGG GAG CCC AAG AA 3’    
Pbx1 Rev:  5’ CAT GAT GCC CAG TCT GTA GGG GT 3’ 
Neo:   5’ CTA TCA GGA CAT AGC GTT GG 3’ 
 
Tie2Cre Fw:  5’ CCC TGT GCT CAG ACA GAA ATG AGA 3’ 
Tie2Cre Rev:  5’ CGC ATA ACC AGT GAA ACA GCA TTG C 3’ 
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Pbx1 Flox Fw: 5’ GAG TTT GTC AGA GGA TTT TGT AGA TCT C 3’ 
Pbx1 Flox Rev: 5’ CAC GTA CAA ATT GAG TTG ATA CAG TGG G 3’ 
 
All experiments were performed with the approval of and in accordance with the Istituto 
Clinico Humanitas Administrative Panel on Laboratory Animal Care. 
Mx1Cre
+
.Pbx1
-/f
 mice were generated with a crossing scheme similar to the one 
described for Tie2Cre
+
.Pbx1
-/f
 mice by our collaborators at Stanford University. 
 
5.2 Hematopoietic stem and progenitor cells 
isolation and flow cytometry 
BM cell suspensions from control or mutant mice were obtained by crushing of multiple 
bones as previously described (Ficara et al., 2008). Briefly, after sacrifice, sternum, 
upper and lower limbs, shoulder blades, hips and vertebral column were dissected. After 
removal of connective tissues and spinal cord, bones were mechanically crushed with 
ceramic pestle and mortar, until BM cells were released from the bones cavity. The 
coarse suspension, made up of cell and bone debris, was then filtered through a 40 m 
filter, centrifuged at 1500 revolutions per minute (rpm), resuspended and counted. All 
bones and cell suspensions were constantly maintained on ice in cold PBS containing 
2% fetal bovine serum (FBS) (Lonza) and 1mM EDTA. This buffer, referred to 
hereafter simply as staining buffer or PBS-FACS, was also used during staining for 
FACS analysis or sorting. 
Hematopoietic progenitor cells were purified with magnetic enrichment systems based 
on the absence of lineage markers expression. We used a Lineage Cell Depletion kit 
(Mouse Hematopoietic Progenitor Cell Enrichment Kit, EasySep™, Stem Cell 
Technologies or Lineage Cell Depletion Kit, MACS, Miltenyi Biotec), and automated 
cell separators (RoboSep™, Stem Cell Technologies, or AutoMACS, Miltenyi Biotec). 
The Lineage negative enriched fraction was then subjected to multicolor cell surface 
staining prior to cytofluorimetric analysis or cell sorting. Cell suspensions were 
incubated for 30 minute on ice (or 15 minute at room temperature) with the proper mix 
of antibodies (final volume/sample = 100 l), washed twice and resuspended at the 
concentration of 1x10
7
cells/ml (or a minimum of 150 l) prior to FACS analysis or cell 
sorting. 
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The following subpopulations were analyzed and/or sorted: HSCs (Lin
-
/cKit
hi
/Sca
hi
/CD34
-
/Flk2
-
 or Lin
-
/cKit
hi
/Sca
hi
/CD150
+
/CD48
-
); MPPs at different stages 
of maturation (Lin
-
/CD127
-
/cKit
hi
/Sca
hi
/CD34
+
/Flk2
-
 or Flk2
int
 or Flk2
high
); CLPs (Lin
-
/CD127
+
/Flk2
high
/cKit
int
/Sca
int
); CMPs (Lin
-
/cKit
+
/Sca
-
/CD34
+
/FcgRII/III
int
); GMPs 
(Lin
-
/cKit
+
/Sca
-
/CD34
+
/FcgRII/III
high
); MEPs (Lin
-
/cKit
+
/Sca
-
/CD34
-
/FcgRII/III
-
). CLPs 
were isolated without EDTA containing buffer, since it has been shown detrimental for 
cell survivial (Karsunky et al., 2008) . 
Fluorochrome-conjugated monoclonal antibodies (mAbs) were purchased from BD 
Biosciences (BD), eBioscience or BioLegend. mAbs and relative concentrations used in 
this study are listed in Table 5.1. 
 
mAb  Fluorochrome Clone Dilution Company 
CD34 FITC RAM34 1:25 eBioscience 
CD135 (Flk-2, Flt-3) PE A2F10 1:50 eBioscience 
Sca1 (Ly-6A/E) FITC D7 1:100 eBioscience 
PE-Cy7 D7 1:400 eBioscience 
APC D7 1:100 eBioscience 
c-Kit  (CD117) APC-eFluor780 2B8 1:100 eBioscience 
CD150 (Arboleda et al.) APC TC15-12F12.2 1:66 Biolegend 
CD48 (BCM1) PE-Cy7 HM48.1 1:200 eBioscience 
CD127 (IL7R) APC A7R34 1:100 eBioscience 
CD16/32 PerCP-Cy5.5 93 1:100 eBioscience 
Mouse hematop. Lineage Cocktail* eFluor450   20 l/test eBioscience 
CD4 eFluor450 RM4-5 1:100 Biolegend 
CD8a eFluor450 53-6.7 1:200 eBioscience 
CD41 eFluor-450 eBioMWReg30 1:50 eBioscience 
Mac1 (CD11b) PE M1/70 1:400 eBioscience 
CD11c PE HL3 1:200 BD 
CD19  PE-Cy7 eBio 1D3 1:300 eBioscience 
B220 (CD45R) PerCP RA3-6B2 1:100 BD 
Gr1 APC RB6-8C5 1:500 eBioscience 
NK1.1 PE-Cy7 PK136 1:100 eBioscience 
 
Table 5.1 Monoclonal antibodies and relative concentrations used in this study. *The lineage 
cocktail is composed by the following eFluor450-conjugated mAbs: Mac1/CD11b (clone M1/70), Gr1 
(Ly-G6) (clone RB6-8C5), B220 (clone RA3-6B2), TER-119 (clone TER-119), CD3 (clone 17A2).  
 
Of note, since magnetic enrichment never reaches 100% purity, Lineage-depleted BM 
cells were further deprived of residual Lin positive cells by including in the combination 
of antibodies an additional PE-Cy7-conjugated Streptavidin (1:500; eBioscience) and 
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monoclonal antibodies (mAbs) to additional T cell and megakaryocyte markers not 
present in the lineage cocktail (CD4, 8, NK1.1 for T cells and in some instances CD41 
for megakaryocytes (See Table 5.1). 
Cytofluorimetric analyses were performed with FACS Canto I or II (BD Biosciences); 
Diva software (BD Biosciences) and FlowJo (Tree Star) were used for data acquisition 
and analysis, respectively. 
Cell sorting was performed using a FACS Aria I, with a fluidic upgrade to the version 
III, (BD Biosciences) equipped with Diva software (BD Biosciences) and data were 
analyzed using FlowJo (Tree Star). Sorted cells were collected in FBS and centrifuged, 
and either resuspended in medium for culture, or frozen in RNAlater® Solution 
(Ambion, Life Technologies) for subsequent RNA extraction. 
 
5.3 Cell culture 
5.3.1 Colony-forming unit (CFU) assay 
Hematopoietic progenitors were sorted and seeded (200-500 cells/ml) into 
methylcellulose-containing medium (methoCult 3234; Stem Cell Technologies) 
supplemented with mSCF (20 ng/ml), hFlt3 ligand (20 ng/ml), mIL-6 (10 ng/ml), mIL-3 
(10 ng/ml), mGM-CSF (10 ng/ml), mTPO (10 ng/ml) and hEpo (3 U/ml). All cytokines 
were purchased from PeproTech, except Epo (R&D Systems). CFU assays were 
performed in duplicate in 35mm dishes.  Colonies composed of at least 50 cells were 
counted and type of colony scored after 9 days of culture by optical microscope. Colony 
counts were normalized to 1000 cells plated.  
After counting, all colonies from each dish were harvested upon dilution of the 
methylcellulose-containing medium with warmed PBS (37°C). Cells were centrifuged 
at 1800 rpm for 10’ and residual methylcellulose was removed by vacuum aspiration. 
Cells were resuspended in PBS-FACS and counted or spotted for cytospyn preparation. 
 
5.3.2 Myeloid differentiation assay 
For in vitro myeloid differentiation freshly sorted MPPs and CMPs were plated in U-
bottomed 96-well plates and cultured in IMDM medium (Lonza) supplemented with 
10% FBS (Lonza) and SCF (20 ng/ml), IL-6, IL-3 (10 ng/ml each) for 3 or 6 days. At 
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each time point cells were harvested by gentle mechanical resuspension, stained with 
fluorochrome-conjugated monoclonal antibodies against Mac1/CD11b, Gr1, and/or with 
other antibodies listed in Table 5.1, and analyzed by FACS. 
 
5.3.3 in vitro B cell differentiation assays 
Freshly sorted LMPPs and CLPs were co-cultured with previously plated sub-confluent 
OP9 stromal cells in MEM-alpha medium supplemented with 10% heat-inactivated FBS 
(Lonza), 50 mM -mercaptoethanol (Gibco, Life Technologies), and mSCF (20 ng/ml), 
hFlt3L (20 ng/ml) and mIL-7 (10 ng/ml) (Peprotech). Cells were then harvested by 
pipetting and analyzed by FACS 4 or 10–11 days later upon staining with 
fluorochrome-conjugated monoclonal antibodies to B220 and CD19  (see Table 5.1). 
For limiting dilution assays, OP9 stromal cell layers were plated the day before in flat-
bottomed 96-well plates and different amounts of prospectively isolated LMPPs and 
CLPs were seeded on each well (10, 30, 90 cells/well and 3, 10, 30 cells/well for mutant 
and control cells, respectively). Medium (see above) was half-replaced every third day. 
Wells with visible hematopoitic growth were scored by optical microscope observation 
at two time points (10 or 13 days) and cells were harvested from each positive well 
individually and analyzed by FACS to assess the presence of B220
+
CD19
+
CD11b
-
Gr1
-
CD11c
-
 B cells. 
 
5.3.4 Cytospin 
Cells obtained from colonies were resuspended in 150 l of PBS-FACS and spotted on a 
glass slide according to standard cytospin protocol.  Briefly a cytofunnel is attached to a 
glass slide and slide carrier. The entire apparatus is inserted into a cytocentrifuge and 
the cell suspension is added. 5’ at 800xg cytospin centrifugation is performed to spot the 
cells. Spotted cells were stained with standard May-Grunwald/Giemsa staining. 
 
5.4 Statistical analysis 
Significance of differences was determined by two-tailed Student’s t-test. Error bars in 
bar graphs indicate s.e.m.  
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5.5 microRNA profiling and Real-time 
quantitative PCR 
MicroRNA profiling experiment was conducted in collaboration with Cleary’s lab in 
Stanford University School of Medicine and with Dr. Yuley Wang in Applied 
Biosystem.  
Briefly two-weeks-old MxCre
+
.Pbx1
-/f
 or MxCre
-
.Pbx1
-/f
 mice (5 mutants and 4 
controls) were given seven poly(I:C) injections every other day and sacrificed 4 weeks 
after the last injection.  
BM cells were obtained from multiple bones of individual mice and 
immunomagnetically selected, then stained with conjugated mAbs (to CD34, CD135, 
Sca-1, Lineage cocktail, and c-Kit) prior to sorting. Cells were maintained on ice when 
possible through all procedures. 
RNA from sorted cell populations (1400–2000 HSCs, 2–6000 Flk2-MPPs) was 
extracted with mirVana™ miRNA Isolation Kit (Applied Biosystems, Life 
Technologies), according to the manufacturer’s protocol and then subjected to 
MegaPlex TaqMan® Assays system (Applied Biosystems, Life Technologies) for 
microRNA profiling. MegaPlex TaqMan® Assays system is a technology based on real-
time PCR that enable analysis of small number of cells and allows simultaneous 
detection of more than 300 different miRNAs, including those expressed at low level. 
The system includes two main steps. The first step is a reverse transcription (RT) 
reaction, in which the miRNA is reversed transcribed into cDNA using a miRNA-
target-specific stem looped RT primer (Chen et al., 2005a) (Figure 5.1). 
In detail, the stem loop primer introduced a universal reverse primer sequence designed 
within a hairpin structure. The stem–loop RT primer displays two major advantages. 
First, it ensures specificity for only the mature form of miRNAs while miRNA 
precursors and other homologous sequences embedded in other transcripts will not be 
recognized. Second, it forms an RT primer/mature miRNA duplex that extends the 3’ 
end of the miRNA, resulting in a longer RT product. This design overcomes a 
fundamental problem in miRNA quantitation: the short length of mature miRNAs (~22 
nucleotides) which prohibits conventional design of a random-primed RT step (Chen et 
al., 2005a). With this strategy the longer cDNA template became suitable for the second 
step which is a standard real-time PCR using TaqMan® Assays, where another level of 
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specificity was provided during the real-time PCR process both by the miRNA specific 
forward primer and the TaqMan® probe. 
 
 
 
 
Figure 5.1 Schematic description of TaqMan miRNA assays. TaqMan-based real-time quantification 
of miRNAs includes two steps, stem–loop RT and realtime PCR. Stem–loop RT primers bind to at the 3’ 
portion of miRNA molecules and are reverse transcribed with reverse transcriptase. Then, the RT product 
is quantified using conventional TaqMan PCR that includes miRNA-specific forward primer, reverse 
primer and a dye-labeled TaqMan probes (from (Chen et al., 2005a)). 
 
 
miRNA RT was done with TaqMan® MicroRNA Reverse Transcription Kit (Applied 
Biosystems, Life Technologies), according to the manufacturer’s protocol.  
For profiling purpose the RT step was performed in Multiplex fashion, in which all the 
mature miRNAs are simultaneously reversed transcribed into cDNAs in one reaction 
using a specific pool of miRNA-stem looped RT primers designed to detect and 
quantitate up to 380 miRNAs (Megaplex™ RT Primers, Rodent Pool A, Applied 
Biosystems, Life Technologies). The same RT step was performed with individual RT 
primers for single analysis purposes with TaqMan miRNA Assays (see below).   
An extra step of multiplexed pre-amplification was introduced between the RT and the 
Real time PCR to further enhance miRNA profiling sensitivity. With this pre-
amplification step, multiplexed cDNA was simultaneously amplified before real time 
detection using another pool of sequence specific PCR primers (Megaplex™ PreAmp 
Primers, Rodent Pool A, Applied Biosystems, Life Technologies). TaqMan® PreAmp 
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Master Mix Kit (Applied Biosystems, Life Technologies) was used to perform pre 
amplification reaction. Twelve rounds of PCR amplification were performed, according 
to the manufacturer’s protocol. Preamplified cDNAs were loaded in a 384 MW plate in 
which 376 TaqMan miRNA and 8 different control assays were preloaded.   
For validation, individual real-time PCR reactions were performed to confirm some of 
the profiled miRNA on cDNA obtained with the above mentioned MegaPlex TaqMan® 
Assays system from freshly sorted HSCs and Flk2
-
MPPs (pool of three/four wt mice). 
RNA was extracted with RNeasy Micro Kit (Qiagen), according to the manufacturer’s 
protocol for recovery long and short RNA molecules. RNA was reverse transcribed in 
Multiplex fashion using TaqMan® MicroRNA Reverse Transcription Kit (Applied 
Biosystems, Life Technologies) with Megaplex™ RT Primers, Rodent Pool A  (Applied 
Biosystems, Life Technologies), and preamplified using TaqMan® PreAmp Master Mix 
Kit (Applied Biosystems, Life Technologies).  
The same Multiplexed analysis is applied to mRNA for validation purposes. RNA was 
reverse transcribed using High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Life Technologies) and cDNA pre amplified using the same TaqMan® 
PreAmp Master Mix Kit and a custom made pool of primers, according to the 
manufacturer’s protocol. Up to one hundred transcripts can be preamplified 
simultaneously.  
Multiplexed cDNA was then subjected to individual real-time PCR for miRNAs and 
mRNA using TaqMan® MicroRNA Assays and TaqMan® Gene Expression Assays 
respectively (all purchased from Applied Biosystems, Life technologies).  
Since extracted RNA is under Nanodrop detection limit, a synthetic not mammalian 
miRNA-spike (cel-miR-39, from C. elegans) was added to the cell lysate prior to 
extraction as technical control. miRNA-spike follows all the extraction and 
preamplification procedures and is neither retrotrancribed nor preamplified with kits for 
mammalian miRNAs. It is separately detected with individual TaqMan® MicroRNA 
Assays. Every sample analyzed gave high reproducible results in term of cel-miR-39 Ct 
values, indicating a good quality of extraction procedure without loss of material. 
TaqMan® Gene Expression Assays used in the present study were: mouse Cd34 assay 
(assay ID: Mm00519283_m1) and mouse Pbx1 assay (assay ID: Mm04207616_m1). 
Mouse bActin assay (assay ID: Mm00607939_s1) was used as endogenous 
housekeeping gene. 
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TaqMan® MicroRNA Assays used in the present study were: mmu-miR-223 assay 
(assay ID: 002295), mmu-miR-221 assay (assay ID: 000524), mmu-miR-99b assay 
(assay ID: 000436), mmu-miR-146a assay (assay ID: 000468) and mmu-let-7e assay 
(assay ID: 002406). U6 snRNA assay (assay ID: 001973) was used as endogenous 
control and cel-miR-39 assay (assay ID: 000200) was used as spike technical control. 
 
5.6 Bioinformatics Analyses 
All bioinformatics analyses were done by Dr. Paolo Uva in the Bioinformatics group of 
the Center for Advanced Studies, Research and Development in Sardinia (CRS4). See 
Result § 3.2 for specific analysis descriptions. 
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APPENDIX A 
Raw data of Pbx1-null and control miRNA profile of HSCs and MPPs (quantile 
normalized) 
 
Control HSCs Control Flk2-MPPs Mutant HSCs Mutant Flk2-MPPs 
"AssayID" # 433 # 434 # 436 # 437 # 433 # 434 # 436 # 437 # 422 # 423 # 424 # 425 # 435 # 422 # 423 # 424 # 425 # 435 
"mmu-let-7b" 27,59 28,92 29,50 29,55 27,50 27,17 27,09 27,09 28,03 28,39 28,46 28,71 28,15 27,33 26,88 27,43 27,69 26,88 
"mmu-miR-7b" 37,95 38,02 37,43 38,28 38,61 38,59 38,86 39,07 36,53 36,66 36,39 37,36 38,15 38,62 38,62 38,25 39,07 38,25 
"Mamm U6" 20,92 20,92 22,05 21,28 20,92 20,92 21,28 20,51 20,51 20,51 20,51 20,51 20,32 20,51 20,51 20,51 20,32 20,44 
"Mamm U6" 20,51 20,44 20,51 20,51 20,51 20,44 20,51 20,32 20,92 20,44 20,12 20,32 20,44 20,32 20,44 20,12 20,12 20,12 
"mmu-miR-9" 34,84 38,02 37,43 38,28 38,61 35,50 38,86 39,07 32,08 38,62 37,36 35,30 32,53 37,36 38,96 39,98 39,71 37,60 
"mmu-miR-10a" 27,17 27,17 27,17 27,00 27,25 27,09 27,43 27,33 26,20 27,69 28,03 28,15 26,71 26,35 26,35 26,57 26,57 26,79 
"mmu-miR-15a" 32,43 33,45 37,43 35,50 31,76 31,07 33,35 31,50 31,29 31,07 32,08 31,29 34,35 30,79 31,07 30,69 31,07 30,79 
"mmu-miR-15b" 26,20 26,46 25,49 26,20 25,73 25,49 25,73 25,90 25,73 25,95 25,60 25,95 26,02 25,49 26,28 25,90 25,90 25,82 
"mmu-miR-16" 22,95 23,14 22,95 23,14 23,14 22,95 23,14 23,37 23,51 22,71 22,71 22,71 23,14 23,37 23,37 23,51 23,37 23,37 
"rno-miR-17-3p" 37,95 38,02 37,43 38,28 35,50 36,08 38,86 38,25 38,96 38,62 37,20 39,07 38,15 39,14 38,59 38,40 37,89 36,95 
"mmu-let-7c" 25,28 25,82 26,02 25,49 25,49 24,93 25,49 25,60 25,82 26,12 25,90 26,46 25,60 25,82 25,15 25,60 26,12 25,60 
"mmu-miR-18a" 32,25 32,19 29,55 29,78 27,78 28,77 27,69 27,78 28,77 29,50 29,38 30,27 31,76 28,15 28,24 27,87 28,15 27,95 
"mmu-miR-19a" 25,60 26,02 25,28 25,60 24,67 24,67 24,67 24,67 26,02 26,46 26,12 26,88 25,90 25,28 25,49 25,49 25,28 24,93 
"mmu-miR-19b" 20,44 20,51 20,32 20,44 20,44 20,51 20,12 21,28 21,28 22,60 21,28 22,41 21,28 21,28 21,28 21,28 21,28 20,92 
"mmu-miR-20a" 22,05 22,41 20,92 22,41 22,05 22,05 22,05 22,05 22,05 22,95 22,60 23,14 22,60 22,05 22,05 22,05 22,05 22,05 
"mmu-let-7d" 27,87 27,50 27,78 27,50 27,17 27,33 27,25 27,25 27,69 27,87 27,69 27,33 27,78 27,59 27,50 27,59 27,87 27,50 
"mmu-let-7e" 27,43 28,15 28,54 27,78 26,79 26,35 26,20 26,12 26,94 26,02 25,95 26,12 27,59 26,46 26,57 26,12 26,46 26,02 
"mmu-let-7g" 29,38 30,27 29,27 29,73 28,97 28,65 28,60 28,54 28,71 28,46 28,39 27,95 29,33 28,46 28,39 28,39 28,54 28,39 
"mmu-let-7i" 28,15 28,97 28,87 27,87 26,57 26,88 26,57 26,71 26,88 27,00 26,35 26,71 28,24 26,71 27,09 26,71 26,71 26,71 
"mmu-miR-1" 31,50 30,37 30,59 29,89 34,95 31,58 32,91 34,25 37,36 36,39 38,79 28,60 30,27 37,74 37,20 37,50 38,65 35,64 
"rno-miR-1" 28,97 29,55 30,27 28,92 31,83 31,40 32,00 33,01 34,95 37,20 36,20 27,50 29,10 36,30 32,74 35,41 38,62 32,53 
"mmu-miR-7a" 34,11 34,25 33,25 34,04 34,63 36,80 35,98 38,18 38,96 32,84 32,00 34,04 38,15 34,04 34,84 36,39 36,53 33,77 
"mmu-miR-20b" 26,71 26,57 26,57 26,79 25,28 25,73 25,15 25,15 26,57 26,88 26,88 27,59 26,28 25,90 25,60 25,28 25,49 25,49 
"mmu-miR-27b" 29,18 31,40 28,15 28,71 28,24 28,39 28,24 28,24 29,89 29,60 29,66 29,78 29,23 28,31 28,60 28,24 28,31 28,24 
"Mamm U6" 21,28 21,28 21,28 20,92 21,28 21,28 20,92 20,92 20,44 20,32 20,32 20,12 20,51 20,44 20,12 20,44 20,51 20,51 
"Mamm U6" 20,32 20,32 20,44 20,32 20,32 20,32 20,32 20,12 20,12 20,12 24,50 20,92 20,12 20,12 20,32 20,32 20,44 20,32 
"mmu-miR-28" 29,73 31,50 30,11 31,40 30,90 30,47 30,47 30,69 30,37 29,89 29,50 29,50 30,07 30,59 30,90 31,17 30,79 31,07 
"mmu-miR-29b" 32,08 38,02 30,37 32,08 32,43 33,25 32,19 34,11 32,34 31,17 32,74 32,08 38,15 32,84 33,35 33,60 32,43 32,43 
"mmu-miR-29c" 31,69 31,83 31,50 32,19 32,34 31,83 31,92 32,08 30,69 30,07 30,79 29,89 31,40 30,90 31,29 31,29 30,90 31,58 
"mmu-miR-30b" 23,70 24,15 23,70 24,15 23,85 23,70 24,15 24,15 23,85 23,85 23,70 23,37 24,50 24,15 23,85 23,85 24,15 23,85 
"mmu-miR-30c" 23,37 22,95 23,37 23,37 23,37 23,37 23,51 23,70 23,70 23,51 23,37 22,95 23,51 23,51 23,70 23,37 23,51 23,51 
"mmu-miR-30d" 28,31 27,87 28,39 28,39 28,46 27,87 28,31 28,31 28,46 27,95 27,33 27,87 28,65 28,24 28,31 28,46 28,46 28,60 
"mmu-miR-32" 37,95 38,02 37,43 33,77 38,61 36,53 36,66 37,06 38,96 36,08 38,79 38,12 38,15 37,06 36,80 36,80 37,06 34,74 
"mmu-miR-34a" 37,95 38,02 37,43 38,28 38,61 38,59 36,53 36,20 34,04 34,11 35,07 34,52 38,15 30,97 32,34 30,90 30,97 34,04 
"mmu-miR-93" 26,46 26,79 26,12 26,71 25,40 25,60 25,40 24,93 27,00 27,09 26,94 27,17 27,25 26,20 25,82 25,73 25,95 25,73 
"mmu-miR-21" 26,35 26,71 26,20 26,46 26,28 26,71 26,46 26,57 25,60 26,28 26,46 26,35 26,88 26,02 25,95 26,28 26,20 26,35 
"mmu-miR-23b" 37,95 38,02 30,79 35,74 32,19 34,04 31,58 31,58 34,74 36,53 37,50 34,25 30,20 31,69 32,25 32,25 31,83 31,76 
"mmu-miR-24" 23,85 23,85 24,15 23,85 23,70 23,85 23,85 23,85 24,67 24,50 24,15 24,67 24,15 23,70 23,51 23,70 23,85 23,70 
"mmu-miR-25" 27,78 28,03 26,79 27,69 27,59 27,50 27,33 27,50 28,65 29,10 28,60 28,97 28,54 27,50 28,03 27,50 27,59 27,09 
"mmu-miR-26a" 25,95 25,60 25,82 25,82 25,90 25,95 25,90 25,95 25,95 25,82 25,73 25,73 25,49 25,95 26,12 26,35 26,28 26,20 
"mmu-miR-26b" 26,12 26,20 26,88 26,28 27,00 26,94 27,17 27,00 26,28 25,73 26,02 25,82 26,12 26,88 27,17 27,25 27,17 27,00 
"mmu-miR-27a" 28,60 28,54 28,60 29,01 28,60 28,97 28,87 28,77 29,73 29,66 29,27 30,20 31,58 28,92 29,23 29,10 28,92 28,77 
"mmu-miR-99a" 29,23 29,73 32,84 30,37 29,99 29,45 30,20 28,92 28,39 32,19 32,19 29,66 31,29 29,18 29,66 29,38 29,33 29,55 
"mmu-miR-125a-3p" 37,95 38,02 37,43 38,28 38,61 38,59 38,86 39,07 37,60 38,62 38,79 37,60 32,84 38,96 39,66 39,71 38,32 37,74 
"mmu-miR-125a-5p" 28,92 29,10 32,62 30,69 29,60 30,20 30,11 30,27 30,07 30,20 29,73 30,11 29,38 30,11 29,60 29,78 29,60 29,78 
"mmu-miR-125b-5p" 28,87 28,39 29,78 26,88 29,33 28,87 29,33 29,23 29,33 30,37 29,99 30,47 29,18 28,77 28,97 28,97 28,97 29,18 
"mmu-miR-126-3p" 26,02 25,28 25,60 25,40 26,02 25,28 24,93 25,49 24,93 25,28 25,40 25,40 24,67 23,85 24,15 24,15 23,70 24,50 
"mmu-miR-126-5p" 30,69 29,33 29,60 29,10 30,37 29,60 29,18 29,33 28,24 28,87 28,92 28,87 27,50 27,95 27,78 28,31 27,33 28,03 
"mmu-miR-127" 31,92 29,27 30,69 33,35 38,61 34,63 37,74 36,80 38,96 38,62 38,79 34,63 38,15 39,25 38,79 39,98 39,25 38,12 
"mmu-miR-128a" 32,62 38,02 32,34 30,07 35,64 38,59 32,62 32,19 30,47 31,40 30,97 31,50 34,95 33,25 35,41 34,04 33,35 34,11 
"mmu-miR-130a" 30,11 30,20 30,47 30,27 29,55 29,38 29,99 29,66 29,66 30,59 31,17 31,69 29,66 29,23 29,55 29,23 29,27 29,50 
"mmu-miR-130b" 29,55 28,46 37,43 29,66 29,10 28,60 28,54 28,71 29,78 29,23 29,60 29,10 29,45 28,87 28,77 28,65 28,87 28,65 
"mmu-miR-99b" 29,33 28,31 29,66 29,45 30,59 30,11 30,79 29,78 29,55 30,79 31,50 30,97 29,89 30,20 30,47 30,47 30,37 30,20 
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"mmu-miR-133a" 25,73 27,33 27,87 27,59 29,78 29,10 28,77 31,69 28,92 34,35 33,13 23,51 26,57 34,35 32,62 31,76 35,83 30,69 
"mmu-miR-135a" 37,95 38,02 37,43 38,28 38,61 38,59 37,06 37,20 38,96 38,62 38,79 39,07 32,91 38,47 38,86 38,62 38,40 37,20 
"mmu-miR-100" 29,66 31,58 32,25 31,76 30,20 29,33 30,37 28,87 27,95 31,83 31,76 28,92 31,50 29,45 29,73 29,73 29,45 29,66 
"mmu-miR-101a" 28,71 28,24 27,95 28,87 28,92 28,92 29,01 29,27 29,45 29,33 29,18 29,38 28,71 29,50 29,27 29,45 29,23 28,97 
"mmu-miR-103" 31,58 33,13 34,04 32,91 31,50 31,29 32,08 30,79 31,58 33,91 34,35 39,07 33,77 31,07 32,00 31,40 31,76 31,40 
"mmu-miR-107" 37,95 38,02 37,43 38,28 32,91 36,66 32,74 34,74 36,39 38,62 36,08 38,02 32,43 33,77 35,20 33,91 34,63 33,91 
"mmu-miR-124" 37,95 32,43 37,43 38,28 36,08 34,84 35,07 38,40 35,30 33,01 33,35 34,84 34,11 37,50 34,11 37,20 36,80 36,66 
"mmu-miR-142-5p" 32,00 32,74 37,43 31,50 31,69 31,50 31,29 32,00 32,00 32,25 31,69 31,76 31,17 32,00 32,53 32,43 32,53 31,69 
"snoRNA135" 24,93 25,15 24,93 25,15 24,93 24,50 25,28 25,28 25,15 25,49 25,15 25,49 25,73 24,93 24,50 24,67 24,93 25,28 
"mmu-miR-145" 30,79 31,76 31,07 31,92 34,11 32,53 32,34 36,08 32,84 38,62 35,41 30,07 30,79 35,74 31,40 34,25 34,84 36,20 
"mmu-miR-146a" 23,14 23,70 24,50 22,71 26,88 26,12 26,79 26,28 22,60 21,28 20,92 21,28 22,95 26,28 26,02 26,02 25,73 25,90 
"mmu-miR-146b" 25,82 25,73 26,28 25,90 26,12 26,02 26,28 26,20 25,49 25,60 25,82 25,90 24,93 25,40 25,28 25,40 25,15 25,15 
"mmu-miR-148a" 26,88 26,88 27,43 26,12 29,18 29,50 28,97 29,73 25,90 25,15 25,28 24,15 26,79 29,55 29,38 29,50 29,89 29,27 
"mmu-miR-148b" 31,29 33,01 37,43 38,28 34,84 35,07 32,53 32,25 32,62 33,13 32,84 33,13 38,15 33,45 34,25 34,35 34,11 32,91 
"mmu-miR-150" 24,67 24,50 23,85 23,70 25,82 25,40 25,95 25,40 23,14 22,41 22,41 22,60 23,85 24,67 25,40 24,93 24,67 25,40 
"mmu-miR-152" 28,24 27,95 28,46 28,03 28,87 29,99 29,78 30,59 28,31 27,25 27,43 26,02 28,31 29,78 30,11 29,99 29,99 29,99 
"mmu-miR-181a" 29,78 30,59 28,24 28,77 28,77 28,54 28,46 28,03 29,23 28,65 28,54 28,46 29,55 28,71 29,18 28,87 29,38 29,10 
"mmu-miR-181c" 34,74 32,53 33,60 34,95 32,00 32,34 33,01 32,34 32,91 33,77 34,11 34,95 32,34 33,01 34,52 33,35 33,45 32,62 
"mmu-miR-138" 37,95 31,17 30,97 30,79 31,29 31,92 31,76 31,29 32,19 31,76 30,90 33,60 31,69 31,83 32,43 32,62 32,34 31,50 
"mmu-miR-139-5p" 30,07 28,60 31,58 28,60 29,50 29,89 29,23 28,60 27,25 27,50 27,59 28,03 29,78 28,54 27,95 28,71 28,65 29,33 
"mmu-miR-140" 26,57 26,35 26,35 26,57 26,94 27,00 26,88 26,88 27,50 26,94 27,25 26,57 26,94 27,00 27,25 27,09 26,94 27,17 
"mmu-miR-142-3p" 24,50 24,93 23,51 24,50 24,50 24,15 24,50 24,50 24,50 24,93 24,93 23,85 25,15 24,50 24,93 24,50 24,50 24,67 
"mmu-miR-182" 37,95 38,02 37,43 33,45 38,61 38,59 34,84 35,64 33,45 31,92 32,25 32,74 34,04 39,96 38,32 39,29 40,00 38,86 
"mmu-miR-193b" 27,69 27,43 27,00 27,09 27,95 27,95 27,95 29,10 26,46 26,20 27,17 28,39 25,95 28,03 27,59 27,95 27,95 27,33 
"mmu-miR-194" 31,40 32,91 32,74 32,43 33,13 32,43 31,40 32,74 31,07 32,34 30,07 30,59 30,97 32,53 31,69 33,25 32,74 32,25 
"mmu-miR-195" 29,27 29,66 29,10 29,38 29,89 29,27 29,55 29,50 29,18 28,92 29,01 28,77 29,01 29,99 29,78 30,11 30,11 29,60 
"mmu-miR-196b" 29,01 28,87 28,97 29,33 27,87 27,69 28,15 28,39 29,10 29,38 29,89 30,79 28,60 27,87 27,87 28,03 28,03 28,15 
"rno-miR-196c" 27,00 27,09 27,59 26,94 26,35 26,28 26,35 26,35 27,17 28,31 28,24 29,18 26,46 26,57 25,90 26,46 26,35 26,46 
"mmu-miR-197" 29,10 29,45 29,73 28,54 33,45 31,69 31,83 31,17 30,20 29,73 30,20 31,40 29,27 31,58 31,17 32,34 32,25 33,01 
"mmu-miR-199a-3p" 37,95 38,02 34,25 38,28 38,61 38,59 37,36 39,07 37,74 38,62 38,79 39,07 38,15 38,86 37,74 38,52 38,86 38,79 
"mmu-miR-200c" 37,95 38,02 37,43 38,28 38,61 38,59 37,60 38,02 35,98 28,03 35,83 33,01 38,15 35,50 36,20 35,83 36,08 36,30 
"mmu-miR-203" 25,15 24,67 25,15 25,73 26,46 26,57 26,94 27,17 26,35 27,33 27,78 27,69 25,28 26,94 27,33 27,00 27,00 27,25 
"mmu-miR-184" 30,90 29,89 37,43 31,69 34,52 38,59 38,86 39,07 32,53 37,36 34,63 39,07 32,19 38,65 36,66 39,14 39,29 34,95 
"mmu-miR-185" 37,95 35,07 37,43 38,28 37,20 36,39 36,08 37,74 38,96 34,84 38,79 34,11 38,15 36,66 38,52 35,98 35,20 38,59 
"mmu-miR-186" 28,46 29,18 28,92 28,65 28,71 28,46 28,65 28,97 29,60 28,54 28,87 28,31 28,39 29,73 28,92 29,01 28,77 28,71 
"mmu-miR-191" 22,41 22,05 22,41 22,05 22,71 22,71 22,71 22,71 22,41 22,05 22,05 22,05 22,41 22,95 22,71 22,95 22,71 22,71 
"mmu-miR-192" 30,47 30,69 31,83 30,97 30,97 32,08 31,50 31,83 31,17 30,69 30,27 29,99 29,99 32,74 32,08 32,00 31,40 31,29 
"snoRNA202" 20,12 20,12 20,12 20,12 20,12 20,12 20,44 20,44 20,32 20,92 20,44 20,44 20,92 20,92 20,92 20,92 20,92 21,28 
"mmu-miR-218" 31,07 34,35 31,29 33,13 35,20 33,45 33,13 32,62 33,13 32,53 35,74 32,91 30,59 34,74 33,91 35,20 34,25 33,35 
"mmu-miR-221" 37,95 38,02 37,43 38,28 29,01 30,27 27,87 27,69 31,83 34,74 37,74 36,30 38,15 27,17 28,15 26,94 27,09 27,69 
"mmu-miR-222" 24,15 23,37 24,67 24,67 23,51 23,51 23,37 23,51 24,15 24,67 24,67 25,60 23,70 23,14 23,14 23,14 23,14 23,14 
"mmu-miR-223" 25,90 25,95 26,94 27,17 24,15 25,15 23,70 23,14 27,33 28,15 28,31 28,54 26,20 25,15 24,67 25,15 25,82 24,15 
"mmu-miR-224" 33,77 34,11 37,43 38,28 32,74 32,84 35,30 31,07 31,50 34,63 32,91 33,77 30,90 31,92 31,92 32,19 31,92 31,83 
"rno-miR-207" 31,76 32,62 37,43 32,62 30,11 30,37 30,59 29,99 31,76 29,99 32,53 31,83 33,60 30,07 29,10 30,20 29,78 30,07 
"mmu-miR-210" 37,95 38,02 37,43 38,28 38,61 38,59 38,86 39,07 38,96 38,62 38,79 39,07 38,15 38,32 39,66 38,32 38,79 39,45 
"mmu-miR-301a" 28,39 29,78 28,03 29,50 28,31 28,24 28,92 28,65 28,87 29,27 29,33 29,60 28,97 28,60 28,71 28,60 28,71 28,46 
"mmu-miR-301b" 30,59 28,65 28,71 29,27 28,15 28,31 28,39 28,46 29,01 29,55 29,55 29,55 29,73 28,65 29,01 28,77 28,60 28,92 
"mmu-miR-320" 28,03 27,78 28,31 28,24 28,39 28,03 28,71 28,15 28,15 27,17 26,57 27,25 28,46 28,97 28,46 28,92 29,18 29,01 
"mmu-miR-324-5p" 32,19 30,11 33,91 30,20 30,27 30,79 30,69 29,89 31,40 30,27 30,11 31,07 31,92 30,47 30,69 30,27 30,47 30,59 
"rno-miR-327" 37,95 38,02 37,43 34,52 38,61 37,20 38,18 35,98 38,18 35,20 33,01 35,74 38,15 37,89 37,06 38,59 37,36 38,96 
"mmu-miR-328" 27,09 26,94 26,71 27,33 27,09 27,43 27,00 26,79 26,71 26,79 26,79 27,00 27,33 27,09 27,43 27,17 27,43 27,59 
"mmu-miR-331-3p" 29,50 29,60 29,89 29,99 29,38 29,23 29,60 29,60 29,38 28,97 28,97 28,65 28,87 29,60 29,50 29,66 29,55 29,73 
"mmu-miR-331-5p" 37,95 38,02 32,53 33,91 33,60 32,62 37,50 34,84 37,20 32,91 34,84 33,25 38,15 35,64 34,35 35,07 34,52 36,39 
"mmu-miR-294" 37,95 34,52 37,43 34,74 38,61 35,64 38,86 38,12 38,96 38,62 35,64 38,25 34,84 39,07 38,12 38,12 38,18 39,45 
"mmu-miR-296-5p" 32,74 32,25 29,99 33,01 32,25 32,19 30,97 31,92 32,43 31,58 30,59 32,34 35,64 32,25 31,76 31,07 32,08 34,52 
"mmu-miR-339-5p" 37,95 38,02 37,43 38,28 35,98 37,06 33,91 34,52 37,50 38,62 36,30 39,07 38,15 32,91 34,63 31,92 32,62 35,41 
"U87" 27,33 27,69 27,33 27,95 27,33 27,59 27,59 27,59 27,43 27,43 27,09 27,78 28,03 27,25 26,79 26,79 26,88 27,78 
"mmu-miR-340-3p" 33,01 30,79 30,20 32,34 29,23 28,71 29,45 29,55 30,27 31,50 31,83 32,00 30,47 29,89 29,45 30,07 30,20 29,45 
"mmu-miR-340-5p" 29,60 30,47 29,33 31,07 29,45 29,18 29,27 29,38 30,59 30,90 30,47 31,17 29,50 29,66 29,89 29,89 29,73 29,38 
"mmu-miR-342-3p" 28,65 29,23 28,65 28,31 31,07 30,90 30,07 30,37 27,09 26,71 27,00 27,43 27,95 31,17 30,59 30,97 30,59 30,97 
"rno-miR-345-3p" 37,95 38,02 32,08 35,83 34,35 36,95 36,20 35,30 38,96 38,62 38,79 37,89 33,35 36,53 35,98 36,95 36,20 35,98 
"mmu-miR-345-5p" 37,95 38,02 37,43 38,28 38,61 38,59 38,02 39,07 36,95 38,62 38,79 37,74 38,15 36,39 37,89 36,30 36,66 39,45 
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"mmu-miR-337-5p" 37,95 35,30 32,00 32,53 36,53 36,20 34,25 36,66 38,96 35,30 34,25 36,66 34,63 38,40 38,65 38,18 38,59 38,18 
"mmu-miR-375" 34,52 31,07 29,01 29,60 31,58 31,76 32,43 32,84 30,97 29,45 28,65 29,73 31,83 35,98 31,83 34,63 35,07 39,45 
"mmu-miR-376b" 26,28 25,90 26,46 24,93 25,15 25,82 26,02 25,82 27,59 25,90 26,71 26,79 27,00 27,69 26,71 27,69 27,50 26,57 
"mmu-miR-379" 37,95 38,02 37,43 38,28 38,61 38,59 38,86 39,07 38,32 35,50 32,43 36,39 38,15 39,29 37,50 39,25 39,96 39,45 
"mmu-miR-383" 34,04 35,20 37,43 33,25 35,83 35,20 35,74 39,07 35,41 35,98 33,45 35,50 35,30 38,52 38,40 39,07 38,25 38,65 
"mmu-miR-350" 34,25 38,02 33,45 38,28 35,30 35,41 35,50 34,35 36,20 36,20 36,80 35,07 35,07 39,96 37,36 37,60 35,74 35,50 
"rno-miR-351" 33,60 33,35 37,43 34,35 31,92 32,74 32,25 32,43 34,11 33,45 33,91 36,80 38,15 34,63 33,01 32,74 32,91 32,34 
"mmu-miR-361" 37,95 38,02 37,43 35,07 35,74 38,59 36,80 33,13 36,66 38,62 37,06 35,20 32,25 34,25 36,08 33,77 34,35 32,19 
"mmu-miR-362-3p" 37,95 31,69 37,43 31,83 32,84 34,25 35,20 37,60 34,52 34,25 38,79 36,53 38,15 34,84 35,83 34,52 34,74 34,63 
"mmu-miR-365" 28,77 29,38 29,23 29,18 30,47 30,59 30,27 30,47 28,60 28,24 27,95 27,09 28,77 30,69 30,79 30,59 30,69 29,89 
"Y1" 30,97 29,50 29,45 30,47 29,66 29,73 29,73 30,11 29,99 29,78 29,78 30,69 30,69 30,37 30,07 29,60 30,07 30,11 
"mmu-miR-434-3p" 32,84 31,92 30,90 31,17 36,95 34,35 33,77 35,41 36,30 34,52 33,77 32,43 32,74 37,60 38,02 37,74 38,47 37,89 
"mmu-miR-450a-5p" 37,95 32,84 37,43 38,28 33,77 33,01 34,35 32,91 33,35 35,83 37,60 39,07 33,91 32,43 32,91 33,01 33,13 32,00 
"mmu-miR-451" 30,37 38,02 31,69 35,98 34,74 38,59 34,52 39,07 35,64 35,41 34,95 39,07 38,15 39,96 38,25 38,02 36,95 36,53 
"mmu-miR-409-3p" 32,53 31,29 31,76 32,00 33,25 33,77 33,25 34,04 32,25 30,47 28,71 31,58 33,25 34,95 33,13 34,84 36,39 35,07 
"mmu-miR-411" 31,83 33,91 37,43 32,84 37,06 38,59 38,86 39,07 38,96 38,62 34,52 38,32 38,15 38,12 39,66 38,86 39,14 39,45 
"mmu-miR-423-5p" 37,95 38,02 37,43 38,28 38,61 38,59 38,86 35,50 38,96 38,62 36,95 38,18 38,15 39,61 39,66 38,96 39,61 37,06 
"mmu-miR-425" 34,63 38,02 33,35 38,28 36,66 36,30 34,95 34,95 35,20 35,74 34,04 36,08 38,15 32,62 34,74 32,08 32,00 32,84 
"mmu-miR-484" 25,49 25,40 25,40 25,28 25,60 25,90 25,60 25,73 25,28 24,15 23,85 24,50 25,40 25,60 25,73 25,82 25,40 25,95 
"mmu-miR-491" 35,07 34,74 37,43 38,28 38,61 34,95 38,86 36,53 37,06 35,64 34,74 33,91 38,15 36,20 35,74 36,66 37,20 38,02 
"mmu-miR-494" 37,95 38,02 33,13 38,28 34,04 34,11 37,20 39,07 36,80 34,95 35,98 36,20 38,15 34,52 32,19 35,50 34,04 37,50 
"mmu-miR-503" 37,95 38,02 37,43 38,28 38,61 38,59 38,86 39,07 38,96 38,62 38,79 39,07 38,15 36,80 39,07 37,06 34,95 38,40 
"mmu-miR-467a" 37,95 34,84 37,43 34,84 33,01 33,13 31,69 33,45 35,74 35,07 35,30 35,98 33,45 33,60 34,95 32,84 32,84 33,45 
"mmu-miR-467c" 37,95 38,02 34,11 35,41 34,25 34,74 36,30 35,83 34,63 36,95 35,50 38,47 35,20 35,30 36,95 34,74 36,30 35,74 
"mmu-miR-542-3p" 37,95 38,02 37,43 33,60 35,41 35,98 34,63 33,77 34,84 34,04 36,53 35,64 38,15 35,07 35,07 35,64 35,41 35,30 
"mmu-miR-544" 37,95 38,02 37,43 38,28 38,61 38,59 35,64 33,91 35,50 37,50 38,79 35,83 32,00 38,59 39,66 39,61 38,02 38,52 
"mmu-miR-574-3p" 30,20 30,90 37,43 30,90 29,73 29,78 29,66 29,45 30,79 29,18 29,23 29,33 30,37 30,27 29,99 30,37 30,27 30,27 
"mmu-miR-532-3p" 29,45 28,71 29,38 29,23 28,65 29,55 29,50 29,18 28,97 29,01 29,45 29,01 29,60 29,01 29,33 29,18 29,10 29,23 
"mmu-miR-532-5p" 37,95 34,95 37,43 34,11 33,35 33,60 33,45 31,40 30,90 30,97 31,92 30,37 35,50 29,38 30,20 29,33 29,50 30,37 
"rno-miR-532-5p" 37,95 38,02 37,43 38,28 38,61 38,59 38,86 38,47 38,02 38,62 38,79 38,40 38,15 35,83 38,18 36,53 35,98 38,47 
"mmu-miR-674" 37,95 38,02 37,43 38,28 38,61 38,59 38,86 39,07 38,25 38,62 38,79 39,07 38,15 37,20 36,30 37,36 37,74 38,32 
"mmu-miR-744" 29,99 29,01 29,18 28,46 28,03 28,15 28,03 27,95 29,27 28,77 28,77 29,27 30,11 28,39 28,65 28,15 28,24 28,31 
"mmu-miR-669a" 37,95 38,02 37,43 38,28 38,61 38,59 38,86 37,36 38,96 38,62 38,79 39,07 38,15 38,02 38,47 38,79 38,52 39,45 
"mmu-miR-671-3p" 34,35 33,60 33,77 32,74 30,69 30,69 30,90 30,97 31,92 33,35 31,07 32,53 33,01 31,76 31,50 31,50 31,50 30,90 
"mmu-miR-872" 32,34 32,08 30,07 32,25 30,79 30,97 31,07 31,76 33,01 33,60 32,34 34,35 38,15 32,19 31,58 32,91 32,19 31,92 
"rno-miR-224" 33,25 34,63 31,92 34,25 32,62 33,35 38,86 33,35 32,74 36,80 36,66 35,41 33,13 33,13 35,30 33,45 33,01 33,13 
"mmu-miR-324-3p" 34,95 38,02 37,43 38,28 35,07 34,52 34,74 33,25 34,25 33,25 35,20 31,92 35,41 32,08 33,77 32,53 33,77 35,83 
"mmu-miR-351" 37,95 38,02 37,43 38,28 36,80 38,59 36,39 36,95 38,96 38,62 38,79 39,07 38,15 36,08 37,60 35,74 35,64 37,36 
"rno-miR-381" 32,91 32,00 31,40 30,59 32,53 32,91 33,60 35,20 33,25 32,62 32,62 33,35 32,08 35,41 36,39 36,20 37,60 36,08 
"rno-miR-450a" 37,95 38,02 37,43 35,30 38,61 38,59 38,86 39,07 38,96 38,62 38,79 39,07 38,15 38,25 39,66 38,65 38,96 39,45 
"mmu-miR-652" 33,13 33,25 32,19 35,20 31,17 31,17 31,17 30,90 31,69 31,69 31,58 32,19 34,74 29,33 30,27 29,55 29,66 30,47 
"mmu-miR-667" 31,17 29,99 31,17 31,29 32,08 32,25 32,84 33,60 33,77 32,08 31,29 32,62 31,07 33,35 33,25 34,95 33,60 33,25 
"mmu-miR-676" 37,95 38,02 37,43 38,28 37,36 35,83 36,95 36,39 35,83 38,62 37,89 37,20 38,15 33,91 35,50 33,13 33,25 35,20 
"mmu-miR-680" 35,20 32,34 37,43 36,08 36,30 35,30 34,11 35,07 33,91 31,29 30,37 32,25 34,25 35,20 32,84 35,30 35,50 33,60 
"mmu-miR-682" 33,35 34,04 32,91 35,64 36,39 38,59 37,89 34,63 34,35 36,30 38,79 37,50 38,15 36,95 35,64 36,08 35,30 36,80 
"mmu-miR-467b" 37,95 38,02 37,43 38,28 38,61 38,59 38,86 37,89 38,12 38,62 38,79 39,07 38,15 38,79 39,14 37,89 37,50 38,62 
"mmu-miR-29a" 25,40 25,49 25,73 25,95 26,20 26,46 26,12 26,46 25,40 25,40 25,49 25,28 25,82 26,12 26,20 26,20 25,60 26,28 
"mmu-miR-30a" 26,94 26,12 25,95 26,35 26,71 26,79 26,71 26,94 26,79 26,35 26,20 26,28 27,09 26,79 26,94 26,88 26,79 26,94 
"mmu-miR-30e" 27,50 27,59 27,25 27,43 27,69 27,78 27,78 27,87 27,78 27,59 27,50 26,94 27,17 27,78 27,69 27,78 27,78 27,87 
"mmu-miR-31" 28,54 28,77 27,69 28,97 30,07 30,07 29,89 30,07 28,54 28,71 29,10 29,45 27,69 29,27 28,54 28,54 28,39 28,54 
"mmu-miR-34b-3p" 30,27 30,97 28,77 30,11 31,40 32,00 34,04 32,53 33,60 32,00 31,40 33,45 32,62 38,18 36,53 38,47 38,12 34,25 
"mmu-miR-92a" 23,51 23,51 23,14 23,51 22,95 23,14 22,95 22,95 23,37 23,70 23,51 25,15 23,37 22,71 22,95 22,41 22,95 22,95 
"mmu-miR-685" 33,45 38,02 37,43 38,28 36,20 35,74 35,41 38,32 36,08 32,43 33,25 32,84 38,15 34,11 34,04 34,11 33,91 34,35 
"mmu-miR-106a" 22,60 22,60 22,71 22,60 22,60 22,60 22,41 22,41 22,95 23,37 23,14 23,70 22,05 22,41 22,41 22,71 22,41 22,60 
"mmu-miR-188-5p" 27,95 27,25 27,09 27,25 29,27 29,66 29,38 30,20 30,11 28,60 28,15 29,23 27,87 31,40 30,37 31,58 31,58 31,17 
"mmu-miR-322" 29,89 30,07 32,43 31,58 28,54 29,01 29,10 29,01 29,50 30,11 30,69 30,90 28,92 29,10 28,87 29,27 29,01 28,87 
"mmu-miR-687" 33,91 33,77 33,01 34,63 33,91 33,91 35,83 36,30 35,07 32,74 33,60 34,74 34,52 32,34 30,97 31,83 31,29 32,08 
"mmu-let-7a" 37,95 38,02 37,43 38,28 38,61 38,59 38,86 37,50 38,96 38,62 38,79 37,06 38,15 31,29 33,45 30,79 31,17 34,84 
"mmu-let-7f" 37,95 38,02 37,43 38,28 38,61 38,59 38,12 35,74 37,89 37,06 38,02 36,95 38,15 31,50 33,60 31,69 31,69 32,74 
"mmu-miR-106b" 26,79 26,28 25,90 26,02 25,95 26,20 25,82 26,02 26,12 26,57 26,28 26,20 26,35 25,73 26,46 25,95 26,02 26,12 
"mmu-miR-155" 27,25 27,00 27,50 28,15 27,43 27,25 27,50 27,43 27,87 27,78 27,87 28,24 27,43 27,43 27,00 27,33 27,25 27,43 
"mmu-miR-17" 22,71 22,71 22,60 22,95 22,41 22,41 22,60 22,60 22,71 23,14 22,95 24,93 22,71 22,60 22,60 22,60 22,60 22,41 
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